var title_f26_3_26672="Keratosis pilaris fair skin";
var content_f26_3_26672=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Keratosis pilaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFFAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5fpaTFLQMKKBS4pgApabSigBaKKKQBRRRQAmaKULk08x8UAMopSDSCgB6VIKhXrUq9KllIVqZTz0ph9qQ2MIxQKcRmmCqRLAUYpaKYgFFFFACYpe1GKKAEAoFLRQAUnWloxQAmKDS0UAJigdRQKWgBwPFOWmDrTxWkRMd2pKcKKsWw2jNKaSlYYopcUgpaomwtOAJpoNPFMGFFBooEGKKUUlAB3oNAoNADKCOaVhzSUANNIac3FNNIZXpaMUVzlhS0oFGKAEpKdgUYFACUD3pcCjFACUuKAKfigByLxT8e9C9KWrEMdOMioSMVZPSoWHPFSxjV609aZinrUMpD6awp45FIwpDI8U0jBqSmMKYmhhoFLzSjrTJDFOC0CgmmMQ9KSg5oHTmlcBMUYopefSi4hMUYo59KOfSi4Cd6UA0c0uDQAlFLjPekouACnoeaZSoeaqLsJomAoIpyEd6cRW+5JEaBUm0UhGKVihtFFAoEAp4NNp4FMTAdOaDS0UxBSGlooAbmkOTz2pxGaMYFADO9L096XHNBwKRQw989aaadTTUsRvz+D9Tj5RYpB7Niq8nhXVkA/0YEH0cV7a1sg+6ACf1pq2ZIxtxXNzM6/ZI8SPhfV1GTaED/eFM/wCEd1Xp9jfP1Fe6f2cpALHJ9KFsowuNoGOgpczD2SPDo/DWrODi0Ix13MBUb+H9URSTZyHHpXupsQQAFGT6im/2cASOMEU+YXskeBvpt6v3rSYf8ANQG3mU4aGUH3U19BjTl+UYXFMfTFBPyJ16kZzRzB7I+e8bTzx9afx617vPocDk74Yj7lBk1Xm8OWLH57SMnt+7HNLmD2VjxNORTsGvYW8IafIeLNAwHpTH8F6fwTaKD9cZq/aWJ9keQEcc0xga9dl8D6fPgiAR45JVqqSeAtPMhVRcH02mk5pj9kzyoClFenv8ObU/dmuF9sioX+HMOMrdy5+g4pXF7OR50veg813zfD04BS9YDvlKib4f3IbAulK/7lK5Xs5HCEYpCK7OfwFfoSYpYmXtnINVJPBGsr92OJzjPD4p3JcGcqRRW/N4T1qM4NmT/usKrSeHdWT71hPg+1NMlxfYyaK0JNH1KLHmWFyM9PkNQNZXKnDW0wPoYzRcVitRT2RlOGRh9VIpvHc0AJRS8HvS4oENopeKCKBiUUuBRigBo4pCKeBRigQwClAFO20Y4oAelOyc01OlPxW8XoS0APHQ0oOab3pcU7isGKQinAGjBHancBAKfim0vancA70tJzilAouIMUlOxTe9MAoPSg5opDEprU40mKQDDSGnkU0jmpGfS6Wx5YkZz90DoKna3UDIB+p7VdMQzlgAO1NI3YBBx2FcZ37srrEo7ZNMEDE4GBVyOAs2WPPYCpTEq4UDLEdaQWM5oigIGM5wcUxbTL7mHA/Sr7RFDgAscdfSnwxMze2OmKC9kZ8ibc7V6eg61LFGoUEgc/jWn9mBGCeKjSxCsSevoTRqS2mUxChYlUUc5z3NI0KmTnbjHpmtQxKBgr+PpTfs8MIZ1Xk+9VexK1M2O3BU8EeppH09XzvJY9a1bZFdcnIz0zSzLhOASCcelS3cpK2hjQ2kSDbEAAO2eDUjQjYQFHscVprAu0hR0pJLZgpbdj/PehFWuzFe33Bdx2Y7CnCBChX734VcSL7QrCNjjOMiprWwMDMGZmJ5yaC7IyoLJOScgn1qX7EuAF2gE9PWtSW15O8c+vpR5ChgxOAOhNArXMpdNbeAwLjp04ApWsYowC8e3tW4h2jGDkUjxsyk4A56UXIau9TEXT4mXcFBIHTFD2EQTDRgmtnyHKAbWHcnpTFgkJJI2j2NHMLkMGbTo8qAqgdgeahOjI2SRnJ4yK3JjHHKokRmY8DArQihJQbFA4zj1FHMNwaRxU/hyI/8sY29MgHms+XwpZEASW0BJ7FK9GEAAUtjnrVc2gaUlEUgnBJOafMSlfc80ufCGmyZ3WUbEDG7biqkngHTXJK2ZX6EivWGsAVwVKr1pr2ijPIB+lHMDimeQS/DrTgwGydcdcMaryfDm08zAkuFA9GBBr2M2ys4yBwc9ODRJYBhgr9AO9HMLkXY8YHw2ty//H1c/TaKjm+HELkC3u54yBzvAOfevX5tNYY8vO7uCcU2Oz2sTJgH1p3Y/ZRaPG0+HDDIe9ds9CqDrVaT4b34wYrqEg9N6kGvb108BvkGTjp6VIunE5LocdOaOYToxseCH4fasHx5lvt7nniq8vgTWU3ELCyjjO/Fe/vaReYys3zdaBYRlMAMc9h3p85PsY9T55/4RDWFJ/0UHHowpreFdZRQRZM2SeFYE19EvpUYBZgAB3xioJNPVmzbooU4qlUsL2EWfPbeF9aWMudOn2g4JGKiOgasBk6dc4z2XNfRS2ADBWwxBzx6+9Nl08Jgq3HcGn7UX1ddz54XQNVIydOuVAzklDUD6Ze55srhVHTKHivo9LLcmE3HPXnpUU1iFUblXA65HWn7UPq/mfN/2K6BObaYf8ANBtJwuTBMB6lDX0b9gVwD5fPcjjimyacmMFCRngGn7YX1fzPnLyXXqjZ/3TSbGX7wx9a+jP7IgdseUB68CmSaBb5B8pD9VFP2wvq/mfOpBHrSdBzkfhX0O/h63JP7mIZ5ztFQv4ct5JHDWsJXH8WP5Ue2D6s+58/cetJXv/8AwithgsLOEHuQo5pg8Kac7sZLCIDgDEYo9qL6u+54ER60iivfB4M0xmObKHH8OE5qSHwjYRBitpD05+QUe1D2DXU8AdcdWA9s1Gete/f8InpROf7PhVwf7lIPCGmH7unwn0wgpe0QewZ2LbQFQcuf73WpxESoz2/DNLBEH3MyMuf88VMyBc5OcDgHrXOdb0K5zEAgO5j1xTwNqp0GalSMFWODn2oMALbnILD9PpQK6IPLYO27G3sM1Ko29Fx3xQtvI8mWYCLqFHUn1NTeXuLgsMdMdqBtoS2jeQs8uAOwHaorosqjbEzNnjHerRXbEFUKqj/PFGGAznpx60Ebu5VjjbjeDk9jzipvJIAbb9M1YC7VIcj8O1DkAgAFj1680r3LSIEi2xku4JPOMU6KAHLl2cHkCnRLMwPmgJzkAelOG+dmWNioz1xyff6UmXYnSFWXhAB6Ed6bLEgx8gx3NTWy/wAIDHjr7Uk0e1fvfN1x6fWghR1M5vlcCNNqjrxUjLmPKfM2c7fU1Zgi3EjBZux9Ksi0RDnIGKCna5jJBLdKftamIA5G1ucVK0aKo45Az0rRaDdhicrj06U0x4OEAOOuOfzoHe+xVgXgMFIB6AipfsYd97sucEYbkD3q3EmFBYoDnp1zTY4GDszvuDfwgcCkMheKPy9sTEnGM4qotvMspLuCvYVoqgIynCg9hTdpLYK4H8qATsVDE+QxjUenvUogYsPlIXHWrgiwvyr+ZppLq/RM+lAtWQfYI5UAlzt6mnrbpHJlf5VYhjlkOcgj0qRoyqENjPtQS77NlCdEOd546kA1nX+jteqkiXMsCqQ3yHGfrWvBG/nNlV2DpxVnzU3FBtPaluWm6bvEy0tNsQEbbsdcjrUTxMcLghvWtibDKWUDgdqrNlcM4JLDoKoV76szng2nCByM5zTFtllBMqMCO44x9a19ingA46n2NOWIhScZB45pkORjvbKq43v+NMcHy8BjnoK1XtmkOI8fXFL9kKAeYNxxzQFzGEaA5k9eo5q3bxFmJiBJHrVvyERspFu46GpoUIQloipx0FLmQ5XaM+cMOSgIHXdVfyT/AAqC3scVppbtKf3keM981ZFqigHaPrjmi4WUTH+xdTjj16UwWxLH5V2g9K3DHvU9vTNQGHb0GWoGjMaEKuAoA7CmNbDqQrY9K1GiBJ3rwD3qGa2DpiJwg74ouNLUy40O7AQY6dKme3aaPC4HNWGtzFEcOD7mpYIcDLc+mKLlOCWqKEVpxggMR2FPazLKQExj8hWiscaglWXjr60TAZU9M/wg5zRcjlbZiLZupCsTtz09aeLRcDgk9BzWrJb8jaSSaWVGRE/vdBgcn/CjmK5WzLNuQvGc9aclodhwucjqavxwEMXYnce2eKsqmV3BcEH9KOYThYxvsnlqTtbHrUZgwGUjnrgdq3/LDdfTo1M+yrtBRRuajmEl3OeW3QkKBnOac0OOEGMd63GhwcEKWHaont1wCFJJIBouNxRVcKihkJGKrySDeM/ebpkU8gsSeSM4B96am453YI7E9cVRkvMeXKruIwoqGR3mOVOwA9T1oeImYOXYKByM8ZqZLdSQzMTgZHoKCrpaksYEa4Jz3z3pGj3MGJYL2BODTreP5Cc575PakOCcZLEcUyFqRoquwDHKY6etWg6RDGcKe+OlQW0Hzs7nJzjYP61NIyhgGGcdB1GalmtkQmQEkxrgk9WqcKd27JBx+P40zY0s24SgbeSByfxqXJBAG7Yp/M0i7dBpDFTnBGcbie/9alC7XQYyD949amiVTtJZd2M8/wCFPGQRgFwx5I9KGTciZ5IyAhLMR+AFKfnIGMtnBPYVO7Kqqka73bqT0HtTwjAEscAcHj+VICu0XlFpB87HtnpUsKNJGvmAgjoo7VYto1Eeclm6Z71NMjpEPJAJPGaES5dCqQcFQMe9RxW6oXZWILkEjP8AOrflthRJ17helCQg8pzjgZ/pQJO2xX+zI/zYJI/Wo5lWNNrthsdBxWksa8hzg47UPboQCVyB1zSGpdzNtYQVBBx3JqWTy1ONxHPQHr9anmkG3MSFh244NUliKSl5NqMc8n+VFzRK+rLMgHl/M2D7VWtrRBKkisdwPc1LMoeMBWKDsQafFbukWyOTPOc9TQNPljoyxErZJ2hVz+fvTp3QKVYgj0HWo45NoK57cnP8qeLRXctuO6mYyWt2VktV89pFG0nnk02REb5FABPXtVm6ZYIWeQEgDtzSWUUMimZc7vXNBetuZkLQ+Uoz0PYnrTkLFVJwSe5qeYqSFUdOBuqCe1Fx8ochMcjpinclR5nqCqzAhgo9xTzCyqNwLHHBFWYLeOKFYyzg44bvT5FbbwevrUtg7X0IFi4z0/rUE8M20mMir1tZvEu4sXzydxpZQG3AZHfFAtnoZkEUzffYbunAqxDBImQ7b/arOG4wMYqC4dlww5A/hHekVq3ZClUTIYnAGag3Nu3LnDd81XlvAJVjaQK2OR/KnSrNI8flOBj73H3qVzRUWtyachY2Z27cCqFvMjuW5U4zk9xWhPCNis7jaOTSwpDKh2BfSmC5UtQXbIOBkCo5IlIOF+Ye3WrMcXlRlYwePzNQSnywzDLcdqozSV9CncQpGudqhvfnms2PzFJZ3BHXArZWEXQG4EpnIqMwoZNgQsFxz60jog7aMpwKZW3gD8auLGEA43HPU9qnNqIiGU9O3anQlZfuHcR696OhDlfVEaSYOWAG78aXOZTleMcGpZI2yVUYJGAM9KaInQneOoHPoaQlZ6kD4LcrgdiBTxETgoOvWpA3LAFcjvTnJ8k+WB5g/SmDESHd/rOex9qbLGiq3lnpT7XzASZQSp7VLIqEEjjj0pXIaszLVWaXDYA+vJqQRbTtLAknoasxW6ZJHJznB6g1F9jKyFwxJznmmrlNo59BjJJOM9e9RSzeWCcgAU6R8/Qd6ilZWZd3YVoc6TvqSW+JVGOatHmMoDz3qusgUqqlcgEgZxg+9PjY8sxyex9KLj5blkMFACqQvfJ71Xmlbc4AKN3PUCngkvtB+XvnrmlIUsc8gUFxVhluh2hjyM5HoKkuIGnjcbmBIwMccVDbpIZ3diGXoFHQYq7GXEO5xmRiTt9qm5razuivaW/9nokYUtxk7jncatwB2O9gFBJAqRYjKoc4x3PpUqE4GGVTjGfQUCcr+pUnBRUWIfMx+ZyM1LE7opDFj9RUiMroWUnGMe5FEQ8xPnYAA9fQe1AX0swgkV/mKtuBx06VJFI0zMJFwnb6VaRFQAKAeO/Ye9IgDHgckdT1FKxPMhlzLJFDttY97jjnpVqFpDCC4AcjLAdqijkUMFJwB2xV6SRUiAHJ7E8UtCZbWsQQAkbnAAOfrT55QAUQjdjAAHeokulYuIzvPenQFEj3yfIp5560txcr3aHQwqEBum3nqVH+easeYjj5dmT2qJEU5YHO7nPoKeFyhKYAP5mmtAauI+xELKpZj6VWbT1nmR2Zgw/hH9a0YE6s4xjp6CplQSZ3ZX1agXO47GQY4pWMZUEqeacsMzMECfuhj5q1PIjPKgD8OTVtYk25+UEcECiwOqlsYpgRDu2g/wC01S/ZvMjGG6kfSrt4IJWUOMKDgAHqamFsscAIU/SmQ57MxZ4oo3xISxY9KWUKrBY0OMck1prChYnbwBjOOfpUdzCUxtQl24A96RcZ9DLlwmCsTO3qO1PklKxh4oi7nAx2FaSKpVdyAMRnbTWiX5QOD6YoLU11RVi3GMGRQG61JuLFVKYz1pimRpnAUbAeueKsRWreYWVyzHoB0xQJ2RG0Tlc7mZD6d8U3YQRhhjPpV0q4KglRuwP/ANVK1uScrgHGM56UyFIoSRsFIRSWNUpvMjQBk3Mxxha3fs7bDg9s89qga1dox3HUVLLhNdTnYdOie4aW4jXf0yPatIICo8tOB+ZoSwkSYu7E8ngelaHksEBA3c+nBppG1Sd2tTLmgMq424HpRBbCFv3a8D8quzWklztKMyL3xVu3tykYUjJI6kUGblZWM2VJJAFQ7cnk47VAYpVQKfm55PStRrd/MO3n9KVotwAyDjt6UrApJGYxRIV3Kdx42j1qWBY9v3Sp/wA8VZgjaWXEiYXqD2NW5bXYmEwD6etFwbWxSaCNlHTaaRLFEXdEF9gKtrbkkZBLH+H0pLjfHGQseW6YHUmi5GuyZQEDKSS3ekkU7tjDjHUU5BLIdrqVZG5X6VIXKYXBf1I6UXL5Win9hKqTEoXjr60hh8tAZTyPX1rXBJjA64HIqk0cxk3sF2f3cc0DjJt6ldSWUArnJ9aS5QbME8+1WykgIKxsVB+9jgVPNZxyFSxzj8OaBcyTRQtwDExHU81AIp1lLMQy46HtWmIoo0IUFgOgFRD5yVYYxz60xc172POomLEEdKWYpCnmSLyOneoQ8hcABdvc1ZULnDgeuD3rQEhYcSIHHBxn61JLMqYzkAnjPJqCQEoBGQBnPPemymTnbtB4wT0FItK5bmuDBGCvJJ5J54q3B86CVh97gDvVRipC5GQBj/GpIXfyyH79O2aBNKxctI8Fg5B59Kk83zGKov3eD71Wi3MANzKMZOBUoBGMHBzyOpxSsIvqwAADBsdv601YixILfMRwSaih355OATwfareeWB5JHcUE7FFy8TMQ5Cdhj86n091eFnccFsD6+9EoVsgjjPU0tvJE25YQCEGTx/Om2Xui/F5ZUAjIPOfWpwi7PQ9sVjpFM9xvSThRjrxW1D8sXJBYdKkmcVEhS1UzeYYwXxzuPAqQos29EbOBkkdAKRCXXDcsc9KS3iWEOIjy3LEnrQJPuyC3tVtUbyQ2WJJ55PtV2ODzbeNJY8E8nHH4UtjHLlnk4B4HtV4QMeFU4POc/wCcUBKbITDtXGScdf8APeq1vbyeY7TOQin5FXkn6+laMuCQivtTvmnzJuz5QwmO47/4UriUn1KEzzkpGigeue1WYyNpBwCOxPWlaOQkkj5j+nv7VnC2mOqK8qt9nxjCdQaCklLQ1bbJlCBcADczH/P6Ve8kNlScEHLdsU2Jh5nzDaqg8dfpTPNB3KFIBBJz1oMJasYklvJduqlGaMYGe2fQVJJLsdVxn3PYetMxDauFA+eRslO+cVOFGG3A57+g9qVh2Q1mYqzRgHaMjio7aV/Jxcxqsh5GOSfb2q0iuY1LEqpONuOapPI8dyyumY/lAJzSCMU9AZ0kkZBH0Gc54/GnIiFQWX2zn+VPKjJ+XcvXt16/pUcZcscx7Ez8gPUimi+UTyg2QgXK9AeM/X/GpIkDoAcDBweOv0pVtgHdsYOQc55qaS289MRuQS3akS7bEKwkPkj5ugTr0p5j2lcZ54AHOParkcaxqFIzgdaiuCypugQMTjj3oJvrYaXX7pXAPTI4JpXQAZ79z0zSyQSyRhACZSMFl6A1JHEoi8tuSP4mOcGkLRGd+6ebYjjcOoUdafICHAXdsXjp1q79jhQtJEqqcffA5OarSzhZVSVgCxHHt707lpp7FZ0KgFFYk9xmpMoURmbbnt2PtVxVZjgEEdsHp7017WJ3Uvk4UkBhx9aCuZdTOEcxmDOgEBOMk8/Wi8DoUMKgkj6A+9Xy6B1Td+8I4Xrn2FV/tEf2sxBcOfvHtx2oBO72EDFoh5mQyjkcYWnRL5iZ3BieBjsasyJFLG0Z6EjIHUe9SRW/k5VU2jkgYxQTdEMWNxRWDN0yKWWFiwU52jgEVm3OpQ2kwV/kZ+MnufpV+3mee3DJ0PvwB7UrhKnKPvEccAZX3DjqMdDUSxRygpwccnAxWoqHCxqPk7c80hhZcE4AHTAxTuLmM1I2Q8Dd+HSmtGsrkpzt6kjFXchhtOMbuADyfcVB9klN2JElRE/hUflmmguNl4jICgjqSexqtc2+fmZ8vxtA4x71enhVsIh2seeuDn1qG1Khy7MPmGMEdaYKXVFQRFQCcnGTwfyqPa8twwHK45boP/1VorC3yhW4XqOBzTL1yhJVF5PHHX3oZSlfQ8gJRQRuywHbtTLdZHuNzN8voKiCKkp3ffbt61NDIzSKq429GyeRWl7m6jbYu7QuOhPYUSRK4Ge1LKGIG04PrSeWGj2E85xkGkSvUlhU8AMrnPY1JHE+fm4BPPvUdtCIOFYZz1q5ESw55zQD7hE42nAyAcVYUAjIwT19qiYomAeGPA9qJ28sjOMNxikTuW4FIjXdg5P+TUr4brw2KqT5ZVRXKt1NDylF3ly2e9K4+VtjZm3Eqpww79vpSWUYiR1Rjlz09abbPDO52ncRwx7VaFv5m3bjA7etDNk+VWZNZ7o92QSCeoP6Vpq4aPK9/WqsUZHGdxHfGKuxwoq/IPlPPFBhOSeowMUDgkYB545FR2si3LSYBAjON2P0qW4GFOCDnk8dqr25hju1UZEjngDv7mkCs0arSxoAWGQBzVwMCqnJw3p6VWIjZeQDVO+uJ4yn2VQ5BH0FMzjFS0LF5atNPGRLtAOcL2q0pMUezcxOcg56UwgmNBj58ZY4xzVOxM7TzrLlY1HynHX1yaktK6t2Lto7eawkBK9j29yatOjJCpxkk856+xqNA8MQdRwOgNRW8rTRBpso3QD1+gqiXrqiWN1D/d2AZ61E0TvIrocIOWIps8HnoUBOfukjqKnhJijEajgAA57mgNtUSJaLJMsw/wBZGeDn+dWUuBLeGBMs4+Yt6VWtwI3dGIJP3snp7+5qx5MayeYgG8gY55980miW+5JAsjSOXYeSAcDvn1qZgkgO7BkHIH8s1Ve5RJ0ikONx4HYHPeknmMdwqxgMC2Cw7D1NSTZssbXG1V2r1OaiEbEnd8xPQ9yKr3Ana7DQsREDhgep/wDrVKTMW+TDNnO48UythilkkWJtu055/wA+tWZ5hHEWUgkDjAyahlYqSH53dcDk+4qKe6igaLzBhjgke/SnYN2TQzuqDzITz055PsaztQnnivWSIlIgC2/GQx7LjtW1IiuitG+cDcvGMimhEwUcDzj90HtSsCkk72GQzT/ZlYA+ZjJ471YikEkOHKncOijvVV5kEYikIWRxkA1Q8u7+1o6tiLGBgdKQuVS8jSigkjnmfzGbaAFXPA/GpTax/aFkmQNLjg+n0pbdQFY7tr4xUjyOuzn5cZyOp+lMhyd9CuZtt08SjOwA4Ufn+PSpAIXZnTO/pyOTn0pGkjjkyi4Ygc9/xqSVwAojPzY4XH60wv2KVzFHGTIcAk8sePwpCIZGJVThRu3DjPsadNGk8bqSGwc8enrVaJ0tWd5ZQEOAued309qSNE7rzNJbfcA2drqN30NEMUvzuzblboD+uKhbfNLESwLLhmC/4/SrE3+rK5Of4WX09KbRm2zndX0JLmfzk5B9e3Ofz4FbNjbta20cZwoHTPOc9qbdT+TDhAJJCwIX096dHNvUEOzKpzwMfmKXKazqznFReyLMquwAjfAIwSMcfjVeRXl8oxkqBnKnndx+lNdx5DANhSeB9e9V4ZJIyZHIfecdOMUWM0tC2wUookJAU9OPzzUJk8ssMg7xjHUL9PeomuRKwiJcnOWLDgegFPZ/KdQx+dlO1QAcD1NMdu46SSNFAZSAPlHHc4pHtgZEZiFO/Ix/EenPtUYm3Lst8ngk7v4T6/zq2jYIEZYkAMSR0pCfukMivHGBAu5gfyqKR1bcFXBHJYdh6VIrQlMM3T5iM8fnVfzIlcSRAs3QEDIJ+lNtDR4k0JNwshZgVHGD0+tWY8RA4HNMDDI6njNEbNvwT071o0dd29C2HJABOAKfBIwLA9eoPrVJJWd2XA2+vvV1f9UVGDnvmkFia2mQy4Qgleee1WWuvKTc/HOOKzbSJondshg3QEd6sOqum1gfTrRYGkX9olljc8Edj1pbkCRwwbJ7GqUc20bTnIHWkS53knnAPNFgUX0NFpGATYNxPBzS3AVo+hHNUftn7/y1T5hjr6e1WluojP5ROWGeAKgtQe4+zt4oHwny85PtWnb45JB6cE9qzbKTzF4G0g4xWrEAV5PJ9aZNXfUdbyM28MOuNrdMVdWTOBzjvVElwpwdxHcCkaR/LKA4Zhw3oaRly3Ls2CWbdhc81GsMTOJQMntnpmoGZlsBHIRxnc3TNTWi+VbxRM5K9VzTC1kWRcAPHGMgMcE1PuDSEKclRngcH6VTYbXLBSR6mp7eRDbqQpBJzyOlAWVi9DJwQhCqefoakQDbkcnOAcdPeqykFX2/fHduM0JIEj2uTuHJJPJzQZtEk915ThnwSffg+1Suu8hT8sjKOPb0+tZd/F9oZCrmModysPvZ7GrtkzTShXk3OmBuYDP40mXypRuJaxSQXRuMM7EFMbsYzx+Yq6kZRFU4XjJx2HvUZYIx2HLk457Z9qjM4WcJM+PlwozjH1poh3kRlXS5F1FLtZFKDIyAD1IHrWhuiSHLPuIGTnv75qC5t0dCjNllHc4A+lM2okJUtuYjbk/zoB6ksckFxEbiJCxXjc3rT/NmAUQpnHVmH3vwqHTo0gikACsc52gd/Uip1kJm2kg5x34X2pJA3Z6D280uHUneo5I7+1ZWo3F6JYhbnK5JJA+8avyuyt5akbR8wBbpUEj7MuTwR1x1+npTsODs72LLPK8Su68kZIBxlvSmxrHMhEkaNJncwem27MYyxbcf4eO30p4UI2WHGcYHX60EPQsCdEnVSzLvXrjp/h9KbJIsRZgSvy4znp7/AFqK5b+MKN4HAY9/X29qorc+bNNDKCARwx53ex9/pQKMb6li01LT7udlVkeaPkjA+X04rQS6gL+WGCydWAPOKwrO3t7S680xqrv8pOOo7VppHF5jSRnc2fvMMDFKxpNQvoaE0yw7pDtG8ZOfSqguDJAzLu68EnAC/wBKa80Y2oVYlRhv9rPamT3CCIBxsUj5h7f/AF6LGSQkrfaAAhUqeAOeT6k1LEHQliSWX5Sc8jPaoI2jMf7lSE789AewqvHdSG4MJQrGOWc8n6e1Mu19iW5mm5CAYBwcD+VKrxzGMT/MR0XHAPrUJmlMqAqgXpnPC1DPEzPvjk2FQQxHf60yl2JZNRkjuEjiQlXHysBjAq+94xjZpSoVRkjPt1xVGLytqg4LjHzE4z/hUkiCSNgzhjnauB29R7UhOzH2+pQT4RJFPHPy56/1pst0kAIfOW4VV/iPvjpSWVrFGpCKD/ujBP09qfNsCBiAAehAz+FAm430Eu2ZovkTawUjA5A+lZ1gt0oPmvucnpjpV6a4DkFuFUcDHLGoPP8AlHylIz+fvRYqMmlYuyTxDdtYDtuVsflVeXM0ZjRtsnOzb1P1NRxyAsSIwp6Dikd1GWUbicjGenvQTezJNPSO0iG9gVGTg4OT7n1pZroEkKcknscbj61QuC0o2yMc9BtHIqOGNEXqNwOSSc0rFaPVjp/OmOTJgHqAcBsdiPSkmvVgcKvmsTjnbgE+nsKtMVWMOGBYKQoPUE9zVG+uGUKRmYDG4qOv0oasVF3djzXaCeCc/wA6hmkCFQMc8U9pYlTcpyw44qIuJDuXBGO1aG0b31LEDDG48VdiAUe1Y8E85utgj/dAdavyysrKqAkd8VNypwZe3jAxjI9e9SQMDyepHeqAZsYX5j0yalWTaQCR+NURYs7lLgE4J7U8KisSF59arqiEiTnirMZIbAX6ZpXC5PHGpfIAHv71JFGgk3bcsOpqGIkTEFTzyD2FWIySvy8E8VNh8zRbjKhOByO+KmibzNxD8g5AxVOxUxAo53bjwfSpm8zcDGBs5zQS9y3CxXIdgwHOe1Nu45CrCM9QOO9JCQF+bFWA4BBz9fpSsTezuNTzJ7RLeeNECckr1NWGhaSFVTI4wGPaozkNuHbtSvcOkDGLkjpTC7k9B9ukkarGzBgOpq8jqAdnQdDVOxnMttGrRGNxnfls7j7VMZ1AVcdTheKYpp3HIChOe3QipXkjUbguWI9KqO5Lk52jsPU0SndbfKev50CRJ0QsrYwPmHp7VW06RRdvcQTgOinjPJ98H+dJErrb7HG4Z5PfFRrbpAzmLCl+Cfb0pM1VldMupdTG7R4+Fzknr/k0+8iinlVgXz1znBOar2cbkndIcE8A+ntUV4L2O7hktih2noeBQKy5tDSaJmh8qNiHfhSOv0pEaYWyRTSA7Rwx4qs7GWXzJGO5TnAPenysJxvldt3Uk9qaIDToZLZ5WMrYk4OTjFOMk5vBNFORtGAo9P6GnJL+4CkfN2rNtp51aaKWNQGJO7Hp2pFRvJtmjOzSxMsDHeeee1Ot57lreOO5ILRrhXzkBf8AH3rPX/WITITkdDx+dTSb2h2xH585HHWgOXoWrRGhmZ/MkYnkA9qtI8jA8j125wQKoWRkRP30mWA5bOfwp5dd24HaQcjPamRJalh33KueAB/F0psczLIDjDdPr75qCSVymQm5fbtVVmuvPQqRjP5D3oGo3NVmEhKFVyOQev8Ak0kt3JbhBGh2Hj5R0qlJcNEu5uOB0qSGYvAjPH8x7HjigjltqX5JN8BIGAcZ2jn8Khjv4LmJ4mWQzKcbMcAev1ps0rHOGHTsOnsKpedFCC7AIrHkkZ+maQ4q5oghOYmJX0I6fWpTtYfMQe+G7H+oqnJLkKFIIIHI4z7VEXaPn07H0/xpkuJYFwpkCyKCcY3Z5A9Kc3zDDrgZ4HqaqTXIjCyhQfQDvSPdMV8xMKw+6p5xQFgv45JItqbhxz3pbdmjjYzOWcnO5RTJrpUQSODtJwe3+frSC5V0GFyATt5/U0FXdrFxZpVVTHtQD+Hvj3ouJ2C7jn1z/hWbHeHz9jKz7uAAen1z2qW5bC7WYknqcdaBNWLEt4JCyrtO3jcDkHjoKpm8CygMcSHgIfT/AAqKFgI5BGRtPG49vpUHlK03mMDwPvbuaEi0kty+LoYKlmPqcd6je+W2YeYsjbhhQnqemarvLnG3JYd/ampM8gUOnIJy3c+lBOj1LQuGYLwFcjgdhRkKQu4lV5qszZHAwBz+PpTGmZsf3PUmkKxrpIxtysIB3R8juGz3qrdTH7RgFSwUbsdC1VpZVtoYy0G8sMswJOT6cUs5jMRaOMIyBWIBz17N71QKPU8zVOdgUhQOoq3GkaxgDjvVQOxXngkVJGjL95sig3bv1LowmSCo9Kcm1iCSBxms25R5RsR9pqxZReSiZwzDg0r6jsrXuaAUk5HIPSk2hnIJ4+lIkhJGeM05mwAynJNURctwriMBumKineUxssWdw6VFHLIc7gFXsaPtSxNjknhTx61L1Kincv2YlWJfOADfXrVhfkBJ4NVnkby8BsZFMWQhOcZ9aYm76l5pXwMDA4NWYGO3luf5VkxXEkgYbceh9antnkCNuOTzipK5TUZBKThulOjcgEnH5VnWrvGmGbIz1qYyOq4JwDwe5oQra2Lwud54zkYJFWYXj3A5HFYkSMku8ucHgg1YubkRxfLt9MngUxOKvobAXYuVIGeg6U5iNhP5GskTiVIyHDqMHIPeqOo6hdxSR/ZwrJkAgjPFK4RpuTsdEIvMRdzfMe/pUnl9Y0x0zjOTVCznkms4zKPLl/iGeKEeRbpXVvlHagizu02X418uMBiSATknpTmeM7do3E881A0owTgYqASqihNwI6LnrTBal3cE+bOcnge9IXYruP3enFUdzqcF93PX0pIpmYOyEMF4JzxmnYrlYSvPHMpjACL39/erMAY4eQ/MQep4FZ0d5m7CTK+wjjaMnNXHjLBTuCsOPb6UbDlpZMsSsEACOc9yD19qo/azMZFWNlk3gIAMgj1JqaVgSByuOfrTxLEFPGAw6D/GkKLt0M2T7XHOhVxtzhiy5zn0rWgOEAJyfSoI7mGeJfKfLd1xyAP5VLDtEgG8DPLZ70DlK+lhryhZxHkKcZAJ6/41PvB+8oLDnp0qreTcFlHzLwH74+tU7W8G4echDcjjt+NAKPMro1fPGCSQPUkdT6Usk0aLvfhOh96zy6eYCzfeOBk8VI5SaN14ZenPT60EtWLsl1H+7Zdrr39qiExaIMXUA9AT19qplwsKqgCrg4/xqrZ2vkuWlkZgcgZOODzTsCUS5LdTRS4GWHTK9c1YMXmAeac8A89qqpwCwOOcA9wKSS5CgYUyAnkAdqB37Fqc7odiMwxxxUQu2DmPDFgO/Qn1pgmZFVnPynkqByKkMiM+5QMdeelBNyKe4aGM70JVTn1NFvMspJKkc8DHX3NNupGUDK7i3GPQVFbpsBbORjIHSgas4l1iJVI+/g4NPyyRY27Seo65qvDIgGwEjtkf1pzXCqMZAIPT+tBm0yNiULMEO9v0FMhu5nDeaACo2jnt/jRJPvDbRkjnmmAoSMnLEcjPBoK9R8TqpbDZBONuelJK5Me1WPJ5OOKhJH2kEsSTgHtSyybm4xwcADoKY7akiuVTBb95nr/WoIrx2cxlMAHJc96Y8oQEgYODk1XyzIRGAW9aRaSNIT7n2McD0FJMwxgNtPYVWWVkXjAb1P0qsZ5Wd12rtJBLnrj0qRKN2bMJjit+bidT5ZlIjIAxn371QmaO2crG8jQuBKC7dWI+8aRt0a2zPdmNgCyr5W7CnjB9c+lQ3jpO+QxfAADldo47AdqbCxxEEwMYPtkH1qaKTc3X8KoKRtwDwfSrETEDBOcdzVIbReAUHgd6VpSvUZPb2qpDcyeYqhQVPGfSrbvGFBcDd70hO6FllZ4gEO3+dWLUMAN5Jbpz6VVMmBgYJ9TTlYuR8wAoHfSxfaZA4TOT0FVJfllDbN2T+VPVRkN19xSOxLD5gBihji7MuRyPJEDgAnt6VNbg7sMaoxsc5B4xUvmKgBLAevPemJmlgKuVXOelVZ7h/M2p+NNW7z0yBUbTQrKoyAx6GkxxbW5pRyqACe3vzU9tOjhsHPODj1rK8wkMCMDtimQstqPl6E9PekVo0bMkwU7TnPanSBm+V1Ab0xzVGSRHXOeQeo/nSG6jGNzcDnJP9ae4l5E32pIrhUfhe5FWo2SXPc9qzUnViCrBh61JDeRl2RThhwQBRsOSbNhAw+h/SnByoOGXJ9apNMxj+9z9KYZXYEkYHagx5bmpHLuA4BJ7GoZ1DzBtxUocVSNx5WN2doFJHN5y7hICOvH9aBqLWpqYCgjj5hjOc1VhtzbOf3mU5IH1/rUJdoYwznI/z+VQNeRyKDG3+8APu+2aLjjfoaaPiRTgHt9KkDscbhzWetwEj4UMTjn1p32nPzMTnbwvbNMlrUmuSzLtU4J9D1pqtvGGJ47VUjummYrghs9ewFKbkByvGe5Pf6UFXtoWodsYcABQf/HvxpoAec7Xywx8oHSqwBeXLN0p5kEZ3YOe+DjNAc/YddXREwj253Z+UdPrQwfygVXOT19fpUBdmfJ4x0p/mOy8nge9KwcxOGWVlVzudvXgCpI2cMCp+X+Ej+dUJwhGSeBz7ULfBlAAAHemJ3ZfMh6HkjrTRJhdpwfpWfNdFoyUIB/hAqMTnBLnnH3Qc0BymhDJJvPIKZwT0qYzJxgkYP4fhWRHfF5PKCsDkgknqP8A69TJcbgFIBx1x0pDlFmp5ochQAxPtnHtSQsY2yWBx0FZ5lzg5xjkHpzS/ajv2jn37UE2NM3SbhGQdx5HFRPhju7eoNZF1emBssNyk87OpFSLdsFDN37Y6elCHy2V0TtPtJUZwRwAelVfLD3hucc7QufYdBVbzN0rEDIBHJHAonu3jx5ak8nrQy1foaE8rrwpGW525oGQME845qpBIxwzsqseRkdKfcylkBTGV9aES+xP5/loRhWJxyeMU6OXzsBeVx0qg0oP+sI+gFC3eWxuAPdRSHbQ0JirgqQdo4/H+tIrBVCrwF7ntVJrjnOe3B9qDc9OcN3pi1sXZTgA5wSfxqAzKclQfrj/ADzUH2kMeCTio0mAlG5S0YPKg4J9eaTBXRtqZ/stuLe3hkjwdwkwSGz15PSs6/aYXGJhHG+BlU6AfhUSz2P3mtJiQP8AnrwP0qGeVXkLW6GKPA+Vjk0MS0Zw8JYMOMD+6KtDkgFsAGqKyEKDn8+9PkmySR90+vNVYOZsvCXYCF7fypWdJ0XLDH1qiswduOW7ipEUoQVIwewpblbamtblY0CE5wOO9SO+1RtGMjNZyFmPoB3qZ5DGmRyDQxLcsxPIwwQSvUk/4Us4dkIjbDetMgYsmMYz+tO3MH5bAFIObUmgDKP3pyfUdKUMsmcDIHBPvVcysGAXB9T7VNFOoGD94+lNDbe5bTCZ6fzpUZC2cDj171U3kEN2PPFOLINyhsHtnsaYrkk920TIq/xEAD3NWwSWKOMOOo681nxIxX99yO1WRKsYKDOfagptdCeGRlcqU+UDv0qnfwm6XYrMgzyf/rVKZUb5Q3NQtOsbjdkZ4oKi2ndFu2CwooIQ47IMAVPbwospkAAZhyT1xVNisibSeO9SQyiIABgT/KgTk3r1NXzAPlU7cdvSoYrnDMi5JB444/GqoZnfKsAMYpJZ1hiLOQMdaViV2NF3SRMPzxSwMkQA4HsD1rLhkR/3sbk560s7FlHlNhu59qLB5NmnNLuTgE/jVaRVaJgCFB7dCKgRmVNpfJx+FJNLkHpnt60IW2w+NmiQIpJIGeTVqKYuP3mSM9ulZkErkEybevTt+NW0uUX5WYE+mKYSuyybkROQv+NMaUs+MckcZ61CJVLFiO/eo2miaUBpFVh0GeaCUrlgSShiM4Ge3f2qXzVx83Pb3qm84zknAHHAqN7k7C2Pu9Md6AauXfPO4qOB1zjiqokuBOdrARHpk/0pouo96iMmTIyzYwFPpzSNMg+Zmwc+lK5WxdZ1DbnORjjNNkZHU7QFJrOuWMiHymKk9SOv4VHbbUjw7bmHQDnFA1HS5ZeVYlBQDrj61Kr5y5Xn19KrklwNuBgVBNcopO5gD0GO9Abl1GSTOznIyaViM5DfL04rPSb5PkbvwPSpg7BO7OT+lMfUvic8A5OBn8aYbg7cjB/rVJCMcnJB4HpUcszs5UnA6kDuaVidGywZzIVbqB09qYt2AzA4B/hUd6rGXbJ8wJPT2NBZFYEjOeuO1Fik0aaykxhv4yPX+dRMcliefU1XFyFCrkZ7HrxUM9xtkB5Y5wBnGKTEtyWaV45VKsGPX/8AVUyTEAb2APeqSS5JLAHvzzg0jSDkls9+aRTehe37xkvwOeOlQxOqOzF8sTkexrOvLnanyDBPTvSWkjspd/vdgO1O9gW1zReYK245AHTNTLMJCQSCB3qgWHOTuJ9u9NWfCMoH5UyWy/GdvJOVBJAI9aessQkHmlin8RXGQPbtWTcXJyNgGRwfeohOynBOWY5x6UhWb3OpgS3mTdDBqMidMqFIJ9qo3Z8m6KKkyDaDtlA3fpUcV+HW2hN08IaB7dkGcI/UPx/+uq+q3aPdZimEhVFR5BkB3A5NMlbnEzSkKME+nFMgmeQfMhXHbPWoi+T68cU2KRt+M4HrU31Ki9LF8ANIrk4I5HrVuO5UKRjIFZ+dxyOP6UEmPkdOlMV77mst4OmDmllvBHjzCMHr7Vlwy54YfjmnyFnwDjaOntTZSsmbdncq+CGOKklk3/KzEZ64rNtwVjG3GR07VOj7c5yTQiW1fQtpMnmHccH24zU4ZBITnkjis4tG3Q5Oc0khJHBwaY9GaZuMYBzikDfxLxnvVOKdUO1+pHXPap/NBb5eB6etAbDpXmJAQnaKtRzHaNxyRiqqzDAVyM1IEzgAk+np+dFht6WZLLt3ggnI6jrTgMld2Rt5GKgliLsFY4wc8d6EkWLCtnnpigfNpoWWfJUKenSkMwiOW/PvSQvu5BAAFV7k7n5ycc59KATvoy0tyx6H8qQTyS/LIv1zUKuoVRwQPWniTenyHI7kUAmTEsi4UgL2B7fhT0lZVJLfMvFUJZXQHYpY9uaA3mRgnhx2HegGrq5pRyhl5JAHfHJqO5uPJRiuSVGTWfExDFWbjrj0qWWVdvzEBR0zTJtZj47svu8wcDBBB4NIkyO+9Xyexqu43cLyD3x2ptuiwOx2/j6UjTToaUV2xbYwxjox9PWo0giNz57jc56e1U2nYPhTkGrCTAgCUkE9xxijchtrYuSzZxgcn1qMSPvIYj86g8xBHxyAeGqjcs5lGGYLxkCk2EFfc2XlUEHjGc5qC5PmZAONwz0qk0u+PG496ckhTnkk9yaLglYuwsAMMR6fSmy9QQ2PaqrSYxkjB7UbwYyH6jnJoFfqW3uEjQKxwBxVSQCSTIJ2t8uPUVXuJA5U4yPUVH9qG0jp2APagadi+GCj5mA9h3qTzA5yCQO5J61jiR8ne+EJBIPqKmklJQhcrnuKYmapk2jAJzjn0qBp9w3Dv3NZ32hlcEElcYyf8KPPyuWIDZ5oElYtNdtHIAwJBH5VLudlOdvTI96oPcRbVIbJ649KjN4HVAp3Z6j0pDv2L4mO07l61C0jOwGCzdTjtVSSdkzkZHShbnzBlQV980WEmXxLwuRgjt61WuJixyjZbrg9qqySlTkn3x/jULSb2JPJ+uKA5upoo2MK+Gbrz3pRdKQWA2jjnFZhn2gFc5Xv3qMynfliNo7dcUA5XNhbl3XC4AOe9I0wVQu7J9RWWk6BRvJDY6k02ScbSqDPOTQS3qaLyoTkFuPXpQJ8DcWyB69DWV9p3Z+YBR0AFPhu3ilR49hKHOGG4fiD1pDudL9oW8srJbW7tovIB3xvII2V8/f565459qz9auEutTLRSiQiNVklQcSOB8zCn20kkGnWjyX+lwCRSUWe23OBnGScfrUOu2s0e+6NxazBAiyC3TZtBHynHQg+ooJ5jihIQV2tgd6swy4wTz61lxz5BHTFTLLgZBOB1pWsO5qmdQcUxpypXGT61nb2PzA8DoalE3yjqeKYI0RIQMk/jjtViKfcq5HA7+1ZqyqyAMMj3qVDhuDnj14oHc1fOZgecenNPWbdkM3z/pWWlwu7ao9yBzUisQ5IIxTuJGtAGXJ3Ar1pzFcjJ7VnLMUUAMcD3qXeeecqecUw1LLxAspDA44qUu0aBV5wepNUvOZWVg3zrTGu8Mo6igtNmgd8mC/yj1q3DOI4wqsCQOM1kCdgAQNvt1qIkyM7LJwflP8A9alcpa6M1xM8kn3sg9KuLgrlskisa3YJn5mz6dKuQycE5z7CmTKXYviRVG4nCn2qDzog5bI+h6VWkm+U89T0qthOx+YcjFAky4Zd8jKp/WrMTsUwz5HtWYkgZnAySOSfSpYzhtxY4+vFBV7IutK2/aPu9aeJcfL1PQVW8xEXrUMjM025T8vtxQTe5ePXJYZ9MUpTenLdDxzVIvJuG3G3NODOA2080A9Cy06qxTksPaq7SuX5AIPr0/CoyxDZJxgc88mmh8k4bkDPTNAXtqWllVACevTmjzBOrCPIwT+Bqq4Ei5YgY9KZ5zKp25wPfmk+w79SaN5TgTHGCfu1KWAHGW9c9qoJIzrlmKjGT/8AWqUOix5L5HXrTCTASyec27IXsfSrUErdQQPU1QaTerYGB61D5pBG1zkHOCO1IV2zWmuY+jEA+ppiyqCCFJx61mOfMZWKkjsCaa7yhsKODx1ouHQ0JZFJ25OT04pjMQST6DnFVUY7AHIz9ae0v0I6AUyb2HJuBLNkjpzUc9xJH246800z7cqevbFQSyofvOSe6ipbBMteaWG8tt74Jps8+0YVsis8ynHBpu/nOQDjr6U7hexc8wAFs/LjpT2kKsuMKW5GO1Z6zDY3OeeTmgT7UAXA9cikgci80+FG+ojfhJSgG1MHoM1RefceWz3yTSSSxlAykHJ6elFxcxeN4rL8xOcc4qM3W4YwR/Oswz7QwZl2tjIpVuShUhfoKLsV0i8Zz5Z6AZz0ppuMEg9cc1my3QJILYPWqzXHGAwz19qBpmubj5vVuoz2pv2sg5yRkVkvceYxJ6nuKY1xgEA/iDSDmRprcPgk4OaU3bBQFKkjPFYjXeOpbPpTHu/lJBwo4NFmLmPQNNIvdMtpNWgg2RgpbySXfkGRc/dxg5AJ68Vna7qlzG95ay2qW87mNWIbIWFB8iKOmO+e9c9/a2m3VnaJqVxeWk9tGYA0MQlWVMkjgn5W5qDxLq5lv4x9mkt0S3jSFJz85jA+Vj7nrTs7E3KSO2Bg1PHPwFOdo5x2rFS4IYZfkdM1ZExyDnJ7jOM0wTNhZhtIBGDUkcnIVvujjr0rHW4JOVJx6VYSfpk5FKwc1jVWVQNmM571Kt0wx37ZrLim3Ptj5fGce1KbogKcggUWLWpqi4UspwQTVpJk7cVhx3JdcleTzU0VzncDgNnAFIZsCUY4YfWpIZipyDn2rIR1DY5P07VN5yKNwHFMm5rC4xgNk5702STeFC/KemT2qgs/HzAj04qXzsDdkjPSmyky8khA2npnk/1qRZlTjsOAfas5ZWOQD+dOjkfGGkzj6UkUmaQmDMGHTPccGp4rjAKgdeuKx/MP3d3BNWEm2HKc4/A07i6F5i25yV4I9cbTQGXjIGKqTyFwNhyepP8ASnCX5gSMe3UCi4XdiYBFkGCW7H3qVWyOSeOgJ61VMmW+Ue/0oLlsgnbnpQSpGgXSReGx+FK8yqCAeelUIT2Bzj0pTISFDHdtBxxQ2BcichMO2falRy2RuOKo+cAQWyMdqabjHIGV60XEXHyHznJ71GjuFJPQnr7VCk8ZkAz1yT6Ae9LvBU9On5UFXsSzOWVtpHpkcVHCzKq+YxYKMfhVZMruO7NNmuNo6Z9fSgSb2Lkku8YHH8vxpCd/BUD2zWe1wcFsdR60i3DkkscY4H0pXG2X2lYAKOF9ah3hDvkbPNQmYAZHPvUUkylSG6Z6etDEpFiS6YkBMkex7UsUrKP3jH6j0rPknVVAT/DIpr3IzwBj+6aQ29DTkmBGI8jPQ1GJiEwQMDn/ACazGu8/xcdxTJbobAvGaLk3NN7hAhY/mT3qt5vzF859jWcsgVu/50xrjcA28Zz93PIo1YXNSS4yuM4phuBv5IH41lPcDP3iage4XnB59z1pk3ZrvcBOnQ/rUMt5hhgkj8hWVJe5J3vnA+XtVWS86AsMZ6Uegrmu92+4kEYPUUjXDYyCMj171iSXiqSCeRUb3A8gzBwFB2k7u9PlY+ZG011gM3APU81C16GQYYhgelYD6gACMgiq0t+c9S340+Qh1EdKZXMTSlgIwcFu3Paqouh13k965s3bZ61G1w7Y5qlAn2qR0jaiBkMck9OeKhl1IbcE9OgFc+0zsACelMLN6mq9mS6ptPqRH8QzSW95FNdxRz3DW8DH55SpfYPXaOtYmT3qW1t57u5jtrWN5p5W2pGg5Y+1PkRHtGdQ8WiFCB4lAJBBP2B8/wA6z/Fuo211qUBsLhriGK0hgMpQpvZFweDzTP8AhE/EH/QGvf8AviszULG6065NvfwSW9wAGMcgwQD0NNRSE5NjknyFBY/XPSrcV2R1askHj3p6SY69KLApNG5HeEEnCkdwasx3YbJBxx09K54TcnaTipUuGGD1FTyGiqG/9pGQHPHqKsCcFQCc1gR3Wc4GKsRXPIAb8zUuJaqI3IpCmOeD+tWxKrAEDn0PesGO5xwWBz6VZSQMDsYke/apsXzXNczbRu6+tS+YnRjuXH8JrJiuQu5XJLcbSBx+JpxmCkDPyn0osNM1kkAVR128A1Os2R04rFW6wAGPFWBOMfIwPPrSsO5qpOejA04zAA1kfaGVslsj0FSJdc/Ifm9zSsVc0jJhgV5FOErBjzyPXpWbFclxtz8uc4J4zU6ygAdx3pWDmNFJicJHjOBzUkUhx85z/WsxJtpAJ5PTPpUizgMcZ/z3p2E5XNPzmyQDjHNBl3N8xA96zfNAH3+B70wXCl8bvl9aCbmlGxBPz5BPTFWfMPHzAY9KxftIA44I75pqXbBGy2V74HSklYd7m0Z8nnnFI0qgAZ+U9gKxjeNt4HP8qf8AbgUXcpBx82TnJpgX3kKs20A57+lRLcSEnJVQOeetZr3uHIdG244x61EJX8zO45NMdzX+2EEqrAg8UhmLN83SskzD73f0z0pguSXVc8k8c4osK5rvKoYlTn61C0vzD5j+VZUl2zsQGx9Kjeck8tk9zSsF7G39o24+aonuN5OWwe1YrXeBgkE9gTUD3hA+9RYm5tyTgKSze3AqKW6AUbSGHrWHLe8cuMelQveRiLfvXrjG7nP0p8ouc3WvBs4JDHg8dqhS6BZlkcLhcj39q599QOzbuyOoFVmvScjpxxV8hLqI6Jrxhyenoe1QteKAxLAEelc99tbDdeRjrUDTOScnPFPkJdU3pNQXBAbkVVk1JmGCQQOlY5ZiaDn1qlAj2jL735PeoZLt26mqtLTUUS5NkvnvkE8gdj3qNmLMW4HtSUU7IV2GTTT1pTRTsIKKKKACiikoAWhdwYFNwYHIK9QfaipLa5ms7mK5tZWiniYMjr1UigCzqeoXeo3X2m4EgmKqrsgYeYQMbj/tHvVFixb95uz/ALWc/rXb3+qeMb2QXdlbazbwuisyJGSm7HJQYyFPXHbNchqV5d39282ozSzXIARml+8McYP0oAq0UnbFFIBaXNJRQA9GG4BiQO5AzT1kxUPelzTAsxynsalS6kjbKsQfQ1RBxgg80pYnqeaVkNNmsL92xvxT1vdud2cdiKx9x9aeHOPSlylKbNlLxexGCPWpob7a4YqGToRnBNYIkxSicjvS5SvatHRpfnBz27Y5p73McjZH61zqXR9cEdDTvtR6E9felyj9qdGs5AJzlfUHpUsdyCCD19c1zS3RXgcg077S69eDS5SvaXOpFwx6E8epo87OM53DuD2rmBfyhcH8DQL6XnMhwe1LlD2iOkNwVYEn73qaBdqeTww965v7YePX1zTvtuSC7Zz1wKOUPaHR/awwIyBxxzUX2lVAJJGea59rwk8Hj9aZ9qJGCaOQPaHRyXseAVfd2wKT7eG6Z3d65s3R2nnimNcscdvpT5Be0OkF6ckdc9O5ofUP3ZV25HYDr+NcybluxOfUGmtM394mjlF7Q6Jr5vK5dME8EfeNQNegK24Zz0yawvMOaGldgAWJA6A9qfKL2hrvfkAbW+tMXUSvBAZQc+lZDMT16UZ460+VE87L7XpY53Y/Gomumz97PNVc0U+VC5mTSTFmPNRtIWbJ5NMop2FccGIIPB55B70mTnJpM0Zp2ELRSZooAM0ZoooAM0ZoooAM0ZoooAQ9KM0GigBaTNHakFACmkoooAXNX9Au4bDXLG7uozJBDKHdQATj1APUjr+FZ9aPhxbRtf08ajs+xmZfM8w4X23e2cZ9qANea1ee4a5HjK0cM27zZJplk+pXGQfas3xXfQajq/nW0jThYY4nuGTaZ3VcGQjtn35rXu7r+0Ly40fxTFa2l4CRb3kMaoIG6hW28NGcjnt1qn47hNtrFrA6orx2Fur7CCCwQZII6/WkBzHmH0FG8+gplFAh4kPtS+Yfao6KBknmH2o3n2plFAEgY+1LuPtUdLQA/cfal3VHS0XAfuNGabmikMfuNG44xmm5paAshc0u4nqT9abRmgLEm8nHzHgYo3H1OKZSigY7J9aM+9NooDQcCaAT/Sm0ooCyFx70D60lAPNAWQ6kI96N1KDmgLIQD3ox70tFAWQY96THvS0UBZBt96NvvRQaAsg2+9G33oooCyDFGKKKNQsgxTdvvTqKA0Exx1pNvvTqTNAaCYpPxp2aKBDaKdRQAmPekI96U+1JQAdqQ/WlozS1ATn1ooop6iDn1pOScDJzxxQa0/DDIuv2RkKL852M/wB0SYOwn2DbaAJB4evvljd7SO6OMWslyizHPQbSeD7HmsmVHikaOVWSRDtZXGCpHYg9K6/7PEus21xM9glpHEIrqCfHnFsYlVkPzNIW3YYe2DxWN4ryNTiWY5uktoluCTlvMC8hj/eAwD7g0AYNFFFMQUUUUDCloooAKWiigBRS0UUAApaKKQBTqKKACiiigaFooooAKWiigYUUUUAFFFFABS0UUAOooooAKKKKACiiigAooooAKKKKACiiigApF6GiigAFFFFAgpKKKAEooooAKSiigGFIaKKBBSEZoooA1E8Q6qiIouyWVdqysimRR6ByNw/OstmLMWYksTkknJJoooA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Keratosis pilaris. Multiple mildly erythematous follicularly-based papules are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_3_26672=[""].join("\n");
var outline_f26_3_26672=null;
var title_f26_3_26673="CPAM newborn CT scan";
var content_f26_3_26673=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography of the chest in a newborn with congenital pulmonary airway malformation (CPAM)*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography of the chest in a newborn with type 2 congenital pulmonary airway malformation (CPAM). Multiple small cysts are demonstrated in the apex of the right upper lobe.",
"    <div class=\"footnotes\">",
"     * CPAM was previously known as congenital cystic adenomatoid malformation (CCAM).",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher M Oermann, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_3_26673=[""].join("\n");
var outline_f26_3_26673=null;
var title_f26_3_26674="IDUS showing CBD PD";
var content_f26_3_26674=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraductal ultrasound demonstrating a normal common bile duct and pancreatic duct",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal intraductal ultrasound examination demonstrating the common bile duct (CBD) and pancreatic duct (PD).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drs. Michael J Levy, Enrique Vazquez-Sequeiros, and Maurits J Wiersema.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_3_26674=[""].join("\n");
var outline_f26_3_26674=null;
var title_f26_3_26675="Red marrow sickle cell";
var content_f26_3_26675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F51573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F51573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distribution of bone marrow in a child with sickle cell disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 434px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The scintigram on the left shows the distribution of erythropoietic (red) marrow in a child with sickle cell disease, as demonstrated by the uptake of transferrin-bound radioactive iron three hours after injection. The child's whole body outline is shown in the photo on the right for localization purposes. Note the marked uptake of isotope in the spine, pelvis, and ribs, a pattern also seen in the adult. Unlike the adult, however, there is also erythropoietic marrow in the skull, jaws, arms, and legs. The latter uptake is most prominent in the region of the knee and ankle joints. The child was not having a painful crisis at the time of this study.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by Stephen A. Landaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_3_26675=[""].join("\n");
var outline_f26_3_26675=null;
var title_f26_3_26676="Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Patient drug information";
var content_f26_3_26676=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/30/18919?source=see_link\">",
"     see \"Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/27/8630?source=see_link\">",
"     see \"Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bebulin&reg; VH;",
"     </li>",
"     <li>",
"      Profilnine&reg; SD",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hemophilia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691426",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat bleeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702098",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to Factor IX or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698078",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever and chills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gallbladder disease, blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695961",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be given at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Most of the time, this drug will be given to you in a doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug is given at home, store unopened vials in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11490 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-218.189.88.190-EF2F3CD7BB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_3_26676=[""].join("\n");
var outline_f26_3_26676=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169679\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019295\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019297\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019296\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019301\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019302\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019304\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019299\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019300\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019305\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019306\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/30/18919?source=related_link\">",
"      Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/27/8630?source=related_link\">",
"      Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_3_26677="Conduction in right bundle branch block";
var content_f26_3_26677=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/56402/condrbb_conv.mp4?title=Conduction+in+right+bundle+branch+block\" style=\"width:408px;height:366px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Development of right bundle branch block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The sinus node generates an impulse that first activates the atria (becomes red) and then the atrioventricular node. The impulse is then conducted along the bundle of His to the left bundle (becomes red) while it fails to activate the right bundle (which remains blue). As a result, the left ventricle depolarizes normally (becomes red) while right ventricular activation is delayed and abnormal, occurring by impulses from the left ventricle. This accounts for the R' seen in the V1 and the S-wave in V6. Green represents repolarization and the T-wave on the ECG.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy Entropy, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_3_26677=[""].join("\n");
var outline_f26_3_26677=null;
var title_f26_3_26678="Silicoproteinosis pathology";
var content_f26_3_26678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute silicosis (silicoproteinosis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is prominent alveolar filling with eosinophilic proteinaceous material. Mild interstitial thickening is also present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. J Parker.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_3_26678=[""].join("\n");
var outline_f26_3_26678=null;
var title_f26_3_26679="Evaluation of couples with recurrent pregnancy loss";
var content_f26_3_26679=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of couples with recurrent pregnancy loss",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/3/26679/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/3/26679/contributors\">",
"     Togas Tulandi, MD, MHCM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/3/26679/contributors\">",
"     Haya M Al-Fozan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/3/26679/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/3/26679/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/3/26679/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/3/26679/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/3/26679/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Couples with recurrent pregnancy loss (RPL) require empathy and understanding as early pregnancy loss is an emotionally traumatic experience, similar to that associated with stillbirth or neonatal death. In addition, evaluation can be frustrating and difficult because the etiology of their RPL may not be determined and there are few evidence-based diagnostic and treatment strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;RPL is classically defined as the occurrence of three or more consecutive losses of clinically recognized pregnancies prior to the 20th week of gestation (ectopic and molar pregnancies are not included). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/6/8298?source=see_link\">",
"     \"Definition and etiology of recurrent pregnancy loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a general consensus that healthy women should not undergo extensive evaluation after a single first trimester or early second trimester spontaneous miscarriage, given these are relatively common, sporadic events: miscarriage occurs in about 10 to 15 percent of clinically recognized pregnancies under 20 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/3\">",
"     3",
"    </a>",
"    ]. In prospective studies, the overall risk of miscarriage in the next pregnancy remains about 15 percent after one miscarriage, but rises to 17 to 31 percent after two consecutive miscarriages and to 25 to 46 percent after three or more miscarriages. Based on these and similar data, most experts initiate evaluation and treatment of RPL after either two or three consecutive miscarriages [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to remember that most women with RPL have a good prognosis for eventually having a successful pregnancy, even when a definitive diagnosis is not made and no treatment initiated. In one representative study, the overall live birth rates after normal and abnormal diagnostic evaluations for RPL were 77 and 71 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/6\">",
"     6",
"    </a>",
"    ]. In another study, 8 of 17 women with six or more consecutive unexplained miscarriages subsequently achieved a successful pregnancy outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HISTORY AND PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The minimum diagnostic workup of couples with RPL consists of a complete medical, surgical, genetic, and family history and a physical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should include a description of the gestational age and characteristics (eg, anembryonic pregnancy, live embryo) of all previous pregnancies. Gestational age is important because RPL typically occurs at a similar gestational age in consecutive pregnancies and the most common causes of RPL vary by trimester. As an example, miscarriage related to chromosomal and endocrine defects tends to occur earlier in gestation than losses due to anatomic or immunological abnormalities; however, there is significant overlap.",
"   </p>",
"   <p>",
"    Additional information to consider:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Has there been uterine instrumentation, which may have caused intrauterine adhesions? (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26101?source=see_link\">",
"       \"Intrauterine adhesions\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Are the menstrual cycles normal? Abnormalities in cycle length may be due to endocrine dysfunction. Is there galactorrhea, which also suggests endocrine dysfunction (hyperprolactinemia)?",
"     </li>",
"     <li>",
"      Is there a history of congenital abnormalities or karyotypic abnormalities, which may be heritable? Was",
"      <span class=\"nowrap\">",
"       embryonic/fetal",
"      </span>",
"      cardiac activity ever detected? RPL prior to detection of embryonic cardiac activity also suggests a chromosomal abnormality. Does the family history display patterns of disease consistent with a strong genetic influence? Is consanguinity present?",
"     </li>",
"     <li>",
"      Is there exposure to environmental toxins, which may be lethal to developing embryos?",
"     </li>",
"     <li>",
"      Is there a history of venous or arterial thrombosis suggestive of antiphospholipid syndrome?",
"     </li>",
"     <li>",
"      What information is available from previous laboratory, pathology, and imaging studies?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination should include a general physical assessment with attention to signs of endocrinopathy (eg, hirsutism, galactorrhea) and pelvic organ abnormalities (eg, uterine malformation, cervical laceration).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Most useful tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Karyotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Karyotyping of couples is part of the evaluation of RPL, despite the low yield of abnormality, cost, and limited prognostic value [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/4,8,9\">",
"     4,8,9",
"    </a>",
"    ]. The purpose is to detect balanced reciprocal or Robertsonian translocations or mosaicism that could be passed to the fetus unbalanced.",
"   </p>",
"   <p>",
"    Because of the low likelihood of an abnormal karyotype in couples with RPL, this is the last test we obtain and only if the preceding work-up yielded negative results. A review of cytogenetic findings in 79 published surveys of couples with two or more pregnancy losses (n = 8208 women and 7834 men) observed the overall prevalence of major chromosome abnormalities was 2.9 percent, which is five to six times higher than that of the general adult population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/10\">",
"     10",
"    </a>",
"    ]. Approximately one-half of the abnormalities were balanced reciprocal translocations, one-quarter were Robertsonian translocations, and one-tenth were sex chromosome mosaicisms in females; the rest consisted of inversions and other sporadic abnormalities. A large database subsequently reported similar findings: 4.7 percent of couples with two or more spontaneous abortions included one carrier of a structural chromosomal abnormality, usually a translocation or inversion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chromosomal abnormalities detectable in parental peripheral blood preparations are an indirect and limited indicator of fetal karyotype [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Therefore, many experts also recommend karyotype of the abortus or products of conception. A normal karyotype suggests (but does not prove) a maternal environmental factor is the cause of pregnancy loss, while an abnormal karyotype (aneuploidy) is usually a sufficient explanation for a nonviable pregnancy. In some cases, karyotype analysis of the abortus indicates a normal chromosomal pattern, but more detailed array comparative genomic hybridization demonstrates major abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/14\">",
"     14",
"    </a>",
"    ]. Structural chromosomal rearrangements in the abortus may be inherited or sporadic, and are an indication for parental karyotype analysis if not already done.",
"   </p>",
"   <p>",
"    If the abortus specimen does not grow in culture, a conventional karyotype cannot be determined. Cells from chromosomally abnormal abortuses, especially trisomy 7 and triploidies, are less likely to grow in culture, thereby skewing the results of cohort studies of the frequency of aneuploidy in products of conception from spontaneously aborted pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/15\">",
"     15",
"    </a>",
"    ]. Array comparative genomic hybridization does not require dividing cells, and therefore can be useful in fetal demise with culture failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Uterine assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anatomic causes of RPL are typically diagnosed using hysterosalpingography (HSG) or sonohysterography. We prefer the latter because it is more accurate than HSG and gives more information than sonography alone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Hysteroscopy, laparoscopy, or magnetic resonance imaging (MRI) can also be performed, as needed, but are more expensive and (except for MRI) more invasive than sonohysterography. Therefore, they are used as second-line tests when additional information is required to determine a diagnosis. Ultrasonography is particularly useful in pregnant women, in whom the other tests are relatively or absolutely contraindicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of congenital anomalies of the uterus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Sonohysterography",
"      </strong>",
"      &mdash; Sonohysterography delineates the internal contours of the uterine cavity and provides concomitant sonographic visualization of the outer surface and wall of the uterus. It provides information on tubal patency and can distinguish between the septate and bicornuate uterus [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/19\">",
"       19",
"      </a>",
"      ]. In comparative studies, sonohysterography was more accurate than HSG and provided more information about uterine abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40823?source=see_link\">",
"       \"Saline infusion sonohysterography\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hysterosalpingogram",
"      </strong>",
"      &mdash; HSG provides some of the same information as sonohysterography. It provides more information about tubal anatomy and patency; however, it does not evaluate the outer contour of the uterus, therefore it cannot reliably differentiate between a septate and a bicornuate uterus unless a laparoscopy to view the uterine fundus is also performed [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24150?source=see_link\">",
"       \"Hysterosalpingography\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hysteroscopy",
"      </strong>",
"      &mdash; Hysteroscopy is considered the standard for diagnosis of intrauterine abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/20,22\">",
"       20,22",
"      </a>",
"      ]. In addition, treatment of many intrauterine lesions can be performed during the procedure. However, it also cannot reliably differentiate between a septate and a bicornuate uterus unless a laparoscopy to view the uterine fundus is also performed. Because of its cost and invasiveness, hysteroscopic uterine assessment is usually reserved for patients who have had a nondiagnostic evaluation of RPL or those in whom intrauterine pathology is suspected and operative hysteroscopy may be necessary. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link\">",
"       \"Overview of hysteroscopy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Ultrasound",
"      </strong>",
"      &mdash; Transvaginal ultrasound (TVS) and transabdominal ultrasound are useful for making the diagnosis of a septate uterus and renal abnormalities, and provide information about the presence and location of uterine myomas [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/20,23\">",
"       20,23",
"      </a>",
"      ]. TVS also provides information about the presence and location of uterine myomas and, in pregnancy, the possibility of cervical insufficiency and assessment of fetal viability [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/24\">",
"       24",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Three-dimensional ultrasound, where available, is accurate in diagnosing uterine anomalies [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/25\">",
"       25",
"      </a>",
"      ]. In contrast to two-dimensional ultrasound, but similar to magnetic resonance imaging, it allows visualization of both the uterine cavity and the external contour of the uterus [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Magnetic resonance imaging",
"      </strong>",
"      &mdash; MRI is useful for distinguishing between a septate and bicornuate uterus suspected on ultrasonography or HSG. It is less invasive and less costly than laparoscopy for this purpose. As an example, a study of 26 women comparing MRI (n = 26), TVS (n = 14), and HSG (n = 20) for classification of m&uuml;llerian duct anomalies reported that MRI diagnosed 24 of 24 cases correctly, TVS was correct in 11 of 12 cases, and HSG was correct in only four cases [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/23\">",
"       23",
"      </a>",
"      ]. For diagnosis of septate uterus, MRI performed better than two-dimensional TVS (sensitivity and specificity of 100 percent for MRI versus 100 and 80 percent, respectively, for TVS). Three-dimensional ultrasound is also reliable, but simpler than MRI for distinguishing septate from bicornuate uteri.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Anticardiolipin antibodies and lupus anticoagulant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The minimum immunology work-up for women with RPL is measurement of anticardiolipin antibody (IgG and IgM) and lupus anticoagulant. Both tests should be done twice, six to eight weeks apart, because a low to mid positive level can be due to viral illness and revert to normal. The anticardiolipin antibody titer is considered elevated if medium or high titers of both IgG and IgM isotypes are present in blood [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/27\">",
"     27",
"    </a>",
"    ]. The detection of the lupus anticoagulant is generally based upon an activated partial thromboplastin time, kaolin plasma clotting time, or dilute Russell viper venom test time [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\", section on 'Classification criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Thyroid function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid function should be assessed in women with clinical manifestations or a personal history of thyroid disease. Screening asymptomatic women for subclinical thyroid dysfunction is controversial. We feel screening is reasonable since there is evidence of an increased risk of miscarriage in women with subclinical hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/30\">",
"     30",
"    </a>",
"    ] and in euthyroid women with thyroid peroxidase (TPO) antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Meta-analyses of case-control and cohort studies have found that the presence of TPO autoantibodies in euthyroid women is associated with an increased risk of spontaneous miscarriage that is two to three times higher than in women without these antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In addition, meta-analysis of two randomized trials of the effect of thyroid replacement in these women found treatment was associated with a significant reduction in risk of miscarriage (relative risk 0.48, 95% CI 0.25-0.92) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/32\">",
"     32",
"    </a>",
"    ]; however, there were methodological limitations to these trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of thyroid disease in pregnancy\", section on 'Thyroid peroxidase antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Less useful tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1414862\">",
"    <span class=\"h3\">",
"     Evaluation of ovarian reserve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian reserve can be evaluated by measurement of antral follicle count (AFC), basal serum follicle stimulating hormone (FSH), anti-m&uuml;llerian hormone (AMH), or inhibin-B. Evaluation of ovarian reserve using a day 3 FSH concentration can be considered in the evaluation of RPL in women of any age. If measurement of FSH levels was limited to women over 34 years of age, one quarter of those with elevated values would be missed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/6/8298?source=see_link&amp;anchor=H32#H32\">",
"     \"Definition and etiology of recurrent pregnancy loss\", section on 'Decreased ovarian reserve'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adequate ovarian reserve is established using either a cycle day 3 FSH concentration less than 15",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    or a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    challenge test (ie, clomiphene citrate 100 mg daily is administered on cycle days 5 to 9. An FSH level less than 15",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    on both days 3 and 10 is normal). High day 3 serum estradiol concentrations of over 80",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    are also associated with reduced oocyte numbers. In one study, FSH or estradiol levels, or both, were elevated in 58 percent of women with unexplained RPL, but also in 19 percent of controls with a known cause for their RPL [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link&amp;anchor=H6#H6\">",
"     \"In vitro fertilization\", section on 'Adequate ovarian reserve'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1414819\">",
"    <span class=\"h3\">",
"     Medical work-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional laboratory tests may be indicated in women with clinical manifestations suggestive of a medical disorder. However, there are many such medical disorders and testing for all of these disorders should not be a part of the routine evaluation of otherwise asymptomatic women with RPL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/6/8298?source=see_link\">",
"     \"Definition and etiology of recurrent pregnancy loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1414783\">",
"    <span class=\"h3\">",
"     Hypercoagulable state",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a large and contradictory literature on the association between maternal inherited thrombophilia and recurrent spontaneous abortion occurring in the first trimester. Evaluation for an inherited thrombophilia can be considered in rare cases of recurrent, unexplained late fetal loss (after nine weeks of gestation) associated with evidence of placental ischemia and infarction and maternal vessel thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Culture and serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine cervical cultures for Chlamydia sp. or Mycoplasma sp., vaginal evaluation for bacterial vaginosis, and toxoplasmosis serology are not useful in the evaluation of RPL among otherwise healthy women [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Autoantibodies and immune function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies have reported the presence of autoantibodies in women with RPL [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/34\">",
"     34",
"    </a>",
"    ]. Only anticardiolipin antibody and lupus anticoagulant have been clearly associated with pregnancy loss. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Anticardiolipin antibodies and lupus anticoagulant'",
"    </a>",
"    above.) The pregnancy outcome of women with and without antinuclear antibody (ANA) is the same [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/35\">",
"     35",
"    </a>",
"    ]; available data do",
"    <strong>",
"     not",
"    </strong>",
"    support testing women with RPL for ANA. With the exception of anticardiolipin antibody and lupus anticoagulant, we recommend not testing women with known autoimmune diseases or unexplained RPL for autoantibodies for the purpose of attempting to predict their risk of pregnancy loss.",
"   </p>",
"   <p>",
"    Selection of appropriate tests for diagnosis of immune-based RPL also requires further investigation and validation. Results from HLA typing, mixed lymphocytotoxic antibody tests and mixed lymphocyte culture reactions are not predictive of pregnancy outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/36\">",
"     36",
"    </a>",
"    ]. The role of differences in the CD56+ population of cells and alterations in cytokines produced by monocytes, CD4+ cells, and endometrium remains investigational [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36201?source=see_link\">",
"     \"Immunology of the maternal-fetal interface\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Screening for diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for diabetes mellitus should be limited to women with clinical manifestations of the disease. Only poorly controlled diabetes is associated with miscarriage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=see_link&amp;anchor=H5#H5\">",
"     \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\", section on 'Spontaneous abortion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Progesterone level",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single or multiple serum progesterone levels are not predictive of future pregnancy outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Endometrial biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of a luteal phase defect had been based upon results of endometrial biopsy. However, high quality data show that this test is not predictive of fertility status [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26679/abstract/40\">",
"     40",
"    </a>",
"    ]; therefore, it is no longer recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=see_link&amp;anchor=H20#H20\">",
"     \"Evaluation of female infertility\", section on 'Endometrial biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37976?source=see_link\">",
"     \"Management of couples with recurrent pregnancy loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/62/20450?source=see_link\">",
"       \"Patient information: Repeated miscarriage (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We evaluate women for recurrent pregnancy loss (RPL) after two or three consecutive miscarriages. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Candidates for evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The history should include a description of the gestational age and characteristics (eg, anembryonic pregnancy, live embryo) of all previous pregnancies. Gestational age is important because RPL typically occurs at a similar gestational age in consecutive pregnancies and the most common causes of RPL vary by trimester. Physical examination should include a general physical assessment with attention to signs of endocrinopathy (eg, hirsutism, galactorrhea) and pelvic organ abnormalities (eg, uterine malformation, cervical laceration). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'History and physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the following tests for the initial evaluation of women with RPL:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Sonohysterography for assessment of uterine abnormalities",
"     </li>",
"     <li>",
"      Anticardiolipin antibody (IgG and IgM) titer and lupus anticoagulant performed twice, six to eight weeks apart",
"     </li>",
"     <li>",
"      Thyroid stimulating hormone (TSH) and thyroid peroxidase antibodies",
"     </li>",
"     <li>",
"      Parental karyotype and karyotype of the abortus if the above examinations are normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional testing depends upon the diagnosis suggested by the history, physical examination, and laboratory results (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Evaluation'",
"    </a>",
"    above)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/1\">",
"      Trott EA, Russell JB, Plouffe L Jr. A review of the genetics of recurrent pregnancy loss. Del Med J 1996; 68:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/2\">",
"      Plouffe L Jr, White EW, Tho SP, et al. Etiologic factors of recurrent abortion and subsequent reproductive performance of couples: have we made any progress in the past 10 years? Am J Obstet Gynecol 1992; 167:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/3\">",
"      Stirrat GM. Recurrent miscarriage. Lancet 1990; 336:673.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Management of recurrent early pregnancy loss. ACOG practice bulletin no. 24, American College of Obstetricians and Gynecologists, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/5\">",
"      Jaslow CR, Carney JL, Kutteh WH. Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses. Fertil Steril 2010; 93:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/6\">",
"      Laufer MR, Ecker JL, Hill JA. Pregnancy outcome following ultrasound-detected fetal cardiac activity in women with a history of multiple spontaneous abortions. J Soc Gynecol Investig 1994; 1:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/7\">",
"      Clifford K, Rai R, Regan L. Future pregnancy outcome in unexplained recurrent first trimester miscarriage. Hum Reprod 1997; 12:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/8\">",
"      Clark DA, Daya S, Coulam CB, Gunby J. Implication of abnormal human trophoblast karyotype for the evidence-based approach to the understanding, investigation, and treatment of recurrent spontaneous abortion. The Recurrent Miscarriage Immunotherapy Trialists Group. Am J Reprod Immunol 1996; 35:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/9\">",
"      Carp H, Guetta E, Dorf H, et al. Embryonic karyotype in recurrent miscarriage with parental karyotypic aberrations. Fertil Steril 2006; 85:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/10\">",
"      Tharapel AT, Tharapel SA, Bannerman RM. Recurrent pregnancy losses and parental chromosome abnormalities: a review. Br J Obstet Gynaecol 1985; 92:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/11\">",
"      De Braekeleer M, Dao TN. Cytogenetic studies in couples experiencing repeated pregnancy losses. Hum Reprod 1990; 5:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/12\">",
"      Hassold T, Jacobs PA, Pettay D. Cytogenetic studies of couples with repeated spontaneous abortions of known karyotype. Genet Epidemiol 1988; 5:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/13\">",
"      Carp H, Feldman B, Oelsner G, Schiff E. Parental karyotype and subsequent live births in recurrent miscarriage. Fertil Steril 2004; 81:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/14\">",
"      Schaeffer AJ, Chung J, Heretis K, et al. Comparative genomic hybridization-array analysis enhances the detection of aneuploidies and submicroscopic imbalances in spontaneous miscarriages. Am J Hum Genet 2004; 74:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/15\">",
"      Fritz B, Hallermann C, Olert J, et al. Cytogenetic analyses of culture failures by comparative genomic hybridisation (CGH)-Re-evaluation of chromosome aberration rates in early spontaneous abortions. Eur J Hum Genet 2001; 9:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/16\">",
"      ACOG Committee Opinion No. 446: array comparative genomic hybridization in prenatal diagnosis. Obstet Gynecol 2009; 114:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/17\">",
"      Goldberg JM, Falcone T, Attaran M. Sonohysterographic evaluation of uterine abnormalities noted on hysterosalpingography. Hum Reprod 1997; 12:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/18\">",
"      Soares SR, Barbosa dos Reis MM, Camargos AF. Diagnostic accuracy of sonohysterography, transvaginal sonography, and hysterosalpingography in patients with uterine cavity diseases. Fertil Steril 2000; 73:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/19\">",
"      Keltz MD, Olive DL, Kim AH, Arici A. Sonohysterography for screening in recurrent pregnancy loss. Fertil Steril 1997; 67:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/20\">",
"      Homer HA, Li TC, Cooke ID. The septate uterus: a review of management and reproductive outcome. Fertil Steril 2000; 73:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/21\">",
"      Reuter KL, Daly DC, Cohen SM. Septate versus bicornuate uteri: errors in imaging diagnosis. Radiology 1989; 172:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/22\">",
"      Malhotra N, Sood M. Role of hysteroscopy in infertile women. J Indian Med Assoc 1997; 95:499, 525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/23\">",
"      Pellerito JS, McCarthy SM, Doyle MB, et al. Diagnosis of uterine anomalies: relative accuracy of MR imaging, endovaginal sonography, and hysterosalpingography. Radiology 1992; 183:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/24\">",
"      Ansari AH, Kirkpatrick B. Recurrent pregnancy loss. An update. J Reprod Med 1998; 43:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/25\">",
"      Caliskan E, Ozkan S, Cakiroglu Y, et al. Diagnostic accuracy of real-time 3D sonography in the diagnosis of congenital Mullerian anomalies in high-risk patients with respect to the phase of the menstrual cycle. J Clin Ultrasound 2010; 38:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/26\">",
"      Bermejo C, Mart&iacute;nez Ten P, Cantarero R, et al. Three-dimensional ultrasound in the diagnosis of M&uuml;llerian duct anomalies and concordance with magnetic resonance imaging. Ultrasound Obstet Gynecol 2010; 35:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/27\">",
"      Roubey RA. Update on antiphospholipid antibodies. Curr Opin Rheumatol 2000; 12:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/28\">",
"      Stephenson MD. Frequency of factors associated with habitual abortion in 197 couples. Fertil Steril 1996; 66:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/29\">",
"      Vinatier D, Dufour P, Cosson M, Houpeau JL. Antiphospholipid syndrome and recurrent miscarriages. Eur J Obstet Gynecol Reprod Biol 2001; 96:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/30\">",
"      Negro R, Schwartz A, Gismondi R, et al. Increased pregnancy loss rate in thyroid antibody negative women with TSH levels between 2.5 and 5.0 in the first trimester of pregnancy. J Clin Endocrinol Metab 2010; 95:E44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/31\">",
"      Chen L, Hu R. Thyroid autoimmunity and miscarriage: a meta-analysis. Clin Endocrinol (Oxf) 2011; 74:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/32\">",
"      Thangaratinam S, Tan A, Knox E, et al. Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. BMJ 2011; 342:d2616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/33\">",
"      Trout SW, Seifer DB. Do women with unexplained recurrent pregnancy loss have higher day 3 serum FSH and estradiol values? Fertil Steril 2000; 74:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/34\">",
"      Cervera R, Balasch J. Autoimmunity and recurrent pregnancy losses. Clin Rev Allergy Immunol 2010; 39:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/35\">",
"      Harger JH, Rabin BS, Marchese SG. The prognostic value of antinuclear antibodies in women with recurrent pregnancy losses: a prospective controlled study. Obstet Gynecol 1989; 73:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/36\">",
"      Coulam CB. Immunologic tests in the evaluation of reproductive disorders: a critical review. Am J Obstet Gynecol 1992; 167:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/37\">",
"      Laird SM, Tuckerman EM, Cork BA, et al. A review of immune cells and molecules in women with recurrent miscarriage. Hum Reprod Update 2003; 9:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/38\">",
"      Clark DA. Is there any evidence for immunologically mediated or immunologically modifiable early pregnancy failure? J Assist Reprod Genet 2003; 20:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/39\">",
"      Ogasawara M, Kajiura S, Katano K, et al. Are serum progesterone levels predictive of recurrent miscarriage in future pregnancies? Fertil Steril 1997; 68:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26679/abstract/40\">",
"      Peters AJ, Lloyd RP, Coulam CB. Prevalence of out-of-phase endometrial biopsy specimens. Am J Obstet Gynecol 1992; 166:1738.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5436 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-85.214.214.87-D5DBC4741A-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_3_26679=[""].join("\n");
var outline_f26_3_26679=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CANDIDATES FOR EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HISTORY AND PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Most useful tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Karyotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Uterine assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Anticardiolipin antibodies and lupus anticoagulant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Thyroid function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Less useful tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1414862\">",
"      - Evaluation of ovarian reserve",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1414819\">",
"      - Medical work-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1414783\">",
"      - Hypercoagulable state",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Culture and serology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Autoantibodies and immune function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Screening for diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Progesterone level",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Endometrial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=related_link\">",
"      Clinical manifestations and diagnosis of congenital anomalies of the uterus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/6/8298?source=related_link\">",
"      Definition and etiology of recurrent pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=related_link\">",
"      Evaluation of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24150?source=related_link\">",
"      Hysterosalpingography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36201?source=related_link\">",
"      Immunology of the maternal-fetal interface",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26101?source=related_link\">",
"      Intrauterine adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37976?source=related_link\">",
"      Management of couples with recurrent pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=related_link\">",
"      Overview of hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/62/20450?source=related_link\">",
"      Patient information: Repeated miscarriage (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=related_link\">",
"      Pregnancy risks in women with type 1 and type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40823?source=related_link\">",
"      Saline infusion sonohysterography",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_3_26680="Congenital ureteropelvic junction obstruction";
var content_f26_3_26680=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Congenital ureteropelvic junction obstruction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/3/26680/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/3/26680/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/3/26680/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/3/26680/contributors\">",
"     Duncan Wilcox, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/3/26680/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/3/26680/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/3/26680/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ureteropelvic junction (UPJ) obstruction is a partial or total blockage of the flow of urine that occurs where the ureter enters the kidney. The etiology of UPJ obstruction includes both congenital and acquired conditions. UPJ obstruction is the most common pathologic cause of antenatally detected hydronephrosis.",
"   </p>",
"   <p>",
"    The epidemiology, pathophysiology, clinical features, and management of congenital UPJ obstruction will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of ureteropelvic junction (UPJ) obstruction is 1 in 500 live births screened by routine antenatal ultrasound; however, not all cases require surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. UPJ obstruction is the most common anatomical cause of antenatal hydronephrosis. In one retrospective study, functionally significant UPJ obstruction was noted in 1 in 1500 fetuses screened by antenatal ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Boys are affected with UPJ obstruction more commonly than are girls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/3\">",
"     3",
"    </a>",
"    ]. Lesions are found more frequently on the left than on the right side. The reported rate of bilateral involvement ranges from 10 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital ureteropelvic junction (UPJ) obstruction is caused by anatomic lesions or functional disturbances that restrict urinary flow across the UPJ, resulting in hydronephrosis (",
"    <a class=\"graphic graphic_figure graphicRef55146 \" href=\"UTD.htm?26/33/27156\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef77143 \" href=\"UTD.htm?16/25/16787\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/1\">",
"     1",
"    </a>",
"    ]. Most cases are thought to be due to partial obstruction, because complete obstruction results in rapid destruction of the kidney. In some cases, partial obstruction may also lead to progressive deterioration of renal function. However, in many infants, an equilibrium state may develop in which renal function remains stable.",
"   </p>",
"   <p>",
"    Development of the equilibrium state resulting in stable renal function depends on:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Urinary rate and output",
"     </li>",
"     <li>",
"      Anatomy and degree of UPJ obstruction",
"     </li>",
"     <li>",
"      Compliance of the renal pelvis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the fetus and infant, the pelvis, because of its increased compliance, can stretch and thereby accommodate large volumes of urine, which results in pelvic dilatation (hydronephrosis). The large capacity volume of a stretched pelvis decreases the risk of high intrapelvic pressure. As a result, kidneys with a large intrarenal pelvis are less vulnerable to damage from obstruction than those with a small intrarenal pelvis, especially during diuresis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital ureteropelvic junction (UPJ) obstruction is usually caused by intrinsic stenosis of the proximal ureter, and less commonly by extrinsic compression of the UPJ.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Intrinsic narrowing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases of UPJ obstruction, the upper segment of the ureter is narrowed or kinked, resulting in obstruction of urinary flow. Although the underlying mechanism is not proven, it is thought that there is an embryologic disruption of the proximal ureter that alters circular musculature development",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    collagen fibers, and composition between and around the muscular cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other causes of intrinsic UPJ obstruction, albeit rare, include valvular mucosal folds, persistent fetal ureteral convolutions, and ureteral polyps.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Extrinsic compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;In about 10 percent of pediatric UPJ obstruction, an aberrant or accessory renal artery or arterial branch may cross the lower pole of the kidney, resulting in compression of the UPJ and blockage of urinary flow (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80130 \" href=\"UTD.htm?17/8/17543\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fetal and neonatal",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the developed world, where maternal ultrasound screening is commonly performed, most cases of ureteropelvic junction (UPJ) obstruction are diagnosed during the postnatal evaluation of antenatal hydronephrosis. The Society of Fetal Urology developed criteria for the diagnosis and grading of antenatal hydronephrosis based upon the degree of pelvic dilatation, number of calyces seen, and the presence and severity of parenchymal atrophy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68377 \" href=\"UTD.htm?12/57/13204\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50549 \" href=\"UTD.htm?32/46/33519\">",
"     image 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42824?source=see_link\">",
"     \"Overview of antenatal hydronephrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of antenatal screening, newborns may present with a palpable abdominal mass caused by an enlarged obstructed kidney. Other presentations include urinary tract infection, hematuria, or failure to thrive. Renal failure is an unusual presentation, and occurs in infants with a single obstructed kidney or with bilateral involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Older children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations in older children include intermittent flank pain or abdominal pain. The pain may worsen during brisk diuresis (for example, after consumption of caffeine or alcohol). These symptoms may be accompanied by nausea and vomiting, leading to an evaluation of the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/5\">",
"     5",
"    </a>",
"    ]. Children may also present with renal injury after experiencing minor trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/6\">",
"     6",
"    </a>",
"    ], hematuria, renal calculi [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/7\">",
"     7",
"    </a>",
"    ], or hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/5,8\">",
"     5,8",
"    </a>",
"    ]. In these cases, an incidental finding of hydronephrosis on ultrasound may be the first clue of the possibility of UPJ obstruction as the underlying diagnosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68377 \" href=\"UTD.htm?12/57/13204\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;UPJ obstruction may be associated with other genitourinary anomalies, such as a horseshoe kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/9\">",
"     9",
"    </a>",
"    ], or be a component or associated with a syndrome such as CHARGE syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ureteropelvic junction (UPJ) obstruction is generally suspected when imaging studies, usually ultrasonography, demonstrate hydronephrosis. The diagnosis is confirmed by diuretic renography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of UPJ obstruction present as a result of detecting hydronephrosis by prenatal ultrasonographic screening (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68377 \" href=\"UTD.htm?12/57/13204\">",
"     image 2",
"    </a>",
"    ). Although UPJ obstruction is the most common anatomical etiology of hydronephrosis, further imaging evaluation is required to differentiate UPJ obstruction from other frequent causes of antenatal hydronephrosis, such as transient and functional hydronephrosis, ureterovesical junction obstruction, and vesicoureteral reflux (VUR).",
"   </p>",
"   <p>",
"    In older children with abdominal pain and suspected UPJ obstruction, an ultrasound examination should be performed during the acute painful episode (Diettel's crisis) to demonstrate hydronephrosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80130 \" href=\"UTD.htm?17/8/17543\">",
"     image 1",
"    </a>",
"    ). The sonogram often is normal when the pain subsides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diuretic renography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretic renography (renal scan and the administration of a diuretic) is used to diagnose urinary tract obstruction. It measures the drainage time from the renal pelvis (referred to as washout) and assesses total and each individual kidney's renal function. The washout measurement correlates with the degree of obstruction. In general, a half-life greater than 20 minutes to clear the isotope from the kidney is considered indicative of obstruction.",
"   </p>",
"   <p>",
"    A more complete description of the diuretic renography is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34119?source=see_link&amp;anchor=H7#H7\">",
"     \"Postnatal management of antenatal hydronephrosis\", section on 'Diuretic renography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) is an alternative to ultrasonography in the symptomatic child (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50727 \" href=\"UTD.htm?9/9/9361\">",
"     image 4",
"    </a>",
"    ); however it is not the preferred modality due to its radiation exposure. In UPJ obstruction, the CT scan typically shows hydronephrosis without a dilated ureter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Voiding cystourethrogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;A voiding cystourethrogram (VCUG) is performed in patients with hydronephrosis to confirm the presence or absence of VUR of both the affected and contralateral kidneys. Ten percent of patients with UPJ obstruction have contralateral low-grade vesicoureteral reflux. In addition, VCUG assesses the patency of the urethra in males to detect posterior urethral valves. Identification of VUR is important because children with concurrent VUR and UPJ obstruction may be at higher risk for severe infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=see_link&amp;anchor=H7#H7\">",
"     \"Presentation, diagnosis, and clinical course of vesicoureteral reflux\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11271?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical presentation and diagnosis of posterior urethral valves\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of ureteropelvic junction (UPJ) obstruction includes other causes of hydronephrosis. Imaging studies (eg, diuretic renography, serial ultrasounds, and VCUG) differentiate UPJ obstruction from the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vesicoureteral reflux (VUR)",
"     </li>",
"     <li>",
"      Transient hydronephrosis",
"     </li>",
"     <li>",
"      Functional hydronephrosis",
"     </li>",
"     <li>",
"      Other urological anomalies including posterior urethral valves, congenital megaureter, ureterocele, and multicystic dysplastic kidney",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Newborn",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of evaluating a newborn with antenatal hydronephrosis is to identify all infants with significant renal or urinary tract abnormalities including ureteropelvic junction (UPJ) obstruction, while limiting unnecessary radiographic studies in infants with clinically insignificant findings or normal infants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34119?source=see_link&amp;anchor=H10#H10\">",
"     \"Postnatal management of antenatal hydronephrosis\", section on 'Approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Imaging studies are performed in a step-wise fashion. Decisions for further imaging depend upon the result of each study as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postnatal ultrasound &ndash; Evaluation begins with a postnatal ultrasound to confirm the presence of persistent hydronephrosis. The timing of performing imaging studies evaluation is dependent upon whether there is bilateral involvement and the severity of antenatal hydronephrosis (",
"      <a class=\"graphic graphic_algorithm graphicRef69172 \" href=\"UTD.htm?5/2/5166\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef74670 \" href=\"UTD.htm?14/15/14591\">",
"       algorithm 2",
"      </a>",
"      ). Infants with bilateral involvement or with a severe hydronephrotic solitary kidney require evaluation in the first few days of life because of the increased likelihood of significant disease and need for early intervention. In general, however, examination should be avoided in the first two days after birth, because hydronephrosis may not be detected because of extracellular fluid shifts that will underestimate the degree of hydronephrosis. Therefore, in unilateral disease regardless of severity, ultrasonography should be performed at least after 48 hours of life. We use the Society of Fetal Urology system to grade the severity of hydronephrosis from grade 0 (no hydronephrosis) to grade IV (severe hydronephrosis) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50549 \" href=\"UTD.htm?32/46/33519\">",
"       image 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Voiding cystourethrogram (VCUG) &ndash; If there is persistent, significant hydronephrosis, a VCUG is performed to detect vesicoureteral reflux, and in males, posterior urethral valves. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34119?source=see_link&amp;anchor=H10#H10\">",
"       \"Postnatal management of antenatal hydronephrosis\", section on 'Approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the VCUG is negative (no reflux) and the infant has persistent postnatal severe hydronephrosis (renal pelvis diameter &ge;15 mm), a diuretic renography is performed to detect possible obstruction. At this stage of evaluation, referral to a center with expertise in pediatric urologic care is warranted because the renal scan is an invasive procedure, requiring placement of an intravenous line and bladder catheter. In general, diuretic renography can be performed after six weeks of life because immediate surgical intervention is rarely required, and the diuretic renography is more difficult to interpret in the newborn period because of immature renal function.",
"     </li>",
"     <li>",
"      If the VCUG is negative (no reflux) and the infant has persistent postnatal hydronephrosis that is not severe (renal pelvis diameter &lt;15 mm), a follow-up ultrasound is performed at three months of age to monitor the degree of hydronephrosis. If dilatation progresses to the threshold of renal pelvis diameter &ge;15 mm, a diuretic renography should be obtained at that time to determine the relative function of the affected kidney.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Older child",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography should be performed in older patients with symptoms that are suggestive of UPJ obstruction. The examination should be conducted when the child is symptomatic, as the obstruction may be intermittent. The diagnosis of intermittent UPJ obstruction is confirmed if hydronephrosis is present when the child is symptomatic, and resolves when the child is well. A diuretic renal scan will document baseline renal function and may also provoke symptoms during the diuretic phase of the study, which confirms the diagnosis. Surgery is indicated to prevent further episodes of symptoms (eg, pain). (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Symptomatic patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials that provide evidence for the optimal management of congenital ureteropelvic junction (UPJ) obstruction. The following discussion is based upon observational studies, and the experience and opinions of experts in the field.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prenatal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unilateral UPJ obstruction does not require prenatal intervention or early delivery, unless prenatal decompression of an enormously dilated renal pelvis is necessary to prevent dystocia or pulmonary compression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. There is no evidence that prenatal intervention in infants with either a single obstructed kidney or bilateral involvement improves renal outcome. Antenatal surgery should only be considered in the rarest of cases and only in select centers with expertise after a complete evaluation is performed. The criteria and setting for antenatal surgery is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42824?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of antenatal hydronephrosis\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are symptomatic usually require operative intervention. If radiographic evaluation reveals hydronephrosis during pain, which resolves when symptoms subside, surgical intervention is warranted. In these patients, pyeloplasty is performed and consists of resecting the atretic or stenotic segment, and reattaching the normal ureter to the renal pelvis, thereby relieving the obstruction. If the obstruction is due to an aberrant renal blood vessel, the UPJ is repositioned anatomically above the blood vessel preventing further obstruction. (See",
"    <a class=\"local\" href=\"#H69596742\">",
"     'Surgical options'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A follow-up ultrasound should be obtained approximately 4 to 12 weeks after surgery. Over time, nearly all patients (up to 95 percent) have radiographic improvement and resolution of their symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Pyelonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with UPJ obstruction who present with acute pyelonephritis are treated with antibiotics. Surgical repair is performed when the infection has resolved. If pyelonephritis does not respond to antibiotics, a temporary percutaneous pyelostomy tube should be placed to relieve the obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Kidney stones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kidney stones sometimes develop in the obstructed renal pelvis. Treatment involves open pyelolithotomy and pyeloplasty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ultimate goal of management is to preserve renal function and avoid unnecessary surgery. Managing asymptomatic patients is challenging, because the natural course of UPJ obstruction is variable. It appears that many patients will have stable renal function and improvement in the degree of hydronephrosis during long periods of observation. However, others will have deterioration of their renal function, and appear to benefit from surgical correction. Because there is no reliable method to predict whether the function of a kidney with UPJ obstruction will remain unaffected or deteriorate with time, there is controversy on the role of watchful observation with surgical intervention only if there is a deterioration in the patient's clinical status (ie, decrease in renal function",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    development of symptoms). This approach may prevent unnecessary surgery in some asymptomatic patients.",
"   </p>",
"   <p>",
"    These points were illustrated in a large retrospective case series of 116 patients with grade III to IV hydronephrosis and obstructive diuretic renograms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/13\">",
"     13",
"    </a>",
"    ]. Of the 116 patients, 83 presented with antenatal hydronephrosis. Management was divided into three categories: observation, immediate pyeloplasty, or pyeloplasty after observation. The choice of therapy was dependent upon ultrasound determination of the grade of hydronephrosis and degree of parenchymal thinning, and renal function on nuclear renal scan. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate pyeloplasty performed in 32 children (28 percent) resulted in a pre- and postop change of average renal function (measured in 27 patients) from 30 to 39 percent and median grade of hydronephrosis from 4 to 3.",
"     </li>",
"     <li>",
"      Observational management performed in 37 patients (32 percent) resulted in a change of median hydronephrosis from grade 4 to 2.25 in 29 patients during an 18-month follow-up. In 15 patients, repeat renal scans were performed because of worsening hydronephrosis that demonstrated stable renal function.",
"     </li>",
"     <li>",
"      Delayed pyeloplasty occurred in 47 patients (41 percent). Before and after pyeloplasty, relative renal function changed from 36 to 42 percent, and median grade of hydronephrosis from 4 to 3.",
"     </li>",
"     <li>",
"      Surgical complications occurred in four patients (3 percent), including uncomplicated bowel injury, urine extravasation, persistent hematuria, and incisional abscess. These were all treated conservatively.",
"     </li>",
"     <li>",
"      Of the 33 symptomatic patients who presented postnatally, 29 underwent pyeloplasty. Of the 83 patients with antenatal presentation, 50 were surgically corrected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded no one diagnostic study could determine when surgical intervention was needed. Their experience suggested that initial renal function based upon renal scan and serial ultrasonographic monitoring were the findings most commonly used in determining whether or not to perform pyeloplasty. In many patients, conservative management of observation alone had no adverse effect, and in some cases, demonstrated improvement.",
"   </p>",
"   <p>",
"    The following sections discuss the two management approaches of observation and surgical repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For experts in the field who consider observation an option, the main criterion for observation in cases with significant hydronephrosis on sonogram is demonstration of greater than 40 percent of split renal function of the affected kidney by diuretic renography, even if washout is delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. This threshold value indicates that the narrowing of the UPJ is not impairing renal function.",
"   </p>",
"   <p>",
"    In these patients, serial renal ultrasounds are obtained to monitor any change in the degree of hydronephrosis that indicate changes in functional obstruction. Renal ultrasound examinations are performed every four months until the child reaches one year of age, every six months for the next two years, and then annually [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/17\">",
"     17",
"    </a>",
"    ]. If the renal sonogram shows increasing hydronephrosis, diuretic renography is repeated to confirm that renal function is stable. If renography shows deterioration of &gt;10 percent on the affected side, or relative function less than 40 percent, surgery is recommended. These studies are performed more frequently (every three to four months) if relative renal function is borderline, and significant hydronephrosis is present. Of note, relative renal function may not be a reliable measure in patients with bilateral involvement. In patients with bilateral disease, glomerular filtration rate can be measured with serum creatinine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by renal scan. If renal function is significantly decreased, surgery is indicated to relieve obstruction.",
"   </p>",
"   <p>",
"    Although antibiotic prophylaxis has been recommended because urinary stasis is believed to be a risk factor for urinary tract infection (UTI), it does not appear that they are beneficial in children with UPJ obstruction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 92 children with severe hydronephrosis secondary to UPJ obstruction who were not treated with antibiotic prophylaxis, UTI occurred in 4.3 percent of the patients after a mean follow-up time of 27 months [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/18\">",
"       18",
"      </a>",
"      ]. The mean age at the time of UTI was 6.1 months. All four patients with UTI presented with fever, and one developed urosepsis. The authors concluded that antibiotic prophylaxis was not beneficial in patients with severe obstruction due to UPJ obstruction.",
"     </li>",
"     <li>",
"      In a Turkish prospective study, there were no UTIs or evidence of renal scarring based on dimercaptosuccinate renography in 84 infants with UPJ obstruction who were not treated with prophylactic antibiotics at the end of one year follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result, in our practice, antibiotic prophylaxis is given in patients with severe, grade IV hydronephrosis until the time of the VCUG. If the VCUG does not show reflux, the antibiotics are discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many clinicians recommend surgery when significant hydronephrosis (Grade IV) is noted on the sonogram regardless of the relative renal function of the two kidneys. The argument for surgical intervention is that function may be preserved or improved with correction of the blockage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69596742\">",
"    <span class=\"h2\">",
"     Surgical options",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical options include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Open dismembered pyeloplasty &ndash; The standard surgical procedure is open dismembered pyeloplasty [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/5\">",
"       5",
"      </a>",
"      ]. Outcomes are excellent, with resolution of the obstruction in 90 to 95 percent of cases, including newborns [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. Ultrasound examination is repeated approximately four to six weeks after surgery. If the hydronephrosis does not improve, a diuretic renogram should be performed to assess for persistent obstruction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a loss of renal function.",
"     </li>",
"     <li>",
"      Laparoscopic pyeloplasty &ndash; Laparoscopic pyeloplasty in infants and children is performed in some centers, with excellent short-term results [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/22-27\">",
"       22-27",
"      </a>",
"      ]. Robotic pyeloplasty also is becoming routinely used, especially in the older child [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/28\">",
"       28",
"      </a>",
"      ]. However, in newborns, overall morbidity may be less with open pyeloplasty than with laparoscopic or robotic techniques, because the classic pyeloplasty incision is the same length as the incision needed for the combined laparoscopic ports, and postoperative morbidity is similar. In general, laparoscopic and robotic techniques are performed transperitoneal in contrast to retroperitoneal for open pyeloplasty. Laparoscopic and robotic techniques also require postoperative placement of internal stents increasing the economic burden of pyeloplasty that are subsequently removed under general anesthesia; these are not usually needed with open procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Others &ndash; Alternative surgical techniques, such as percutaneous and retrograde endopyelotomy, have been used in adults. However, experience is limited in children [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon our clinical experience, observation is appropriate for asymptomatic patients with UPJ type hydronephrosis that is mild to moderate in severity (ie, Society of Fetal Urology [SFU] grade II to III) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50549 \" href=\"UTD.htm?32/46/33519\">",
"     image 3",
"    </a>",
"    ). We follow these patients with ultrasound examination every four (Grade III) to six (Grade II) months in the first year of life, then every 12 to 18 months thereafter. If there is an increase in the degree of hydronephrosis, diuretic renography is performed. If the affected kidney has less than 40 percent of split renal function, or there is a serial loss greater than 10 percent from a previous study, surgical intervention is recommended.",
"   </p>",
"   <p>",
"    Newborns who have persistent SFU grade IV hydronephrosis require closer observation. In these patients, we obtain a diuretic renogram at six to eight weeks of age. If the hydronephrotic kidney has decreased renal function (less than 40 percent of split renal function) compared with its normal contralateral mate, we recommend surgical intervention. More commonly, the hydronephrotic kidney will have equal function compared with the normal contralateral kidney. In this case, we repeat a sonogram in four to six weeks. If the sonogram shows improvement, we continue to follow with serial ultrasounds at three to four month intervals. if we see any worsening of the hydronephrosis, we repeat a diuretic renogram. These serial sonograms usually show continued SFU grade IV hydronephrosis without substantial change from previous studies. In this case, we offer the family either continued observation, which will require ongoing monitoring with sonograms and possible diuretic renography, or surgical intervention.",
"   </p>",
"   <p>",
"    Of note, in our practice, the washout curve or half-life calculation is not typically used to determine the need for surgery in any of these patients; however, others use a delay in excretion indicative of obstruction and renal function in considering surgical correction. The relative renal function typically does not change if the initial and follow-up renograms demonstrate stable renal function.",
"   </p>",
"   <p>",
"    Surgical intervention is performed for the following indications:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptoms including pain, infection, and renal stones",
"     </li>",
"     <li>",
"      Increasing grade of hydronephrosis, and decrease in function of the affected kidney so that it is less than the threshold of 40 percent of split renal function, or there is a serial loss greater than 10 percent",
"     </li>",
"     <li>",
"      Parental",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      patient preference to avoid continued invasive testing, and allow definitive correction of the problem.",
"     </li>",
"     <li>",
"      Massive hydronephrosis with a renal pelvic diameter &gt;50 mm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This approach appears to limit surgical correction to one-half of patients diagnosed with antenatal UPJ obstruction. This was illustrated in a long-term retrospective study of 343 children with UPJ obstruction detected by antenatal ultrasound that reported 52 percent of patients underwent surgical correction based upon renal deterioration of greater than 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/31\">",
"     31",
"    </a>",
"    ]. In this cohort of patients, 235 patients had initial relative renal function (RRF) &gt;40 percent, 68 had RRF between 30 and 40 percent, and 40 had RRF &lt;40 percent. Initial RRF &lt;40 percent and initial grade III and IV hydronephrosis were independent predictors for surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616087124\">",
"    <span class=\"h3\">",
"     Postoperative follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal ultrasonography is performed four to six weeks postoperatively. If the ultrasound shows improvement (ie, decrease in the severity of hydronephrosis), the patient can then be followed by repeat ultrasound at increasing time intervals (ie, initially one year and then every two to three years) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/32\">",
"     32",
"    </a>",
"    ]. If the follow-up ultrasound does not show improvement, diuretic renography is performed to detect persistent obstruction, which may require an additional surgical procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data on the long-term outcome of children with ureteropelvic junction (UPJ) obstruction, which is confined to those who underwent pyeloplasty. In one series of 49 postpubertal adolescents with antenatally diagnosed UPJ obstruction who underwent surgical repair between 1989 and 1992, relative renal function improved from 37 percent preoperative to 43 percent after puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/33\">",
"     33",
"    </a>",
"    ]. There was also a decrease in time for isotope washout. Two patients (4 percent) required additional surgery for increasing hydronephrosis. Another study of 401 children who underwent open pyeloplasty reported a similar rate of 5 percent of recurrent obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26680/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It remains unknown what proportion of patients with congenital UPJ obstruction who do not undergo surgical correction will become symptomatic as adults",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    require surgical intervention. It also is not known whether there is a difference in long-term renal function between the observational and initial surgical approaches. It is clear that long-term follow up studies are needed to answer these questions so that optimal management decisions can be made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/45/3794?source=see_link\">",
"       \"Patient information: Prenatal hydronephrosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ureteropelvic junction (UPJ) obstruction is a partial or total blockage of the flow of urine that occurs where the ureter enters the kidney, and results in hydronephrosis (",
"      <a class=\"graphic graphic_figure graphicRef55146 \" href=\"UTD.htm?26/33/27156\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef77143 \" href=\"UTD.htm?16/25/16787\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the etiology of UPJ obstruction includes both congenital and acquired conditions, congenital causes are more common. UPJ obstruction is the most common pathologic cause of antenatally detected hydronephrosis with a reported incidence of up to 1 in 500 fetuses screened by antenatal ultrasound. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Congenital UPJ obstruction is usually caused by intrinsic stenosis of the proximal ureter, less commonly by extrinsic compression of the UPJ by an aberrant or accessory renal artery or arterial branch and rarely from an intraluminal fold. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the developed world, most cases of UPJ obstruction are diagnosed during the postnatal evaluation of antenatal hydronephrosis. In the absence of antenatal screening, infants may present with an abdominal mass (enlarged obstructed kidney), urinary tract infection, hematuria, or failure to thrive. In older children, the most common clinical manifestations of UPJ obstruction are intermittent flank and abdominal pain. Other symptoms include renal injury after experiencing minor trauma, hematuria, renal calculi, or rarely hypertension. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of UPJ obstruction is generally suspected when imaging studies, usually ultrasonography, demonstrate hydronephrosis. The diagnosis is confirmed by diuretic renography. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Imaging studies (eg, diuretic renography, serial ultrasounds, and voiding cystourethrogram [VCUG]) differentiate UPJ from other causes of hydronephrosis, including vesicoureteral reflux (VUR), transient and functional hydronephrosis, and other urological anomalies (eg, posterior urethral valves, congenital megaureter, ureterocele, and multicystic dysplastic kidney). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial evaluation of a patient with suspected UPJ obstruction includes ultrasonography to demonstrate persistent hydronephrosis, VCUG to detect the presence or absence of VUR, and a diuretic renogram that demonstrates the delay in isotope clearance at the UPJ confirming partial or total blockage of urinary flow. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no randomized trials that provide evidence for the optimal management of congenital UPJ obstruction. The following management regimen is based upon observational studies, and the experience and opinions of the author.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest",
"      <strong>",
"       NOT",
"      </strong>",
"      to perform prenatal intervention or early delivery in fetuses with unilateral UPJ obstruction (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In extremely rare cases, decompression of an enormously dilated renal pelvis may be considered to prevent dystocia or fetal pulmonary compression. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Prenatal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In symptomatic patients, we recommend surgical intervention to relieve the obstruction and resolve symptoms (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Symptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In asymptomatic patients with unilateral UPJ obstruction and a split renal function greater than 40 percent of the affected kidney, we suggest observation and monitoring with serial ultrasounds and diuretic renography (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Indications for surgical intervention include increasing hydronephrosis and decrease in split renal function below 40 percent or a serial loss greater than 10 percent in subsequent studies, the development of symptoms, massive hydronephrosis with a renal pelvic diameter greater than 50 mm,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      parental and patient preference. This approach limits surgical correction to about half of affected children. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Asymptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limited long-term data confined to children who underwent surgical correction demonstrate a correction of the obstruction defined by stable or improved renal function, decreased hydronephrosis, and lack of symptoms in most patients. The rate of recurrent obstruction requiring additional intervention is about 5 percent. Long-term data on patients who were managed by observation alone are not currently available. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Koff SA, Mutabagani KH. Anomalies of the kidney. In: Adult and Pediatric Urology, 4th ed, Gillenwater JY, Grayhack JT, Howards SS, Mitchell ME (Eds), Lippincott Williams and Wilkins, Philadelphia 2002. p.2129.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/2\">",
"      Liang CC, Cheng PJ, Lin CJ, et al. Outcome of prenatally diagnosed fetal hydronephrosis. J Reprod Med 2002; 47:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/3\">",
"      Morin L, Cendron M, Crombleholme TM, et al. Minimal hydronephrosis in the fetus: clinical significance and implications for management. J Urol 1996; 155:2047.",
"     </a>",
"    </li>",
"    <li>",
"     Shulam PG. Ureteropelvic junction obstruction. Available at: file://kidney.niddk.nih.gov/statistics/uda/Ureteropelvic_Junction_Obstruction-Chapter09.pdf (Accessed on April 22, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/5\">",
"      Gonz&aacute;lez R, Schimke CM. Ureteropelvic junction obstruction in infants and children. Pediatr Clin North Am 2001; 48:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/6\">",
"      McAleer IM, Kaplan GW, LoSasso BE. Congenital urinary tract anomalies in pediatric renal trauma patients. J Urol 2002; 168:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/7\">",
"      Tekin A, Tekgul S, Atsu N, et al. Ureteropelvic junction obstruction and coexisting renal calculi in children: role of metabolic abnormalities. Urology 2001; 57:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/8\">",
"      de Waard D, Dik P, Lilien MR, et al. Hypertension is an indication for surgery in children with ureteropelvic junction obstruction. J Urol 2008; 179:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/9\">",
"      Cascio S, Sweeney B, Granata C, et al. Vesicoureteral reflux and ureteropelvic junction obstruction in children with horseshoe kidney: treatment and outcome. J Urol 2002; 167:2566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/10\">",
"      Ragan DC, Casale AJ, Rink RC, et al. Genitourinary anomalies in the CHARGE association. J Urol 1999; 161:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/11\">",
"      Flake AW, Harrison MR, Sauer L, et al. Ureteropelvic junction obstruction in the fetus. J Pediatr Surg 1986; 21:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/12\">",
"      Drake DP, Stevens PS, Eckstein HB. Hydronephrosis secondary to ureteropelvic obstruction in children: a review of 14 years of experience. J Urol 1978; 119:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/13\">",
"      Heinlen JE, Manatt CS, Bright BC, et al. Operative versus nonoperative management of ureteropelvic junction obstruction in children. Urology 2009; 73:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/14\">",
"      Koff SA. Postnatal management of antenatal hydronephrosis using an observational approach. Urology 2000; 55:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/15\">",
"      Josephson S. Antenatally detected pelvi-ureteric junction obstruction: concerns about conservative management. BJU Int 2000; 85:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/16\">",
"      Ulman I, Jayanthi VR, Koff SA. The long-term followup of newborns with severe unilateral hydronephrosis initially treated nonoperatively. J Urol 2000; 164:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/17\">",
"      Moslehi J, Herndon CD, McKenna PH. Posterior urethral valves presented at birth despite normal prenatal ultrasound scans. Urology 2001; 57:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/18\">",
"      Roth CC, Hubanks JM, Bright BC, et al. Occurrence of urinary tract infection in children with significant upper urinary tract obstruction. Urology 2009; 73:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/19\">",
"      Islek A, G&uuml;ven AG, Koyun M, et al. Probability of urinary tract infection in infants with ureteropelvic junction obstruction: is antibacterial prophylaxis really needed? Pediatr Nephrol 2011; 26:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/20\">",
"      Sutherland RW, Chung SK, Roth DR, Gonzales ET. Pediatric pyeloplasty: outcome analysis based on patient age and surgical technique. Urology 1997; 50:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/21\">",
"      Baek M, Park K, Choi H. Long-term outcomes of dismembered pyeloplasty for midline-crossing giant hydronephrosis caused by ureteropelvic junction obstruction in children. Urology 2010; 76:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/22\">",
"      Yeung CK, Tam YH, Sihoe JD, et al. Retroperitoneoscopic dismembered pyeloplasty for pelvi-ureteric junction obstruction in infants and children. BJU Int 2001; 87:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/23\">",
"      Piaggio LA, Franc-Guimond J, Noh PH, et al. Transperitoneal laparoscopic pyeloplasty for primary repair of ureteropelvic junction obstruction in infants and children: comparison with open surgery. J Urol 2007; 178:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/24\">",
"      Tanaka ST, Grantham JA, Thomas JC, et al. A comparison of open vs laparoscopic pediatric pyeloplasty using the pediatric health information system database--do benefits of laparoscopic approach recede at younger ages? J Urol 2008; 180:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/25\">",
"      Vemulakonda VM, Cowan CA, Lendvay TS, et al. Surgical management of congenital ureteropelvic junction obstruction: a Pediatric Health Information System database study. J Urol 2008; 180:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/26\">",
"      Penn HA, Gatti JM, Hoestje SM, et al. Laparoscopic versus open pyeloplasty in children: preliminary report of a prospective randomized trial. J Urol 2010; 184:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/27\">",
"      Turner RM 2nd, Fox JA, Tomaszewski JJ, et al. Laparoscopic Pyeloplasty for Ureteropelvic Junction Obstruction in Infants. J Urol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/28\">",
"      Riachy E, Cost NG, Defoor WR, et al. Pediatric standard and robot-assisted laparoscopic pyeloplasty: a comparative single institution study. J Urol 2013; 189:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/29\">",
"      Yiee JH, Baskin LS. Use of internal stent, external transanastomotic stent or no stent during pediatric pyeloplasty: a decision tree cost-effectiveness analysis. J Urol 2011; 185:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/30\">",
"      Tan HL, Najmaldin A, Webb DR. Endopyelotomy for pelvi-ureteric junction obstruction in children. Eur Urol 1993; 24:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/31\">",
"      Chertin B, Pollack A, Koulikov D, et al. Conservative treatment of ureteropelvic junction obstruction in children with antenatal diagnosis of hydronephrosis: lessons learned after 16 years of follow-up. Eur Urol 2006; 49:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/32\">",
"      Almodhen F, Jednak R, Capolicchio JP, et al. Is routine renography required after pyeloplasty? J Urol 2010; 184:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/33\">",
"      Chertin B, Pollack A, Koulikov D, et al. Does renal function remain stable after puberty in children with prenatal hydronephrosis and improved renal function after pyeloplasty? J Urol 2009; 182:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26680/abstract/34\">",
"      Braga LH, Lorenzo AJ, B&auml;gli DJ, et al. Risk factors for recurrent ureteropelvic junction obstruction after open pyeloplasty in a large pediatric cohort. J Urol 2008; 180:1684.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6585 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-125.39.66.146-3A500C5829-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_3_26680=[""].join("\n");
var outline_f26_3_26680=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Intrinsic narrowing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Extrinsic compression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fetal and neonatal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Older children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diuretic renography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Voiding cystourethrogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Newborn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Older child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prenatal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Kidney stones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Observation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69596742\">",
"      Surgical options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H616087124\">",
"      - Postoperative follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6585\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6585|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?5/2/5166\" title=\"algorithm 1\">",
"      Postnatal evaluation of severe bilateral prenatal hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?14/15/14591\" title=\"algorithm 2\">",
"      Eval uni prenatal hydroneph",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6585|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/8/17543\" title=\"diagnostic image 1\">",
"      UPJ obstruct blood vessel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/57/13204\" title=\"diagnostic image 2\">",
"      UPJ obstruction ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/46/33519\" title=\"diagnostic image 3\">",
"      SFU grading fetal hydronephr",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/9/9361\" title=\"diagnostic image 4\">",
"      CT scan UPJ obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6585|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/33/27156\" title=\"figure 1\">",
"      UPJ obstruction schematic drawing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6585|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/25/16787\" title=\"picture 1\">",
"      UPJ obstruction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11271?source=related_link\">",
"      Clinical presentation and diagnosis of posterior urethral valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42824?source=related_link\">",
"      Overview of antenatal hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/45/3794?source=related_link\">",
"      Patient information: Prenatal hydronephrosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34119?source=related_link\">",
"      Postnatal management of antenatal hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=related_link\">",
"      Presentation, diagnosis, and clinical course of vesicoureteral reflux",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_3_26681="Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis";
var content_f26_3_26681=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/3/26681/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/3/26681/contributors\">",
"     Igor J Koralnik, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/3/26681/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/3/26681/contributors\">",
"     Francisco Gonzalez-Scarano, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/3/26681/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/3/26681/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/3/26681/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive multifocal leukoencephalopathy (PML) is a severe demyelinating disease of the central nervous system that is caused by reactivation of the polyomavirus JC (JC virus) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Asymptomatic primary infection with JC virus occurs in childhood and antibodies can be found in 86 percent of adults [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/4\">",
"     4",
"    </a>",
"    ]. In most individuals, JC virus remains latent in kidneys and lymphoid organs, but, in the context of profound cellular immunosuppression, JC virus can reactivate, spread to the brain, and induce a lytic infection of oligodendrocytes, which are the CNS myelin-producing cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1734?source=see_link\">",
"     \"Epidemiology of JC and BK virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, clinical features, and diagnosis of PML will be reviewed here. The treatment of PML is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17336?source=see_link\">",
"     \"Progressive multifocal leukoencephalopathy: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive multifocal leukoencephalopathy occurs almost exclusively in immunosuppressed individuals. There are only isolated case reports of PML in patients without apparent immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. There are, however, reports of PML affecting patients who have conditions associated with minimal or occult immunosuppression, such as hepatic cirrhosis and renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PML was initially described in patients with lymphoproliferative and myeloproliferative diseases such as chronic lymphocytic leukemia, chronic myeloid leukemia, and Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]. It was subsequently reported in rare patients with solid organ malignancies, granulomatous and inflammatory diseases, solid organ transplant recipients, and with the use of certain drugs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of PML was estimated to be 0.07 percent among patients with hematologic malignancies [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/17\">",
"       17",
"      </a>",
"      ] and 0.8 percent in a retrospective autopsy study of liver transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another report reviewed 427 cases of heart or lung transplant recipients and identified 3 cases of PML, with a calculated incidence rate of 1.2 cases per 1000 post-transplantation years [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective population-based study that analyzed a health insurance database, the incidence rates of PML in patients with systemic lupus erythematosus, autoimmune vasculitis, non-Hodgkin lymphoma, chronic lymphocytic leukemia, and bone marrow transplantation were 2.4, 10.8, 8.3, 11.1, and 35.4 per 100,000 person-years [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/20\">",
"       20",
"      </a>",
"      ]. There were no PML cases among patients with rheumatoid arthritis, multiple sclerosis, Sj&ouml;gren disease, or solid organ transplantation. However, the confidence intervals around the incidence rates for these groups with and without PML cases were wide and overlapping. Thus, the group differences in the incidence of PML were",
"      <strong>",
"       not",
"      </strong>",
"      statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prior to the widespread use of highly active antiretroviral therapy (HAART) in the United States and Europe, PML was recognized as a major opportunistic infection associated with AIDS in adults, with a prevalence of 1 to 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/17,21-23\">",
"     17,21-23",
"    </a>",
"    ]. In a review of 61 patients with PML seen between 1995 and 2004, 79 percent had AIDS, 13 percent had hematologic malignancies, 5 percent were bone marrow transplant recipients, and one patient each had thymoma and dermatomyositis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/24\">",
"     24",
"    </a>",
"    ]. PML has also been described in HIV-infected children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/25-27\">",
"     25-27",
"    </a>",
"    ], at an estimated rate of 0.06 per 100 person-years prior to HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/27\">",
"     27",
"    </a>",
"    ], and in HIV-negative patients with idiopathic CD4+ lymphocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30009?source=see_link&amp;anchor=H18#H18\">",
"     \"Idiopathic CD4+ lymphocytopenia\", section on 'Other opportunistic infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the widespread use of HAART, the incidence of PML in patients with HIV infection has decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In a population-based study from Denmark involving a nationwide cohort of patients aged 16 and older with HIV infection, the incidence of PML declined over three observation periods as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      1995 to 1996 (pre-HAART): 3.3",
"      <span class=\"nowrap\">",
"       cases/1000",
"      </span>",
"      patient-years at risk [PYR] (95% CI 1.9-5.7)",
"     </li>",
"     <li>",
"      1997 to 1999 (early HAART): 1.8",
"      <span class=\"nowrap\">",
"       cases/1000",
"      </span>",
"      PYR (95% CI 1.0-3.2)",
"     </li>",
"     <li>",
"      2000 to 2006 (late HAART): 1.3",
"      <span class=\"nowrap\">",
"       cases/1000",
"      </span>",
"      PYR (95% CI 0.8-1.9)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, PML may improve or stabilize with potent antiretroviral therapy, leading to prolonged survival. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17336?source=see_link&amp;anchor=H4#H4\">",
"     \"Progressive multifocal leukoencephalopathy: Prognosis and treatment\", section on 'Highly active antiretroviral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the above findings from the United States and Europe, PML has been rarely reported in HIV-infected patients in India and Africa. The reason for this phenomenon is not clear, but nonrecognition, lack of simple diagnostic tests, underreporting, premature deaths due to other infections, potential interactions between JC virus and different HIV clades, or host genetic differences may be implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PML has also been reported in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/41/43669?source=see_link\">",
"     belatacept",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], brentuximab [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/34\">",
"     34",
"    </a>",
"    ], efalizumab [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], fludarabine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/12-16\">",
"     12-16",
"    </a>",
"    ], infliximab [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/37\">",
"     37",
"    </a>",
"    ], rituximab [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/38-40\">",
"     38-40",
"    </a>",
"    ], mycophenolate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/41-43\">",
"     41-43",
"    </a>",
"    ], and glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/44\">",
"     44",
"    </a>",
"    ] alone, or in combination with other immunosuppressive medications (eg, cyclophosphamide, leflunomide, methotrexate) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/37,45\">",
"     37,45",
"    </a>",
"    ]. Many of these patients had an underlying hematologic malignancy or collagen vascular disease.",
"   </p>",
"   <p>",
"    Rare cases of PML have been observed in CD8-positive T-cell leukopenic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/46\">",
"     46",
"    </a>",
"    ], and in those with multiple sclerosis and Crohn's disease who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    , an immunomodulatory drug that prevents normal trafficking of leukocytes by binding to integrin receptors. These associations are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23032?source=see_link&amp;anchor=H4#H4\">",
"     \"Natalizumab for relapsing-remitting multiple sclerosis in adults\", section on 'Risk of progressive multifocal leukoencephalopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3429?source=see_link&amp;anchor=H4#H4\">",
"     \"Natalizumab for treatment of Crohn's disease in adults\", section on 'Adverse events'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the name implies, classic PML is progressive, multifocal, and involves the white matter. However, atypical presentations are increasingly recognized. Since PML can also present as a single lesion, may not always be progressive, and may involve the gray matter, the term PML may be misleading for clinicians confronted with the non-classic form of this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/11\">",
"     11",
"    </a>",
"    ]. JC virus encephalopathy may better encompass all disease manifestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Classic PML",
"    </span>",
"    &nbsp;&mdash;&nbsp;PML usually manifests with subacute neurologic deficits including altered mental status, motor deficits (hemiparesis or monoparesis), limb ataxia, gait ataxia, and visual symptoms such as hemianopia and diplopia. Most patients with HIV infection and PML are profoundly immunosuppressed with CD4-positive T-cell counts &lt;200 per mm",
"    <sup>",
"     3",
"    </sup>",
"    . Initial symptoms may vary greatly from patient to patient, depending on the location of their lesions in the central nervous system (CNS) white matter. PML typically spares the optic nerves and the spinal cord, although incidental finding of PML lesions in the spinal cord has been reported in the post-mortem examination of one patient with HIV infection who died from hemispheric PML [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although PML lesions are located mainly in the white matter, PML symptoms are frequently indicative of a cortical disorder. These cortical symptoms have been attributed to white matter lesions that undercut relevant cortical areas. As examples, aphasia may result from lesions underlying the language areas in the left frontal and temporal lobes, and lesions in the occipital lobe white matter can mimic symptoms of cortical blindness. However, neuropathologic study has revealed that cortical demyelination is a frequent finding with PML, suggesting that cortical symptoms in PML may arise from cortical demyelinating lesions. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Neuropathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Seizures are usually thought to be a manifestation of cortical injury rather than white matter disease. Nonetheless, seizures occur in up to 18 percent of patients with PML, mainly when PML lesions are located immediately adjacent to the cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disease course of PML is usually progressive and fatal. The median survival of patients without HIV infection is only a few months. Survival in the era of highly active antiretroviral therapy is longer, but survivors are often left with severe neurologic sequelae. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17336?source=see_link&amp;anchor=H2#H2\">",
"     \"Progressive multifocal leukoencephalopathy: Prognosis and treatment\", section on 'Natural history and prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60052309\">",
"    <span class=\"h3\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical appearance of PML on neuroimaging studies consists of symmetric or asymmetric multifocal areas of white matter demyelination that do not conform to cerebrovascular territories and exhibit neither mass effect nor contrast enhancement.",
"   </p>",
"   <p>",
"    On cranial CT, PML lesions can appear as hypodense patchy or confluent white matter regions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/49\">",
"     49",
"    </a>",
"    ]. On MRI, the lesions of PML are seen as areas of decreased signal on T1-weighted images and increased signal on T2-weighted and fluid attenuated inversion recovery (FLAIR) sequences (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72702 \" href=\"UTD.htm?14/20/14656\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. In addition, PML lesions may be hyperintense on diffusion-weighted sequences (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65187 \" href=\"UTD.htm?2/50/2854\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. PML lesions are usually bilateral and localized preferentially to the periventricular areas and the subcortical white matter, and may involve the corpus callosum, brainstem, pyramidal tracts, and cerebellum [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. Involvement of the deep gray structures, including basal ganglia and thalamus, can be found in up to 17 percent of cases; this is always in conjunction with white matter disease (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65187 \" href=\"UTD.htm?2/50/2854\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/54\">",
"     54",
"    </a>",
"    ]. Of note, cortical demyelination in PML is not discernible with conventional MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Neuropathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The lesions of PML generally do not enhance with contrast or develop surrounding edema [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/54\">",
"     54",
"    </a>",
"    ]. As a result, substantial mass effect on adjacent structures is usually absent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/54\">",
"     54",
"    </a>",
"    ]. However, atypical enhancing PML lesions, biopsy-proven, have been described on neuroimaging studies. These unusual radiologic findings have been observed most often in patients with HIV infection who initiated HAART and then became neurologically symptomatic from PML disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. They also have been found in patients without HIV infection, including some with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    -associated PML [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. These atypical inflammatory lesions may become more common as the presentation of PML is altered by immune reconstitution with antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Inflammatory PML'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Neuropathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early neuropathologic studies of PML found demyelination only involving the subcortical white matter. However, later reports have shown that JC virus causes infection of cortical neurons and that demyelinating lesions of PML frequently involve gray matter [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study examined autopsy brain tissue from 13 patients with PML and HIV infection found cortical demyelinating lesions in all 13 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/61\">",
"       61",
"      </a>",
"      ]. Two types of demyelinating lesions were detected in these patients:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Leukocortical lesions extended to the cortex from underlying white matter and accounted for the highest percentage of demyelination in PML brains",
"     </li>",
"     <li>",
"      Intracortical lesions were located entirely within the cortex and were typically small (0.03 to 0.6 mm",
"      <sup>",
"       3",
"      </sup>",
"      ) and numerous",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In another report that looked at neuropathologic tissue from 49 patients with PML, demyelinating lesions were present in the white matter and gray-white junction in 96 percent and in the gray matter in 57 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/62\">",
"       62",
"      </a>",
"      ]. While most of the cells infected with JC virus were glial, JC virus infection of neurons was found in approximately one-half of patients. In addition, JC virus infection of gray matter neurons located outside of demyelinating lesions was present in 11 percent of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, it is now recognized that PML-associated demyelination affects both the cortex and subcortical white matter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Inflammatory PML",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although HAART has improved the clinical outcome of patients with HIV infection who have PML, it has also been associated with new onset or clinical worsening of PML. This occurs mainly in patients who display a marked increased in CD4-positive T-cell counts and a decrease in HIV plasma viral load, indicating a recovery of the immune system. This paradoxical development of PML is usually accompanied by an inflammatory reaction in PML lesions known as the immune reconstitution inflammatory syndrome (IRIS) and demonstrated by contrast enhancement on brain MRI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The co-occurrence of IRIS with PML has been observed also in patients with multiple sclerosis treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23032?source=see_link&amp;anchor=H4#H4\">",
"     \"Natalizumab for relapsing-remitting multiple sclerosis in adults\", section on 'Risk of progressive multifocal leukoencephalopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17336?source=see_link&amp;anchor=H12#H12\">",
"     \"Progressive multifocal leukoencephalopathy: Prognosis and treatment\", section on 'Natalizumab-associated PML'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the initial worsening, observational studies suggest that the clinical outcome from inflammatory PML is generally more favorable than classic PML [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/56\">",
"     56",
"    </a>",
"    ], although some cases are fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/66\">",
"     66",
"    </a>",
"    ]. In a retrospective review with data for 54 patients with PML and IRIS, the mortality rate was 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     JC virus cerebellar granule cell neuronopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to PML, JC virus may cause a productive and lytic infection of cerebellar granule cell neurons, leading to ataxia and cerebellar atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. This novel syndrome has been named JC virus granule cell neuronopathy (JCV GCN).",
"   </p>",
"   <p>",
"    The data indicate that JC virus, at least in certain individuals, is also capable of infecting neurons, and not only glial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. In a study examining brain tissue (nearly all derived from autopsy) from patients with PML, JC virus infection of granule cell neurons was detected in 15 of 19 tested samples (79 percent), including some cases without PML lesions in the nearby cerebellar white mater (",
"    <a class=\"graphic graphic_figure graphicRef67660 \" href=\"UTD.htm?26/55/27514\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/70\">",
"     70",
"    </a>",
"    ]. Mutations in the structure of the JC virus VP1 capsid protein have been identified in a few patients with JCV GCN, suggesting that VP1 protein mutations are important to the pathogenesis of GCN [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    JC virus GCN should be differentiated from the cerebellar syndrome which is frequently found in PML when lesions occur in the cerebellar white matter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     JC virus encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;JC virus infection can result in a novel gray matter syndrome characterized by encephalopathy. A case report describes a patient who developed aphasia and progressive cognitive decline in the absence of focal neurologic deficits after chemotherapy for non-small cell lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/72\">",
"     72",
"    </a>",
"    ]. The course was rapidly fatal. Polymerase chain reaction detected JC virus in cerebrospinal fluid and brain biopsy tissue. Neuropathologic examination showed focal areas of cell loss in the cortex and limited demyelination. JC virus infection of enlarged cortical pyramidal neurons was confirmed by immunostaining and electron microscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gold standard for diagnosis of PML is the brain biopsy. Histological examination of PML lesions reveals single or multiple areas of demyelination with the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      JC virus-infected oligodendrocytes with enlarged amphophilic nuclei located at the periphery of the lesions",
"     </li>",
"     <li>",
"      Reactive gliosis with enlarged, bizarre astrocytes, some sustaining a restrictive, non-lytic JC virus infection",
"     </li>",
"     <li>",
"      Macrophages containing phagocytosed myelin and cellular debris",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of JC virus-infected glial cells should be confirmed by immunohistochemistry for polyomavirus proteins, or in situ hybridization for JC virus DNA. Antibodies used for immunohistochemistry are usually raised against the simian virus 40, a polyomavirus endemic in monkeys that cross reacts with JC virus.",
"   </p>",
"   <p>",
"    PML lesions are usually devoid of inflammatory infiltrates. In the context of an immune reconstitution inflammatory syndrome (IRIS), active inflammatory changes may be present, including intraparenchymal and perivascular CD8+ T-lymphocyte infiltration associated with the presence of abundant JC virus as well as areas of perivenous leukoencephalitis devoid of JC virus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Brain biopsy has a sensitivity of 64 to 96 percent and a specificity of 100 percent for the diagnosis of PML [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/73\">",
"     73",
"    </a>",
"    ]. However, the risk of morbidity and mortality associated with brain biopsy in patients with HIV infection is estimated to be 8.4 and 2.9 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/74\">",
"     74",
"    </a>",
"    ]. Furthermore, some patients may not be able to tolerate brain biopsy, or lesions may be inaccessible. As an alternative to brain biopsy, the diagnosis of PML can be established by polymerase chain reaction (PCR) detection of JC virus DNA in the cerebrospinal fluid (CSF) in patients with appropriate neurologic and neuroradiologic features.",
"   </p>",
"   <p>",
"    JC virus PCR for the diagnosis of PML had a sensitivity of 72 to 92 percent and specificity of 92 to 100 percent before the HAART (highly active antiretroviral therapy) era [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/75\">",
"     75",
"    </a>",
"    ]. However, it is now common to find negative CSF JC virus PCR results in patients with AIDS who have clinical presentation indistinguishable from PML [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/76\">",
"     76",
"    </a>",
"    ]. A plausible explanation for this discrepancy is that HAART-induced recovery of the immune system leads to decreased viral replication and clearance of JC virus DNA from CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/77\">",
"     77",
"    </a>",
"    ]. Based on a consensus for PML terminology [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/78\">",
"     78",
"    </a>",
"    ], these patients should be considered as \"possible PML\" cases and managed accordingly, after appropriate exclusion of other neurologic conditions such as primary central nervous system lymphoma, HIV encephalopathy, and toxoplasmosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with HIV infection, the differential diagnosis of PML includes HIV encephalopathy and primary central nervous system lymphoma. Whereas PML lesions are usually asymmetric, distributed throughout the white matter, well demarcated, and associated with focal neurologic deficits, the lesions of HIV are more likely to be symmetrical, poorly demarcated, and located in the periventricular areas; they may be associated with cognitive problems and an elevated HIV CSF viral load, but not with focal sensory, motor, or visual deficits.",
"   </p>",
"   <p>",
"    Primary CNS lymphoma may also mimic PML lesions. However, cortical involvement, moderate edema, diffuse post-contrast enhancement patterns, and positive CSF cytology or Epstein Barr virus PCR should help differentiate these entities. The radiological presentation of these disorders in patients with HIV infection is covered in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=see_link\">",
"     \"Approach to HIV-infected patients with central nervous system lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients without HIV infection, PML may be initially mistaken for a stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/24\">",
"     24",
"    </a>",
"    ] or brain tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/79\">",
"     79",
"    </a>",
"    ]. However, clinical suspicion for PML should be heightened if the neuroimaging features are those of a multifocal process limited to the white matter that does not conform to vascular territories and exhibits neither mass effect nor contrast enhancement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prognostic markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in the knowledge of the immune response against JC virus, in nucleic acid amplification techniques and in neuroimaging, have translated into valuable tools that may predict disease evolution in PML.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      JC virus levels may be prognostic markers in patients with PML. A small study found that patients with a low JC virus burden (50 to 100",
"      <span class=\"nowrap\">",
"       copies/mL)",
"      </span>",
"      in the CSF had a longer survival than patients with high JC virus burden [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/80\">",
"       80",
"      </a>",
"      ]. Another study measured JC virus DNA levels from sequential CSF samples in 24 patients with PML and HIV infection and found that patients who showed PML stabilization with HAART therapy exhibited a progressive decline in JC virus DNA levels compared with patients who had progressive fatal PML with or without HAART therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/81\">",
"       81",
"      </a>",
"      ]. Other studies have also found that detection of a JC virus-specific immune response in blood and CSF is associated with a favorable outcome in PML [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/82-86\">",
"       82-86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The development of an inflammatory immune response against JC virus in the CNS may be instrumental in stabilization of the disease. The following observations support this hypotheses:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The presence of contrast enhancement of PML lesions, while atypical, is suggestive of development of an inflammatory response with breakdown of the blood brain barrier. Although data are scant, contrast enhancement has been associated with a better prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/87\">",
"       87",
"      </a>",
"      ]. An inflammatory immune response in patients with PML and HIV infection may be facilitated with CD4-positive T-cell counts above 300 per mm",
"      <sup>",
"       3",
"      </sup>",
"      .",
"     </li>",
"     <li>",
"      Myoinositol is a metabolite that increases during brain inflammation and is primarily synthesized in glial cells. An analysis of brain metabolism and myoinositol levels using 1H-magnetic resonance spectroscopy (MRS) found that acute PML lesions in those who survived the disease showed an increased ratio of myoinositol to creatine compared with those who had progressive neurologic deterioration [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26681/abstract/88\">",
"       88",
"      </a>",
"      ]. In addition, JC virus-specific cellular immune response was detected only in the peripheral blood of PML survivors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PML is a deadly demyelinating disease of the central nervous system caused by a reactivation of the JC virus that occurs almost exclusively in immunosuppressed individuals.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PML is a major opportunistic infection associated with HIV infection and AIDS, with a prevalence of about 5 percent. Outside of HIV infection, PML occurs rarely in patients with lymphoproliferative and myeloproliferative diseases, solid organ malignancies, granulomatous and inflammatory diseases, and organ transplant recipients. Rare cases of PML have been reported in patients treated with the immunomodulatory medication",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PML typically presents with subacute neurologic deficits including altered mental status, visual symptoms such as hemianopia and diplopia, hemiparesis or monoparesis, and appendicular or gait ataxia. Seizures occur in up to 18 percent of patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Classic PML'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      New onset or clinical worsening of PML may occur shortly after the initiation of highly active antiretroviral therapy (HAART) due to the immune reconstitution inflammatory syndrome (IRIS). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Inflammatory PML'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      JC virus granule cell neuronopathy presents with ataxia and cerebellar atrophy in patients with HIV infection who do not have obvious PML lesions in the cerebellum. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'JC virus cerebellar granule cell neuronopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical suspicion for PML should be heightened if neuroimaging reveals a multifocal process limited to the white matter that does not conform to vascular territories and exhibits neither mass effect nor contrast enhancement. In patients with HIV infection, the differential diagnosis of PML includes HIV encephalopathy and primary CNS lymphoma. (See",
"      <a class=\"local\" href=\"#H60052309\">",
"       'Neuroimaging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=see_link\">",
"       \"Approach to HIV-infected patients with central nervous system lesions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Brain biopsy is the gold standard for diagnosis of PML but is associated with clinically significant morbidity and mortality. In patients with appropriate neurologic and neuroradiologic features, the diagnosis of PML can usually be established by polymerase chain reaction detection of JC virus DNA in the cerebrospinal fluid if brain biopsy is not desired. However, the sensitivity of polymerase chain reaction for the diagnosis of PML in patients with HIV infection appears to be declining since the advent of HAART therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/1\">",
"      ASTROM KE, MANCALL EL, RICHARDSON EP Jr. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958; 81:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/2\">",
"      Padgett BL, Walker DL, ZuRhein GM, et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971; 1:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/3\">",
"      Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/4\">",
"      Weber T, Trebst C, Frye S, et al. Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis 1997; 176:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/5\">",
"      Rockwell D, Ruben FL, Winkelstein A, Mendelow H. Absence of imune deficiencies in a case of progressive multifocal leukoencephalopathy. Am J Med 1976; 61:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/6\">",
"      Bolton CF, Rozdilsky B. Primary progressive multifocal leukoencephalopathy. A case report. Neurology 1971; 21:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/7\">",
"      Fermaglich J, Hardman JM, Earle KM. Spontaneous progressive multifocal leukoencephalopathy. Neurology 1970; 20:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/8\">",
"      Aquino K, Koralnik IJ, Silvers D. Clinical Reasoning: An 83-year-old woman with progressive hemiataxia, tremor, and infratentorial lesions. Neurology 2011; 77:e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/9\">",
"      Tan IL, Koralnik IJ, Rumbaugh JA, et al. Progressive multifocal leukoencephalopathy in a patient without immunodeficiency. Neurology 2011; 77:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/10\">",
"      Gheuens S, Pierone G, Peeters P, Koralnik IJ. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry 2010; 81:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/11\">",
"      Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name? Ann Neurol 2006; 60:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/12\">",
"      Garc&iacute;a-Su&aacute;rez J, de Miguel D, Krsnik I, et al. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 2005; 80:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/13\">",
"      Gonzalez H, Bolgert F, Camporo P, Leblond V. Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP). Hematol Cell Ther 1999; 41:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/14\">",
"      Vidarsson B, Mosher DF, Salamat MS, et al. Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease. Am J Hematol 2002; 70:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/15\">",
"      Saumoy M, Castells G, Escoda L, et al. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine. Leuk Lymphoma 2002; 43:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/16\">",
"      Cid J, Revilla M, Cervera A, et al. Progressive multifocal leukoencephalopathy following oral fludarabine treatment of chronic lymphocytic leukemia. Ann Hematol 2000; 79:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/17\">",
"      Power C, Gladden JG, Halliday W, et al. AIDS- and non-AIDS-related PML association with distinct p53 polymorphism. Neurology 2000; 54:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/18\">",
"      Martinez AJ, Ahdab-Barmada M. The neuropathology of liver transplantation: comparison of main complications in children and adults. Mod Pathol 1993; 6:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/19\">",
"      Mateen FJ, Muralidharan R, Carone M, et al. Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol 2011; 70:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/20\">",
"      Amend KL, Turnbull B, Foskett N, et al. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 2010; 75:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/21\">",
"      Holman RC, Janssen RS, Buehler JW, et al. Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data. Neurology 1991; 41:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/22\">",
"      Levy RM, Bredesen DE, Rosenblum ML. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. J Neurosurg 1985; 62:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/23\">",
"      Berger JR, Kaszovitz B, Post MJ, Dickinson G. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med 1987; 107:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/24\">",
"      Koralnik IJ, Schellingerhout D, Frosch MP. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-2004. A 66-year-old man with progressive neurologic deficits. N Engl J Med 2004; 350:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/25\">",
"      Berger JR, Scott G, Albrecht J, et al. Progressive multifocal leukoencephalopathy in HIV-1-infected children. AIDS 1992; 6:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/26\">",
"      Vandersteenhoven JJ, Dbaibo G, Boyko OB, et al. Progressive multifocal leukoencephalopathy in pediatric acquired immunodeficiency syndrome. Pediatr Infect Dis J 1992; 11:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/27\">",
"      Dankner WM, Lindsey JC, Levin MJ, Pediatric AIDS Clinical Trials Group Protocol Teams 051, 128, 138, 144, 152, 179, 190, 220, 240, 245, 254, 300 and 327. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J 2001; 20:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/28\">",
"      Haider S, Nafziger D, Gutierrez JA, et al. Progressive multifocal leukoencephalopathy and idiopathic CD4+lymphocytopenia: a case report and review of reported cases. Clin Infect Dis 2000; 31:E20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/29\">",
"      Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002; 8 Suppl 2:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/30\">",
"      Engsig FN, Hansen AB, Omland LH, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 2009; 199:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/31\">",
"      Shankar SK, Satishchandra P, Mahadevan A, et al. Low prevalence of progressive multifocal leukoencephalopathy in India and Africa: is there a biological explanation? J Neurovirol 2003; 9 Suppl 1:59.",
"     </a>",
"    </li>",
"    <li>",
"     Nulojix (belatacept): Risk Evaluation and Mitigation Strategy (REMS). Increased risk of post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system (CNS), and progressive multifocal leukoencephalopathy (PML). www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm262210.htm (Accessed on July 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/33\">",
"      Griny&oacute; J, Charpentier B, Pestana JM, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010; 90:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/34\">",
"      von Geldern G, Pardo CA, Calabresi PA, Newsome SD. PML-IRIS in a patient treated with brentuximab. Neurology 2012; 79:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/35\">",
"      Talamonti M, Spallone G, Di Stefani A, et al. Efalizumab. Expert Opin Drug Saf 2011; 10:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/36\">",
"      Kothary N, Diak IL, Brinker A, et al. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 2011; 65:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/37\">",
"      Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum 2010; 62:3191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/38\">",
"      Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002; 99:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/39\">",
"      Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007; 56:2116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/40\">",
"      Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/41\">",
"      Neff RT, Hurst FP, Falta EM, et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 2008; 86:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/42\">",
"      Manfro RC, Vedolin L, Cantarelli M, et al. Progressive multifocal leukoencephalopathy in a kidney transplant recipient after conversion to mycophenolic acid therapy. Transpl Infect Dis 2009; 11:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/43\">",
"      Pavlovic AM, Bonaci-Nikolic B, Kozic D, et al. Progressive multifocal leukoencephalopathy associated with mycophenolate mofetil treatment in a woman with lupus and CD4+ T-lymphocyte deficiency. Lupus 2012; 21:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/44\">",
"      Newton P, Aldridge RD, Lessells AM, Best PV. Progressive multifocal leukoencephalopathy complicating systemic lupus erythematosus. Arthritis Rheum 1986; 29:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/45\">",
"      Warnatz K, Peter HH, Schumacher M, et al. Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheum Dis 2003; 62:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/46\">",
"      McGuire JL, Fridman V, W&uuml;thrich C, et al. Progressive multifocal leukoencephalopathy associated with isolated CD8+ T-lymphocyte deficiency mimicking tumefactive MS. J Neurovirol 2011; 17:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/47\">",
"      Bernal-Cano F, Joseph JT, Koralnik IJ. Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient. J Neurovirol 2007; 13:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/48\">",
"      Lima MA, Drislane FW, Koralnik IJ. Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology 2006; 66:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/49\">",
"      Whiteman ML, Post MJ, Berger JR, et al. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology 1993; 187:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/50\">",
"      Skiest DJ. Focal neurological disease in patients with acquired immunodeficiency syndrome. Clin Infect Dis 2002; 34:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/51\">",
"      Sahraian MA, Radue EW, Eshaghi A, et al. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis. Eur J Neurol 2012; 19:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/52\">",
"      Bergui M, Bradac GB, Oguz KK, et al. Progressive multifocal leukoencephalopathy: diffusion-weighted imaging and pathological correlations. Neuroradiology 2004; 46:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/53\">",
"      K&uuml;ker W, Mader I, N&auml;gele T, et al. Progressive multifocal leukoencephalopathy: value of diffusion-weighted and contrast-enhanced magnetic resonance imaging for diagnosis and treatment control. Eur J Neurol 2006; 13:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/54\">",
"      Post MJ, Yiannoutsos C, Simpson D, et al. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. AJNR Am J Neuroradiol 1999; 20:1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/55\">",
"      Lassmann H, Lucchinetti CF. Cortical demyelination in CNS inflammatory demyelinating diseases. Neurology 2008; 70:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/56\">",
"      Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 2003; 9 Suppl 1:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/57\">",
"      Koralnik IJ. New insights into progressive multifocal leukoencephalopathy. Curr Opin Neurol 2004; 17:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/58\">",
"      Huang D, Cossoy M, Li M, et al. Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients. Ann Neurol 2007; 62:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/59\">",
"      Yousry TA, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2012; 72:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/60\">",
"      Arnaud FX, Hissene A, M&eacute;tivier D, et al. Gadolinium enhancement in brain magnetic resonance imaging in progressive multifocal leukoencephalopathy after natalizumab monotherapy: is it really atypical? J Neuroradiol 2012; 39:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/61\">",
"      Moll NM, Rietsch AM, Ransohoff AJ, et al. Cortical demyelination in PML and MS: Similarities and differences. Neurology 2008; 70:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/62\">",
"      W&uuml;thrich C, Koralnik IJ. Frequent infection of cortical neurons by JC virus in patients with progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 2012; 71:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/63\">",
"      Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011; 77:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/64\">",
"      Gheuens S, Smith DR, Wang X, et al. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology 2012; 78:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/65\">",
"      Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011; 76:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/66\">",
"      Vendrely A, Bienvenu B, Gasnault J, et al. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol 2005; 109:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/67\">",
"      Tan K, Roda R, Ostrow L, et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009; 72:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/68\">",
"      Du Pasquier RA, Corey S, Margolin DH, et al. Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual. Neurology 2003; 61:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/69\">",
"      Koralnik IJ, W&uuml;thrich C, Dang X, et al. JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol 2005; 57:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/70\">",
"      W&uuml;thrich C, Cheng YM, Joseph JT, et al. Frequent infection of cerebellar granule cell neurons by polyomavirus JC in progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 2009; 68:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/71\">",
"      Dang X, Vidal JE, Oliveira AC, et al. JC virus granule cell neuronopathy is associated with VP1 C terminus mutants. J Gen Virol 2012; 93:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/72\">",
"      W&uuml;thrich C, Dang X, Westmoreland S, et al. Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol 2009; 65:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/73\">",
"      Koralnik IJ, Boden D, Mai VX, et al. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 1999; 52:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/74\">",
"      Skolasky RL, Dal Pan GJ, Olivi A, et al. HIV-associated primary CNS lymorbidity and utility of brain biopsy. J Neurol Sci 1999; 163:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/75\">",
"      Cinque P, Scarpellini P, Vago L, et al. Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. AIDS 1997; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/76\">",
"      Marzocchetti A, Di Giambenedetto S, Cingolani A, et al. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 2005; 43:4175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/77\">",
"      Cinque P, Bossolasco S, Lundkvist A. Molecular analysis of cerebrospinal fluid in viral diseases of the central nervous system. J Clin Virol 2003; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/78\">",
"      Cinque P, Koralnik IJ, Clifford DB. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol 2003; 9 Suppl 1:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/79\">",
"      Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/80\">",
"      Yiannoutsos CT, Major EO, Curfman B, et al. Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. Ann Neurol 1999; 45:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/81\">",
"      Bossolasco S, Calori G, Moretti F, et al. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis 2005; 40:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/82\">",
"      Koralnik IJ. Overview of the cellular immunity against JC virus in progressive multifocal leukoencephalopathy. J Neurovirol 2002; 8 Suppl 2:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/83\">",
"      Du Pasquier RA, Kuroda MJ, Schmitz JE, et al. Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1(p36) in patients with proven or possible progressive multifocal leukoencephalopathy. J Virol 2003; 77:11918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/84\">",
"      Du Pasquier RA, Kuroda MJ, Zheng Y, et al. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004; 127:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/85\">",
"      Du Pasquier RA, Autissier P, Zheng Y, et al. Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies. AIDS 2005; 19:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/86\">",
"      Lima MA, Marzocchetti A, Autissier P, et al. Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy. J Virol 2007; 81:3361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/87\">",
"      Berger JR, Levy RM, Flomenhoft D, Dobbs M. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 1998; 44:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26681/abstract/88\">",
"      Katz-Brull R, Lenkinski RE, Du Pasquier RA, Koralnik IJ. Elevation of myoinositol is associated with disease containment in progressive multifocal leukoencephalopathy. Neurology 2004; 63:897.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1694 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B3512DFB86-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_3_26681=[""].join("\n");
var outline_f26_3_26681=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Classic PML",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H60052309\">",
"      - Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Neuropathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Inflammatory PML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      JC virus cerebellar granule cell neuronopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      JC virus encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prognostic markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1694\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1694|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/20/14656\" title=\"diagnostic image 1\">",
"      Brain MRI of PML in HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/50/2854\" title=\"diagnostic image 2\">",
"      PML after organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1694|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/55/27514\" title=\"figure 1\">",
"      JC virus granule cell neuronopathy in PML",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=related_link\">",
"      Approach to HIV-infected patients with central nervous system lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1734?source=related_link\">",
"      Epidemiology of JC and BK virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30009?source=related_link\">",
"      Idiopathic CD4+ lymphocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23032?source=related_link\">",
"      Natalizumab for relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3429?source=related_link\">",
"      Natalizumab for treatment of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17336?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Prognosis and treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_3_26682="Prognosis and management of congenital long QT syndrome";
var content_f26_3_26682=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prognosis and management of congenital long QT syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/3/26682/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/3/26682/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/3/26682/contributors\">",
"     Stephen P Seslar, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/3/26682/contributors\">",
"     Charles I Berul, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/3/26682/contributors\">",
"     Mark E Josephson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/3/26682/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/3/26682/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/3/26682/contributors\">",
"     Samuel Asirvatham, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/3/26682/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/3/26682/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/3/26682/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long QT syndrome (LQTS) represents a diverse group of disorders of myocardial repolarization that is characterized by prolongation of the QT interval on the electrocardiogram (ECG). LQTS is important clinically because it is associated with an increased risk of a life-threatening form of polymorphic ventricular tachycardia called torsades de pointes (TdP) or \"twisting of points\" (",
"    <a class=\"graphic graphic_waveform graphicRef53891 graphicRef73827 \" href=\"UTD.htm?3/40/3719\">",
"     waveform 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    LQTS can be inherited or acquired. The congenital forms are caused either by autosomal dominant or less often by autosomal recessive genetic mutations, almost all of which encode for abnormal cardiac ion channels (",
"    <a class=\"graphic graphic_table graphicRef58151 \" href=\"UTD.htm?31/27/32189\">",
"     table 1",
"    </a>",
"    ). The acquired forms are caused by a large number of stimuli, most frequently antiarrhythmic and other types of drugs and electrolyte and metabolic abnormalities (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link\">",
"     \"Genetics of congenital and acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An important distinction between the congenital and acquired forms is that the latter can usually be reversed by correction of the underlying disorder or discontinuation of the offending drug. However, some patients with acquired LQTS appear to have a \"forme fruste\" of congenital LQTS in which a mutation or polymorphism in one of the LQTS genes is clinically silent until the patient is exposed to a particular drug or other predisposing factor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link&amp;anchor=H11#H11\">",
"     \"Acquired long QT syndrome\", section on 'Mutations in LQTS genes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The heterogeneity of LQTS makes the diagnosis, therapy, and prognosis of this disorder imprecise and difficult. Nonetheless, certain generalizations and guidelines can be made concerning the management of these patients.",
"   </p>",
"   <p>",
"    The natural history, prognosis, and treatment of congenital LQTS will be reviewed here. Clinical manifestations and criteria for the diagnosis of congenital LQTS and issues related to the management of acquired LQTS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link\">",
"     \"Clinical features of congenital long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=see_link\">",
"     \"Diagnosis of congenital long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is difficult to determine accurately, the incidence of congenital LQTS in the United States has been estimated to be one in 7000 to 10,000 in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Congenital LQTS is thought to account for 3000 to 4000 of the annual sudden deaths in childhood in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features of congenital long QT syndrome\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The natural history and prognosis of the LQTS have been elucidated largely from epidemiologic studies and by genetic identification of affected patients and families.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiologic studies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     International LQTS Registry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest descriptive data available for LQTS comes from prospective reports from the International LQTS Registry [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. This ongoing study, begun in 1979 with the creation of an international registry, was designed to determine the natural history of LQTS in the index affected subjects (probands) and their family members. Subjects with the LQTS as well as their first-degree and second-degree relatives were evaluated annually.",
"   </p>",
"   <p>",
"    A 1998 report assessed 479 probands with 1041 affected family members [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/5\">",
"     5",
"    </a>",
"    ]. All had a corrected QT interval (QTc) &gt;0.44 sec (440 msec). The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 76 percent of probands and 22 percent of affected family members had a cardiac event, defined as syncope, aborted cardiac arrest, and sudden cardiac death (SCD).",
"     </li>",
"     <li>",
"      Approximately 70 percent of probands were women. A higher risk of TdP in women has also been noted with acquired LQTS caused by a class IA or III antiarrhythmic drug [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Male probands tended to have their first cardiac event at an earlier age than female probands (8&plusmn;7 years versus 14&plusmn;10 years). The risk of a cardiac event was higher in males until puberty and higher in females during adulthood (",
"      <a class=\"graphic graphic_figure graphicRef68308 \" href=\"UTD.htm?37/37/38493\">",
"       figure 1",
"      </a>",
"      ). A first cardiac event after age 15 occurred in only 8 percent of males compared to 40 percent of females. A similar pattern was seen in affected family members.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lower event rates in adult men may be explained by the findings in patients with LQTS types 1 and 2 (LQT1 and LQT2) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/8\">",
"     8",
"    </a>",
"    ], which account for the great majority of identified mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/9\">",
"     9",
"    </a>",
"    ]. In these syndromes and particularly at slow heart rates, men have shorter mean QTc values (by 12 to 22 msec) than do women or children.",
"   </p>",
"   <p>",
"    Another report from this registry evaluated the risk of a cardiac event in 637 first- or second-degree relatives (513 were not taking beta blockers) of 151 probands [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/10\">",
"     10",
"    </a>",
"    ]. The findings among these family members included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A QTc &gt;0.44 sec was seen in 50 percent; 10 percent had a QTc &gt;0.50 sec.",
"     </li>",
"     <li>",
"      Cardiac events (syncope, aborted cardiac arrest, or SCD) occurred in 17 percent. An event was more common in those receiving a beta blocker (46 versus 10 percent), perhaps because these patients had had a prior cardiac event. Among family members not taking a beta blocker, the risk of a cardiac event before age 40 increased with higher QTc values.",
"     </li>",
"     <li>",
"      As in probands, adult women had higher event rates than adult men (20 versus 13 percent). No such gender relationship was observed in those less than 18 years of age.",
"     </li>",
"     <li>",
"      First-degree relatives had a higher incidence of cardiac events than second degree relatives (26 versus 10 percent).",
"     </li>",
"     <li>",
"      The clinical severity of the LQTS (QTc interval, age at first cardiac event, incidence of a cardiac event by age 40) in the proband did not predict the clinical severity of the LQTS syndrome in parents or siblings [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The QTc was a strong and significant predictor of a cardiac event rate. The odds ratio was 2.18 in those with a QTc &gt;0.44 to 0.46 sec, 3.93 when the QTc was &gt;0.46 to 0.50 sec, and 9.66 when the QTc was &gt;0.50 sec.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Schwartz study",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second retrospective study evaluated the clinical course of 233 patients for a period of up to 15 years after their initial syncopal episode [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/12\">",
"     12",
"    </a>",
"    ]. Approximately one-half of the patients were either taking beta blockers or had undergone a left cervicothoracic sympathectomy, while the rest were on no specific antiadrenergic therapy.",
"   </p>",
"   <p>",
"    This is the only study that examined the effect of different treatment regimens on mortality in patients with congenital LQTS. The more important results of this study are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who were not treated with antiadrenergic therapy had a mortality rate of over 20 percent at one year and 53 percent by the 15th year.",
"     </li>",
"     <li>",
"      Patients treated with antiadrenergic therapy had a mortality rate of approximately 9 percent at three years, and thereafter remained stable.",
"     </li>",
"     <li>",
"      Thirty-nine percent of family members had QTc intervals that were considered prolonged (greater than 0.44 sec). Twenty percent of family members with prolonged QT intervals had a history of presyncope, syncope, or cardiac arrest. Interestingly, family members with normal QTc intervals also had an appreciable incidence (5 percent) of cardiac arrest.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     International Pediatric Electrophysiology Study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Pediatric Electrophysiology Society published a retrospective analysis of the clinical features of 287 children (mean age 6.8 years). with the LQTS in 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/13\">",
"     13",
"    </a>",
"    ]. Despite the limitations of this study (which are beyond the scope of this review), the authors identified two factors associated with a very high risk for SCD or syncope: a QTc greater than 0.60 sec and medical noncompliance after an event. Cardiac arrest was the presenting manifestation in 9 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major risk factors for syncope or SCD in probands derived from these three epidemiologic studies were [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/3,12,13\">",
"     3,12,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Congenital deafness",
"     </li>",
"     <li>",
"      History of syncope",
"     </li>",
"     <li>",
"      Documented history of ventricular arrhythmias",
"     </li>",
"     <li>",
"      Family history of SCD",
"     </li>",
"     <li>",
"      Female gender",
"     </li>",
"     <li>",
"      A QTc length of greater than 0.60 sec",
"     </li>",
"     <li>",
"      Medical noncompliance after an event",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Affected family members (QTc &gt;0.44 sec) were at an increased risk of a significant cardiac event if they were a female older than 18 years of age or were a first degree relative with a QTc above 0.50 sec.",
"   </p>",
"   <p>",
"    An assessment of risk factors in adults (age 18 to 40 years) with LQT1, 2, or 3 was derived from a study of 812 mutation-confirmed LQTS patients (probands and affected family members) from the International LQTS registry described above [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/14\">",
"     14",
"    </a>",
"    ]. Factors associated with an increased risk of aborted cardiac arrest or LQTS-associated death in adulthood included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Female gender (hazard ratio [HR] 2.68, CI 1.10 to 6.50)",
"     </li>",
"     <li>",
"      QTc 500 to 549 msec (HR 3.34, CI 1.49 to 7.49)",
"     </li>",
"     <li>",
"      QTc &ge;550 msec (HR 6.35, CI 2.82 to 14.32)",
"     </li>",
"     <li>",
"      Syncopal events after age 18 (HR 5.10, CI 2.50 to 10.39)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the analysis was limited to the 570 patients who had no history of cardiac events prior to age 18, the same risk factors with similar hazard ratios were noted. Patients with LQT2 were more likely than those with LQT1 or 3 to experience the combined endpoint that included syncope, aborted sudden death, and LQTS-related death. However, in analyses limited to life-threatening events (aborted sudden death and LQTS-related death), genotype was not an independent predictor or outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Importance of genotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seven different genetic defects have thus far been identified in the congenital LQTS: five involve potassium channels, one involves the sodium channel, and one involves ankyrin B, a plasma membrane protein that physically links the lipid bilayer to the membrane skeleton (",
"    <a class=\"graphic graphic_table graphicRef58151 \" href=\"UTD.htm?31/27/32189\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link\">",
"     \"Genetics of congenital and acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of genetic analysis permits unambiguous detection of affected individuals, while measurement of the QTc does not. This was illustrated in a study that found significant overlap in QTc durations between carriers and noncarriers of LQT1 within families [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/15\">",
"     15",
"    </a>",
"    ]. Using a QTc interval of 0.44 sec as the cutoff, 5 percent of carriers were classified as normal, while 15 percent of noncarriers were classified as abnormal. Thus, in families affected by the long QT syndrome, measurement of the QTc interval alone may not permit an accurate diagnosis. Consistent with the above studies, 63 percent of carriers had a history of syncope and 4 percent of aborted SCD.",
"   </p>",
"   <p>",
"    Genetic testing to identify the type of LQTS is commercially available for clinical use. The practical application of genetic testing is limited by the inability to detect mutations in many patients, meaning that a negative test does not exclude disease. As an example, testing was performed for LQT1, LQT2, LQT3, LQT5, and LQT6 in a study of 262 unrelated individuals; a mutation was identified in only 177 (68 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=see_link&amp;anchor=H24#H24\">",
"     \"Diagnosis of congenital long QT syndrome\", section on 'Genetic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic data in patients with LQTS have been used to assess the correlation between genotype and clinical events. In two studies, the LQTS genotype was determined and compared with the frequency of cardiac events (syncope, aborted cardiac arrest, or SCD) through age 40 and prior to any medical treatment, with differing results. These studies evaluated patients with known LQT1, LQT2, and LQT3, which account for more than 90 percent of cases of congenital LQTS (42, 45, and 8 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/9,16\">",
"     9,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The International LQTS Registry evaluated 541 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/17\">",
"       17",
"      </a>",
"      ]. The frequency of cardiac events (syncope, aborted cardiac arrest, or SCD) was significantly higher in patients with mutations at the LQT1 and LQT2 loci compared to those with mutations at LQT3 (63 and 46 versus 18 percent, respectively); however, the cumulative mortality through age 40 was similar in the three groups (",
"      <a class=\"graphic graphic_figure graphicRef75990 \" href=\"UTD.htm?36/10/37038\">",
"       figure 2",
"      </a>",
"      ). Thus, the likelihood of dying during a cardiac event was significantly higher in families with LQT3 (20 versus 4 percent in LQT1 and LQT2).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to a higher frequency of cardiac events, LQT1 was also associated with an earlier onset of events. Approximately 53 percent had a first cardiac event by age 15, compared to 29 and 6 percent in LQTS 2 and LQTS 3, respectively (",
"    <a class=\"graphic graphic_figure graphicRef75990 \" href=\"UTD.htm?36/10/37038\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In contrast to these findings, a later report from Italy of 647 patients found that the frequency of cardiac events (syncope, aborted cardiac arrest, or sudden death) before the age of 40 was lower for patients with mutations at the LQT1 locus compared to those with mutations at LQT2 and LQT3 (30 versus 46 and 42 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differences between these two studies may be explained by differences between patient populations, selection bias (the inclusion of only those family members who had come to clinical attention), and the inclusion in the studies of multiple members from the same family (which may confound the findings with the effects of other genes and the variable malignancy of specific mutations).",
"   </p>",
"   <p>",
"    Another study from the LQTS registry evaluated the impact of specific genetic abnormalities among 600 patients with LQT1 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/19\">",
"     19",
"    </a>",
"    ]. Cardiac event rates were significantly higher in patients with mutations in the transmembrane portion of the ion channel and in those that caused more than a 50 percent reduction in the potassium channel current.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Triggers of arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is also an association between genotype and triggers of arrhythmia (",
"    <a class=\"graphic graphic_figure graphicRef64239 \" href=\"UTD.htm?9/27/9662\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/16,20-22\">",
"     16,20-22",
"    </a>",
"    ]. In particular:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with LQT1 primarily have exercise-related arrhythmic events; in a review that included 371 patients with LQT1, exercise was the trigger in 62 percent of arrhythmic events [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/16\">",
"       16",
"      </a>",
"      ]. In addition, events related to swimming (occurring either immediately after diving into water or during recreational or competitive swimming activities) may be specific for LQT1 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/21,23,24\">",
"       21,23,24",
"      </a>",
"      ]. The sensitivity of patients with LQT1 to exercise may be related to exaggerated prolongation of the QT interval during exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Events triggered by auditory stimuli, such as an alarm clock or telephone ringing, are most typically seen in LQT2 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acute arousal events (such as exercise, emotion, or noise) are much more likely triggers in LQT1 and LQT2 than LQT3 (85 and 67 versus 33 percent in one report) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/16,22\">",
"       16,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with LQT3 are at highest risk of events when at rest or asleep, while the risk is low during sleep in LQT1, accounting for only 3 percent of events [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/16\">",
"       16",
"      </a>",
"      ]. Patients with LQT3 may have fewer events with exercise or stress because they significantly shorten their QTc with tachycardia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/26\">",
"       26",
"      </a>",
"      ] and therefore become less susceptible to catecholamine-induced arrhythmias. These findings are consistent with clinical observations that these patients derive less or perhaps no benefit from therapy with beta blockers [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/16,27\">",
"       16,27",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Beta blockers'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Jervell and Lange-Nielsen syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a series of 186 patients, this autosomal recessive form of congenital LQTS was associated with a more malignant phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/28\">",
"     28",
"    </a>",
"    ]. Although referral bias may have contributed to these results, the young age at onset of symptoms and the poor response to medical therapy suggest the need to consider aggressive therapy in these patients (ie, an implantable cardioverter-defibrillator). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical features of congenital long QT syndrome\", section on 'Congenital sensorineural deafness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Influence of pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is accompanied by a variety of changes that can provoke new or exacerbate previously occurring arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7674?source=see_link\">",
"     \"Ventricular arrhythmias during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14362?source=see_link\">",
"     \"Supraventricular arrhythmias during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of pregnancy in patients with congenital LQTS and the possible influence of genotype is discussed separately. Beta blockers appear to be protective [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical features of congenital long QT syndrome\", section on 'Influence of pregnancy'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H15\">",
"     'Beta blockers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients with congenital and acquired LQTS differs to some extent because of pathophysiologic differences between the two forms (",
"    <a class=\"graphic graphic_table graphicRef70083 \" href=\"UTD.htm?29/46/30443\">",
"     table 3",
"    </a>",
"    ). As an example, a bradycardia is usually associated with TdP in acquired LQTS, whereas catecholamine surges trigger TdP in some types of congenital LQTS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9591?source=see_link\">",
"     \"Pathophysiology of the long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following discussion is limited to the treatment of congenital LQTS. The management of acquired LQTS is presented separately; it involves acute therapy of arrhythmia, discontinuation of any precipitating drug, and correction of any metabolic abnormalities, such as hypokalemia or hypomagnesemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The therapeutic approach to congenital LQTS begins with medical interruption of the sympathetic input to the myocardium with beta blockers. If necessary, other medications may be added to control nonmalignant ventricular arrhythmias. Surgical left cervicothoracic sympathectomy is another method to reduce cardiac sympathetic input but is no longer frequently performed in the United States. Other therapies include permanent cardiac pacing, an implantable cardioverter-defibrillator (ICD), and targeted pharmacologic interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the appreciable risk of TdP and SCD without treatment (",
"    <a class=\"graphic graphic_figure graphicRef68308 \" href=\"UTD.htm?37/37/38493\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef75990 \" href=\"UTD.htm?36/10/37038\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/5,17\">",
"     5,17",
"    </a>",
"    ], all symptomatic patients with congenital LQTS should be treated. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Clinical course'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some have suggested that the decision to treat asymptomatic patients be determined by an assessment of the risk of developing ventricular arrhythmias. As an example, one expert recommended definitive treatment of asymptomatic patients with congenital LQTS in the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Newborns and infants",
"     </li>",
"     <li>",
"      Patients with sensorineural hearing loss",
"     </li>",
"     <li>",
"      Affected siblings with LQTS and SCD",
"     </li>",
"     <li>",
"      Extremely prolonged QTc (&gt;0.60 sec) or T wave alternans",
"     </li>",
"     <li>",
"      To prevent family or patient anxiety",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, it is difficult to identify patients who will become symptomatic and SCD can be the first manifestation of the disease (occurring in 9 percent in an international study in children) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/13\">",
"     13",
"    </a>",
"    ]. As a result, we recommend therapy in",
"    <strong>",
"     all",
"    </strong>",
"    patients with congenital LQTS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers are a mainstay of therapy in both asymptomatic and symptomatic patients with congenital LQTS, since they reduce both syncope and SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/30\">",
"     30",
"    </a>",
"    ]. Beta blockers interrupt the \"trigger\" for TdP and may shorten the QT interval by decreasing activation from the left stellate ganglion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9591?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathophysiology of the long QT syndrome\", section on 'Increased sympathetic activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goal of beta blocker therapy is to blunt the maximal heart rate achieved during exertion, and is particularly important in patients with LQT1 who are at increased risk during exercise. A theoretical concern is that beta blockers also decrease the sinus rate, a property that may prolong repolarization and potentially predispose to TdP. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Triggers of arrhythmia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The overall benefit of beta blocker therapy in congenital LQTS has been demonstrated in a number of observational studies, with many of the patients recruited from the International LQTS Registry [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/14,16,27,31-33\">",
"     14,16,27,31-33",
"    </a>",
"    ]. In a series of 869 registry patients treated with a beta blocker, the following findings were noted when five-year periods before and after beta blocker therapy were compared [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta blockers reduced the rate of cardiac events (syncope, aborted cardiac arrest, or SCD) in probands (0.97 versus 0.31 events per year on therapy) and in affected family members (0.26 versus 0.15 events per year).",
"     </li>",
"     <li>",
"      Despite this benefit, 32 percent of patients with syncope or aborted cardiac arrest before beta blocker therapy had another cardiac event during the five-year period while on a beta blocker (hazard ratio 5.8 when compared to those who were asymptomatic before therapy).",
"     </li>",
"     <li>",
"      Recurrent cardiac arrest occurred in 14 percent of patients with a history of aborted SCD before therapy (hazard ratio 12.9 compared to patients who were asymptomatic before therapy); almost one-half of these events occurred within the first six months of therapy (",
"      <a class=\"graphic graphic_figure graphicRef78184 \" href=\"UTD.htm?5/13/5342\">",
"       figure 4",
"      </a>",
"      ). Prior syncope was less of a risk factor for cardiac arrest during therapy (hazard ratio 3.1). These risks were increased in children who were younger than 10 years of age when beta blockers were started.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Beta blockers also markedly decrease the risk for cardiac events in women with LQTS during the postpartum period from 1 in 50 pregnancies to 1 in 2500 pregnancies (odds ratio 0.023) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because various beta blockers differ in their pharmacologic properties (eg, beta-1 selectivity, lipophilicity, half life, etc), there appear to be differences in the efficacy of beta blockers on QT shortening and clinical outcomes. In a retrospective cohort study of 382 patients (56 percent female, median age 14 years) with LQT1 or LQT2 who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    (134 patients),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    (147 patients), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    (101 patients) and followed for up to eight years, the following findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      had significantly greater QTc shortening (27 versus 14 versus 12 milliseconds with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"       nadolol",
"      </a>",
"      , respectively).",
"     </li>",
"     <li>",
"      Patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      had significantly more breakthrough clinical events (syncope, aborted cardiac arrest, ICD shock, sudden cardiac death) compared with those receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"       nadolol",
"      </a>",
"      (29 versus 8 versus 7 percent, respectively; odds ratio 3.9, 95% CI 1.2-13.1 for metoprolol versus any other beta blocker).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Though limited by its retrospective nature and some baseline differences in clinical characteristics between the cohort groups, the above data suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    might be the preferred beta blocker for therapy of patients with LQT1 or LQT2. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Role of beta blockers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Effect of genotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical efficacy of beta blockers in relation to genotype has been examined in several observational studies of patients with LQT1, LQT2, or LQT3 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/16,27,31\">",
"     16,27,31",
"    </a>",
"    ], which account for over 90 percent of known mutations in congenital LQTS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients with LQT1 derived the greatest benefit and those with LQT2 derived some benefit. Efficacy in patients with LQT3, which is least common, is less clear. The following illustrates the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 271 patients treated with a beta blocker, those with LQT1 were highly likely to be free from recurrence of cardiac events and had a very low SCD rate (81 and 4 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/16\">",
"       16",
"      </a>",
"      ]. The freedom from recurrence rate with beta blockers was lower in patients with LQT2 and LQT3 (59 and 50 percent), and the rate of SCD was highest in patients with LQT3 (17 percent).",
"     </li>",
"     <li>",
"      In a study of 139 patients whose cardiac outcomes were compared in matched five-year periods before and after beta blocker therapy, beta blockers significantly reduced the proportion of patients with a cardiac event in those with LQT1 (19 versus 57 percent before beta blockers) and LQT2 (36 versus 57 percent before beta blockers), but not in LQT3 patients (14 percent both before and after beta blockers) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 335 patients with genotyped LQTS treated with beta blockers for an average of five years, the reduction in the proportion of patients experiencing events during therapy was greatest in those with LQT1 (10 versus 39 percent), and significantly less in those with LQT2 (23 versus 58 percent) or LQT3 patients (32 versus 57 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of compliance with beta blocker therapy in LQT1 was highlighted in a retrospective study of 216 genotyped patients followed for a median time of 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/35\">",
"     35",
"    </a>",
"    ]. Among the 12 patients who suffered sudden cardiac arrest or sudden cardiac death after beta blockers were prescribed, 11 were either noncompliant",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    on a QT-prolonging drug. The only death in a beta blocker-compliant patient not on a QT-prolonging drug occurred in a patient with Jervell and Lange-Nielsen syndrome, which is a more malignant form of LQT1. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Jervell and Lange-Nielsen syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The increased efficacy of beta blockers in LQT1 is probably related to the sympathetic sensitivity in this disorder. In animal models that mimic LQT1, LQT2, and LQT3, beta-adrenergic stimulation induced TdP in LQT1 and LQT2 by enhancing transmural dispersion of repolarization, while it suppressed TdP in LQT3 by decreasing dispersion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/36\">",
"     36",
"    </a>",
"    ]. Beta blockade prevented the induction of TdP in LQT1 and LQT2, but facilitated its induction in LQT3.",
"   </p>",
"   <p>",
"    Most humans with LQT1 show paradoxical prolongation of the QT interval after an infusion of epinephrine, which can also be used to unmask latent mutation carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link&amp;anchor=H4#H4\">",
"     \"Genetics of congenital and acquired long QT syndrome\", section on 'LQT type 1'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, patients with LQT3 significantly shorten their QT interval with tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/26\">",
"     26",
"    </a>",
"    ], making them less susceptible to catecholamine-induced arrhythmias. This could explain both the reduced efficacy of beta blockers and the lower rate of events triggered by exercise or stress in this disorder (",
"    <a class=\"graphic graphic_figure graphicRef64239 \" href=\"UTD.htm?9/27/9662\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/16,27\">",
"     16,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations for beta blocker use and appropriate dosing are discussed below. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Role of beta blockers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Left cardiac sympathetic denervation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left cardiac sympathetic denervation (also known as left stellate cardiac ganglionectomy) is another method to reduce cardiac events in patients with congenital LQTS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Because of the availability of other options, we rarely perform this procedure. Our main indications are failure of medical therapy and frequent shocks with an ICD despite medications. However, this procedure is more commonly utilized in some centers outside the United States and a few centers in the United States.",
"   </p>",
"   <p>",
"    Left cardiac sympathetic denervation interrupts the major source of norepinephrine released in the heart via preganglionic denervation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/41\">",
"     41",
"    </a>",
"    ]. Since denervation is preganglionic, there is no reinnervation; since the procedure does not completely eliminate catecholamines in the ventricles, it does not lead to postdenervation supersensitivity to catecholamines [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Left cervicothoracic sympathectomy (LCTS) involves resection of the left stellate ganglion, as well as the first four or five thoracic ganglia. The procedure results in significant cardiac denervation with an associated Horner's syndrome. Left stellectomy alone without removal of the upper thoracic ganglia provides inadequate sympathetic denervation and has been associated with a high rate of arrhythmia recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some surgeons perform an alternative procedure involving a high thoracic left sympathectomy (HTLS) in which the lower part of the stellate ganglion is removed along with the first four thoracic ganglia. This procedure, unlike LCTS, provides adequate cardiac denervation without a Horner's syndrome.",
"   </p>",
"   <p>",
"    The largest reported experience with cardiac sympathectomy for LQTS included 147 patients who underwent LCTS or HTLS between 1970 and 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/39\">",
"     39",
"    </a>",
"    ]. Indications for surgery included previous cardiac events (syncope or aborted cardiac arrest) in 145 and a family history of recurrent SCD in two. Previous therapy included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Beta blockers in 121 patients (with recurrent events in 91)",
"     </li>",
"     <li>",
"      Pacemakers in 12 patients (with recurrent events in all)",
"     </li>",
"     <li>",
"      ICDs in six patients (with repeated device discharges in five)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients had had multiple cardiac events prior to surgery (median six events); the median age at surgery was 17 years. At a median follow-up of eight years, the following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac sympathectomy significantly reduced the mean annual rate for any cardiac event (from 1.32 to 0.19 events per year) and for SCD or aborted cardiac arrest (from 0.13 to 0.06 events per year)",
"     </li>",
"     <li>",
"      Survival rates at five years free of SCD, SCD or aborted cardiac arrest, and any event were 95, 82, and 45 percent, respectively",
"     </li>",
"     <li>",
"      Patients with a QTc &ge;500 msec after surgery had a significantly higher subsequent event rate (13.4 versus 5.7 percent per year)",
"     </li>",
"     <li>",
"      Cardiac sympathectomy appeared to be more effective in patients with LQT1 than in those with LQT2 (subsequent event rate 9.7 versus 21.9 percent per year)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cardiac pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pacing has been employed in patients with congenital LQTS who remain symptomatic despite beta blockers, particularly those in whom bradycardia facilitates TdP. It has been suggested that patients with LQT3 may derive particular benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/43\">",
"     43",
"    </a>",
"    ], since bradycardia is not uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/44\">",
"     44",
"    </a>",
"    ] and dispersion of repolarization worsens during bradycardia in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/36\">",
"     36",
"    </a>",
"    ], which promotes pause-dependent arrhythmias.",
"   </p>",
"   <p>",
"    The best results with pacing have been achieved in patients on beta blockers with dual chamber pacing at a rate that reduces the QTc [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/43,45\">",
"     43,45",
"    </a>",
"    ]. Most authorities advocate dual chamber pacing because of the predisposition of these patients to have atrioventricular (AV) block, particularly in conjunction with beta blockers. In addition, AV synchrony may also limit ventricular premature beats, which can act as triggers of arrhythmia. Despite these potential advantages, ventricular pacing can cause heterogeneous depolarization that can predispose to ventricular arrhythmias. As a result, we recommend atrial pacing whenever feasible.",
"   </p>",
"   <p>",
"    The efficacy of combined beta blockade and long-term pacing in a report of 37 patients with a LQTS (one-half under age 18); 23 had recurrent syncope or TdP while on beta blockers",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    after HTLS and received a pacemaker [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/45\">",
"     45",
"    </a>",
"    ]. All of these patients were treated with maximally tolerated doses of beta blockers (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    50 to 200",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    50 to 200",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    60 to 120",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and permanent pacing at a mean rate of 82 beats per minute (range 60 to 100). The mean QTc during pacing was 0.50 sec, which represented an approximately 0.05 sec reduction from baseline. During a mean follow-up of 6.3 years, 76 percent remained free of symptoms. The incidence of SCD or aborted cardiac arrest was 24 percent overall and 17 percent in those who continued to take beta blockers.",
"   </p>",
"   <p>",
"    These data suggest that, although the combination of beta blockers and pacing is an effective therapy, the high mortality in patients with recurrent syncope or TdP while on beta blockers justify the use of an implantable cardioverter-defibrillator (ICD), which also has pacing capability [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Role of DDD pacing'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link\">",
"     \"General principles of the implantable cardioverter-defibrillator\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Implantable cardioverter-defibrillator",
"    </span>",
"    &nbsp;&mdash;&nbsp;ICDs have become an important component of therapy for patients with congenital LQTS who have recurrent symptoms on beta blockers, pacing, and in some instances, left cardiac sympathectomy. As these devices have become smaller and easier to implant, the indications for implantation have markedly increased.",
"   </p>",
"   <p>",
"    The potential efficacy of ICD has been demonstrated in a few small series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an initial report of 14 children (mean age 15 years) with congenital LQTS who underwent ICD placement, eight subsequently had appropriate shocks [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second study involved 35 patients (mean age 29, 15 age 21 or younger) with LQTS retrospectively identified from databases of two ICD manufacturers [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/47\">",
"       47",
"      </a>",
"      ]. Aborted SCD had occurred in 74 percent, syncope in 17 percent, and symptomatic TdP in 9 percent. After a mean follow-up of 31 months, there were no deaths and only three patients had complications related to the device (infection in two and a lead problem in one).",
"     </li>",
"     <li>",
"      A series from the Mayo Clinic included six adolescents (age 14 to 18) with congenital LQTS in whom an ICD was placed because of syncope with seizures despite beta blocker therapy, out-of-hospital cardiac arrest, or a family history of SCD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/48\">",
"       48",
"      </a>",
"      ]. Four had appropriate discharges for ventricular fibrillation at a median follow-up of three years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although no large trials are available, it is now accepted clinical practice to place ICDs in patients with persistent TdP despite conventional therapy, aborted cardiac arrest, or other high risk features. Patients who have had an episode of aborted cardiac arrest before beta blocker therapy have an appreciable risk of recurrent nonfatal or fatal cardiac arrest after therapy (14 percent at five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Role of ICD'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Complications are common with ICDs. These include infection, lead fracture and dislodgement, inappropriate discharges, psychiatric sequelae, and electrical storm [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Use in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general principles of ICD use and efficacy in children are mostly similar to those in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/46\">",
"     46",
"    </a>",
"    ]. However, there are several issues that are specific to children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/50\">",
"     50",
"    </a>",
"    ]. These include the longevity of the device and lead, the size of the patient relative to the device, and the increased physical activity and sports participation for children. In addition, many children with ICDs outlive their devices and leads, necessitating complex extraction and multiple replacement procedures.",
"   </p>",
"   <p>",
"    These issues need to be carefully considered when evaluating therapeutic options in children with congenital LQTS. The risks and benefits of each approach differ by age, size, symptoms, and, as noted above, LQTS mutation. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Importance of genotype'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Guidelines for use of an ICD in patients with congenital LQTS are presented below. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Role of ICD'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Targeted pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Programmed cardiac stimulation induces TdP in only about 10 percent of patients with congenital LQTS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/13,51\">",
"     13,51",
"    </a>",
"    ]. As a result, electrophysiology testing has not become a part of the routine evaluation and management of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advances in the genetics of the LQTS suggest that future therapeutic measures may be based upon drugs specific for the abnormal potassium or sodium channels in given subsets of patients with congenital LQTS. Such genotype-specific therapies are currently being evaluated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link\">",
"     \"Genetics of congenital and acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of other medical interventions have been proposed. All are adjunctive therapies to chronic beta blocker therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that potassium supplementation to produce long-term mild increases in serum potassium might improve repolarization abnormalities in patients with LQT2, a disorder characterized by mutations in HERG, a gene encoding a cardiac potassium channel that is modulated by extracellular potassium (",
"    <a class=\"graphic graphic_table graphicRef58151 \" href=\"UTD.htm?31/27/32189\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. On the other hand, reductions in serum potassium predispose to drug-induced acquired LQTS. Virtually all of the drugs that produce LQTS act by blocking the IKr current mediated by the potassium channel encoded by the HERG gene. The increase in risk with hypokalemia may be related to enhanced drug blockade of IKr [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of raising the serum potassium via potassium supplementation in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    was evaluated in a study of eight patients with LQT2 (with six different HERG mutations) who were treated for four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/53\">",
"     53",
"    </a>",
"    ]. This regimen raised the serum potassium from 4.0 to 5.2",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    a change that was associated with a significant 20 percent reduction in QTc (0.53 to 0.42 sec). In addition, QT dispersion and T wave morphology improved in most patients. Further studies are required to determine if this regimen will reduce the incidence of life-threatening events and how well tolerated it will be over the long-term [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Mexiletine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"     Mexiletine",
"    </a>",
"    is a class IB antiarrhythmic drug that acts as a sodium channel blocker. It exerts its predominant effect on the depolarized cell by shortening the plateau phase of the action potential. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    followed by exercise were evaluated in seven patients with LQT2 (which is caused by mutations in the cardiac potassium channel HERG gene) and six patients with LQT3 (which is caused by mutations in the cardiac sodium channel SCN5A gene) (",
"    <a class=\"graphic graphic_table graphicRef58151 \" href=\"UTD.htm?31/27/32189\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/26\">",
"     26",
"    </a>",
"    ]. Increased heart rate reduces the QT interval by accelerating repolarization and shortening the action potential. Fifteen control patients also exercised but did not receive mexiletine. The following results were obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The QTc duration significantly shortened after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"       mexiletine",
"      </a>",
"      only in patients with LQT3. This was expected because LQT3 results from a failure to inactivate sodium channels.",
"     </li>",
"     <li>",
"      Increased heart rate shortened the QTc interval into the normal range in patients with LQT3. The decrease in the QTc interval was greater than seen in patients with LQT2 or the healthy controls. Why this occurred is not clear, but it may explain the different circumstances associated with symptomatic events in the two types of congenital LQTS. Patients with LQT3 most often experience cardiac events while at rest or during sleep, while patients with LQT2 tend to experience events in the setting of heightened emotions or exercise (",
"      <a class=\"graphic graphic_figure graphicRef64239 \" href=\"UTD.htm?9/27/9662\">",
"       figure 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/16,26\">",
"       16,26",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Triggers of arrhythmia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Preliminary evidence suggests that differing in vivo responses to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    among LQT3 patients with various SCN5A mutations are mirrored by differing in vitro biophysical profiles among the mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/56\">",
"     56",
"    </a>",
"    ]. LQT3 patients who demonstrate a shortened QT interval in response to mexiletine, but not those without such a response, carry mutations that shift the steady-state inactivation curves to negative voltages and have greater mexiletine-induced use-dependent block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Flecainide",
"    </span>",
"    &nbsp;&mdash;&nbsp;LQT3 is caused by mutations in the sodium channel gene (SCN5A) (",
"    <a class=\"graphic graphic_table graphicRef58151 \" href=\"UTD.htm?31/27/32189\">",
"     table 1",
"    </a>",
"    ). Although class IB sodium channel blockers, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    , can shorten the QTc in patients with LQT3 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/26\">",
"     26",
"    </a>",
"    ], they are ineffective in carriers of one SCN5A mutation, D1790G [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/57\">",
"     57",
"    </a>",
"    ]. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    (a class IC antiarrhythmic drug) significantly shortened repolarization and normalized the marked baseline dispersion of repolarization in carriers of this mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another report, 6 of 13 of patients with LQT3 who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    developed ST segment elevation in leads V1 through V3 that were typical of Brugada syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/58\">",
"     58",
"    </a>",
"    ]. The latter disorder, which is characterized by similar ECG changes, may also be associated with mutations in SCN5A, and the differences in clinical manifestations between LQT3 and Brugada syndrome are probably due to differences in the electrophysiologic abnormalities induced by the specific mutations. Since Brugada syndrome is associated with an increased risk of SCD, the induction of Brugada ECG changes by flecainide raises questions about its safety in patients with LQTS 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link&amp;anchor=H12#H12\">",
"     \"Brugada syndrome\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Nicorandil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nicorandil, a specific potassium channel opener, was administered to six patients with LQT1 during an infusion of epinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/59\">",
"     59",
"    </a>",
"    ]. As noted above, epinephrine prolongs the QTc in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Nicorandil shortened the QT interval and monophasic action potential (MAP) duration, decreased the dispersion of the MAP durations, and abolished early afterdepolarizations. The addition of propranolol to nicorandil completely abolished all of the effects of epinephrine.",
"   </p>",
"   <p>",
"    In an animal study, nicorandil also shortened the QT interval and prevented spontaneous and induced TdP in models mimicking LQT1 and LQT2, but not LQT3 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Radiofrequency ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available on the use of radiofrequency ablation for LQTS. In an initial report, four patients with LQTS and episodes of ventricular fibrillation or syncope were found to have frequent premature beats triggering ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/61\">",
"     61",
"    </a>",
"    ]. After radiofrequency ablation, no recurrent symptomatic ventricular arrhythmias were observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     MAJOR SOCIETY GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines for the management of ventricular arrhythmias and the prevention of SCD included recommendations for reducing the risk of SCD in LQTS patients with lifestyle modification, medical therapy, and ICD implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/30\">",
"     30",
"    </a>",
"    ]. The role of ICD implantation in LQTS patients was also addressed in the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    guidelines for device-based therapy of cardiac rhythm abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/62\">",
"     62",
"    </a>",
"    ]. These two sets of guidelines were in general agreement in areas in which they overlapped.",
"   </p>",
"   <p>",
"    The following recommendations and suggestions were included in one or both of these guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lifestyle modification was recommended for all patients with either a clinical or genetic diagnosis of LQTS [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'General measures'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Beta blockers &mdash; Beta blocker therapy was recommended for patients with QT prolongation and suggested for patients with a molecular diagnosis of congenital LQTS but a normal QT interval [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Beta blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ICD implantation was recommended for survivors of a cardiac arrest who have a reasonable expectation of survival with a good functional status for at least one year [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/30,62\">",
"       30,62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ICD implantation was suggested for patients who experience sustained VT",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a syncopal event consistent with a tachyarrhythmia while on beta blocker therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/30,62\">",
"       30,62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Beta blocker therapy should be initiated or continued in all patients who receive an ICD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines also stated that evidence was less well established for the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left cardiac sympathetic denervation for patients with syncope, TdP, or cardiac arrest while receiving beta blockers [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ICD implantation combined with beta blocker therapy for patients in categories at an increased risk of SCD (eg, LQT2 or LQT3) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/30,62\">",
"       30,62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/25/19859?source=see_link\">",
"       \"Patient information: Long QT syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goals of therapy in patients with congenital LQTS are prevention of SCD and reduction of serious symptoms such as syncope. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Natural history and prognosis'",
"    </a>",
"    above.) Management strategies beyond the use of beta blockers hinge on the presence or absence of symptoms as well as the genotype",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    family history. In addition, a large variable relates to the patient's personal philosophy about the potential risks of their illness.",
"   </p>",
"   <p>",
"    Our recommended approach is in general agreement with the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    and 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA/HRS",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/30,62\">",
"     30,62",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Major society guidelines'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;General measures in both symptomatic and asymptomatic patients include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance of drugs that prolong the QT interval (",
"      <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"       table 2",
"      </a>",
"      ) or reduce the serum concentrations of potassium or magnesium.",
"     </li>",
"     <li>",
"      Avoidance of competitive sports or strenuous activity [",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/30,63\">",
"       30,63",
"      </a>",
"      ]. Exercise is a particularly common precipitating event in patients with LQT1 but also can precipitate events in LQT2 and LQT3 (",
"      <a class=\"graphic graphic_figure graphicRef64239 \" href=\"UTD.htm?9/27/9662\">",
"       figure 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link&amp;anchor=H28#H28\">",
"       \"Risk of sudden cardiac death in athletes\", section on 'Congenital long QT syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Genotype-specific therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing to identify the type of congenital LQTS may be important therapeutically, since the triggers of arrhythmia (",
"    <a class=\"graphic graphic_figure graphicRef64239 \" href=\"UTD.htm?9/27/9662\">",
"     figure 3",
"    </a>",
"    ) and the response to therapy are so variable [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Triggers of arrhythmia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following recommendations are based upon knowledge of the patient's genotype; the supportive data is presented in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical features of congenital long QT syndrome\", section on 'Influence of genotype'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     LQT1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with LQT1, strenuous exercise and stress should be limited, because they are common triggers of arrhythmia (",
"    <a class=\"graphic graphic_figure graphicRef64239 \" href=\"UTD.htm?9/27/9662\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/16\">",
"     16",
"    </a>",
"    ], and beta blockers are highly likely to be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/16,25\">",
"     16,25",
"    </a>",
"    ]. The sensitivity of these patients to exercise may be related to exaggerated prolongation of the QT interval during exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/25\">",
"     25",
"    </a>",
"    ]. Events related to swimming (occurring either immediately after diving into water or during recreational or competitive swimming activities) may be specific for LQT1 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/21,23,24\">",
"     21,23,24",
"    </a>",
"    ]. Such patients should be advised against unsupervised swimming unless they have an ICD. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Beta blockers'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     LQT3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with LQT3, the risk of events is highest when at rest or asleep; exercise as a trigger is relatively uncommon (",
"    <a class=\"graphic graphic_figure graphicRef64239 \" href=\"UTD.htm?9/27/9662\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients with LQT3 may have fewer events with exercise or stress because they significantly shorten their QTc with tachycardia and therefore become less susceptible to catecholamine-induced arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/26\">",
"     26",
"    </a>",
"    ]. These findings are consistent with clinical observations that these patients derive less or perhaps no benefit from therapy with beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/16,27\">",
"     16,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    may be beneficial, acting in part by shortening the QTc [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/26\">",
"     26",
"    </a>",
"    ]. LQT3 results from a failure to inactivate sodium channels and mexiletine is a sodium channel blocker.",
"   </p>",
"   <p>",
"    In addition, patients with LQT3 may derive particular benefit from pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/43\">",
"     43",
"    </a>",
"    ], since bradycardia is not uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/44\">",
"     44",
"    </a>",
"    ] and dispersion of repolarization worsens during bradycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/36\">",
"     36",
"    </a>",
"    ], which promotes pause-dependent arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Role of beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with congenital LQTS, whether asymptomatic or symptomatic, should be treated with a beta blocker in the absence of a contraindication (",
"    <a class=\"graphic graphic_table graphicRef69969 \" href=\"UTD.htm?9/51/10045\">",
"     table 4",
"    </a>",
"    ). Beta blockers are given as monotherapy in patients who are asymptomatic or who do not clearly have syncope related to TdP. The rationale for treating asymptomatic patients is the ongoing risk of both cardiac events and mortality over time, particularly in females (",
"    <a class=\"graphic graphic_figure graphicRef68308 \" href=\"UTD.htm?37/37/38493\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef75990 \" href=\"UTD.htm?36/10/37038\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/5,17\">",
"     5,17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Clinical course'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Beta blockers are also effective in patients who have had syncope or aborted cardiac arrest, but there is an appreciable",
"    <strong>",
"     persistent risk",
"    </strong>",
"    of recurrent nonfatal or fatal cardiac arrest among patients who have had aborted cardiac arrest (14 percent at five years) (",
"    <a class=\"graphic graphic_figure graphicRef78184 \" href=\"UTD.htm?5/13/5342\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/27\">",
"     27",
"    </a>",
"    ]. Prior syncope is a lesser risk factor for future events.",
"   </p>",
"   <p>",
"    Among the major causes of congenital LQTS, beta blockers are most effective in LQT1 and least effective in LQT3 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/16,27\">",
"     16,27",
"    </a>",
"    ]. We have not discontinued beta blockers in symptomatic patients who are known to have LQT3, but have added",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    which shortens the QTc in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Beta blockers'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The goal of beta blocker therapy is to blunt the maximal heart rate achieved during exertion. Both nonselective and cardioselective beta blockers have been prescribed for LQTS patients. Longer-acting agents or sustained-release formulations may improve patient satisfaction and compliance, while cardioselective beta blockers (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ) may have fewer noncardiac side effects, such as fatigue and mood changes. However, most of the long-term clinical studies have been performed with nonselective beta blockers (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    ). Not all beta blockers appear to have the same QT shortening effect or clinical outcomes. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Beta blockers'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Variable doses of beta blockers have been used in published reports [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/27,45\">",
"     27,45",
"    </a>",
"    ]. In the above study of 869 patients, the following were the average last recorded doses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       Atenolol",
"      </a>",
"      &ndash; 65",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (1.3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       Metoprolol",
"      </a>",
"      &ndash; 121",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (1.8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       Propranolol",
"      </a>",
"      &ndash; 108",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (2.9",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"       Nadolol",
"      </a>",
"      &ndash; 79",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (1.4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In small children, we start with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    at an initial dose of 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in divided doses every six to eight hours; the dose is titrated upward every three to seven days to achieve a usual dose of 2 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day.",
"   </p>",
"   <p>",
"    It is not known if higher doses would have reduced the incidence of recurrent events in patients with a history of aborted cardiac arrest. In a report cited above of patients treated with pacing plus maximally tolerated doses of beta blockers, there remained an appreciable incidence of SCD or aborted cardiac arrest at follow-up (24 percent in all patients and 17 percent in compliant patients at a mean of 6.3 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/45\">",
"     45",
"    </a>",
"    ]. Adolescents are at relatively high risk of breakthrough episodes, probably due at least in part to noncompliance with daily beta blocker therapy.",
"   </p>",
"   <p>",
"    Beta blockers should be continued during pregnancy and for at least 40 weeks postpartum, the time of greatest risk [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/29\">",
"     29",
"    </a>",
"    ]. Among women with a personal history of syncope or aborted cardiac arrest, beta blockers can reduce the risk of cardiac events by as much as 98 percent in the postpartum period. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Influence of pregnancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Role of left cardiac sympathetic denervation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, left cardiac sympathetic denervation is an effective therapy in patients with persistent arrhythmias on beta blockers and in those who cannot tolerate beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/2,39,40\">",
"     2,39,40",
"    </a>",
"    ]. However, although this technique produces significant reductions in the number of subsequent cardiac events per patient, there is still a 5 percent incidence of SCD at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/39\">",
"     39",
"    </a>",
"    ]. Thus, high-risk patients may be better treated with an ICD. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Role of ICD'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because of the persistent risk of cardiac events and the availability of other options (such as the ICD), we rarely perform left cardiac sympathetic denervation. Our main indication is failure of medical therapy and frequent shocks with an ICD despite medications. However, this procedure is more commonly utilized in some centers outside the United States and in a few centers in the United States. Limited data suggest that the technique may be more effective in patients with LQT1 than in those with LQT2 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Role of DDD pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient is symptomatic and has experienced either syncope or TdP, the use of a beta blocker plus a DDD pacemaker programmed at a rate that shortens the QTc to less than 0.44 sec can substantially reduce the incidence of recurrent symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/45\">",
"     45",
"    </a>",
"    ]. It has been suggested that patients with LQT3 may derive particular benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/43\">",
"     43",
"    </a>",
"    ], since bradycardia is not uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/44\">",
"     44",
"    </a>",
"    ] and dispersion of repolarization worsens during bradycardia in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there remains an appreciable incidence of SCD and aborted cardiac arrest after the addition of pacing (24 percent in all patients and 17 percent in compliant patients in one report at a mean follow-up of 6.3 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/45\">",
"     45",
"    </a>",
"    ]. Thus, when contemplating permanent pacemaker implantation in a symptomatic patient with congenital LQTS, an ICD should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/30\">",
"     30",
"    </a>",
"    ]. The ICD can function as an antibradycardia pacemaker, while providing the backup antitachycardia defibrillation when necessary.",
"   </p>",
"   <p>",
"    The rationale for choosing a permanent pacemaker over an ICD should be individualized, based upon factors such as patient size, device size and longevity, cost, and the overall",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio. Possible settings in which are pacemaker alone might be used include patients at lower risk who might benefit from pacing because of bradycardia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    AV block, or known LQT3 phenotype which is associated with higher risk at slow heart rates [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Role of ICD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding observations of ongoing risk with beta blockers and DDD pacing or with sympathetic denervation suggest that an ICD should generally be used in survivors of aborted cardiac arrest and in patients with recurrent syncope or TdP on beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/45\">",
"     45",
"    </a>",
"    ]. This approach is in keeping with the 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA/HRS",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Major society guidelines'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An ICD can also be considered as primary therapy in selected high-risk patients, such as those in whom aborted cardiac arrest is the initial presentation, there is a strong family history of SCD, or when compliance with or intolerance to drugs is a concern.",
"   </p>",
"   <p>",
"    Early ICD therapy also may be considered in selected patients with Jervell and Lange-Nielsen syndrome who appear to have a higher risk of malignant arrhythmias and, because the disease is transmitted in an autosomal recessive fashion, the family history may not be informative [",
"    <a class=\"abstract\" href=\"UTD.htm?26/3/26682/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/1\">",
"      Vincent GM. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death. Annu Rev Med 1998; 49:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/2\">",
"      Schwartz PJ. The long QT syndrome. Curr Probl Cardiol 1997; 22:297.",
"     </a>",
"    </li>",
"    <li>",
"     Schwartz P, Locati E, Napolitano C, Priori S. The long QT Syndrome. In: Cardiac Electrophysiology: From cell to bedside, Zipes D, Jalife J (Eds), WB Saunders, Philadelphia 1995. p.788.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/4\">",
"      Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome: a prospective international study. Circulation 1985; 71:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/5\">",
"      Locati EH, Zareba W, Moss AJ, et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation 1998; 97:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/6\">",
"      Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270:2590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/7\">",
"      Lehmann MH, Hardy S, Archibald D, et al. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 1996; 94:2535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/8\">",
"      Lehmann MH, Timothy KW, Frankovich D, et al. Age-gender influence on the rate-corrected QT interval and the QT-heart rate relation in families with genotypically characterized long QT syndrome. J Am Coll Cardiol 1997; 29:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/9\">",
"      Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000; 102:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/10\">",
"      Zareba W, Moss AJ, le Cessie S, et al. Risk of cardiac events in family members of patients with long QT syndrome. J Am Coll Cardiol 1995; 26:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/11\">",
"      Kimbrough J, Moss AJ, Zareba W, et al. Clinical implications for affected parents and siblings of probands with long-QT syndrome. Circulation 2001; 104:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/12\">",
"      Schwartz PJ, Locati E. The idiopathic long QT syndrome: pathogenetic mechanisms and therapy. Eur Heart J 1985; 6 Suppl D:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/13\">",
"      Garson A Jr, Dick M 2nd, Fournier A, et al. The long QT syndrome in children. An international study of 287 patients. Circulation 1993; 87:1866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/14\">",
"      Sauer AJ, Moss AJ, McNitt S, et al. Long QT syndrome in adults. J Am Coll Cardiol 2007; 49:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/15\">",
"      Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med 1992; 327:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/16\">",
"      Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001; 103:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/17\">",
"      Zareba W, Moss AJ, Schwartz PJ, et al. Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med 1998; 339:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/18\">",
"      Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003; 348:1866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/19\">",
"      Moss AJ, Shimizu W, Wilde AA, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation 2007; 115:2481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/20\">",
"      Wilde AA, Jongbloed RJ, Doevendans PA, et al. Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). J Am Coll Cardiol 1999; 33:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/21\">",
"      Moss AJ, Robinson JL, Gessman L, et al. Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol 1999; 84:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/22\">",
"      Ali RH, Zareba W, Moss AJ, et al. Clinical and genetic variables associated with acute arousal and nonarousal-related cardiac events among subjects with long QT syndrome. Am J Cardiol 2000; 85:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/23\">",
"      Ackerman MJ, Tester DJ, Porter CJ. Swimming, a gene-specific arrhythmogenic trigger for inherited long QT syndrome. Mayo Clin Proc 1999; 74:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/24\">",
"      Batra AS, Silka MJ. Mechanism of sudden cardiac arrest while swimming in a child with the prolonged QT syndrome. J Pediatr 2002; 141:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/25\">",
"      Takenaka K, Ai T, Shimizu W, et al. Exercise stress test amplifies genotype-phenotype correlation in the LQT1 and LQT2 forms of the long-QT syndrome. Circulation 2003; 107:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/26\">",
"      Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 1995; 92:3381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/27\">",
"      Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000; 101:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/28\">",
"      Schwartz PJ, Spazzolini C, Crotti L, et al. The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome. Circulation 2006; 113:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/29\">",
"      Rashba EJ, Zareba W, Moss AJ, et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS Investigators. Circulation 1998; 97:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/30\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/31\">",
"      Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004; 292:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/32\">",
"      Hobbs JB, Peterson DR, Moss AJ, et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA 2006; 296:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/33\">",
"      Goldenberg I, Moss AJ, Peterson DR, et al. Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation 2008; 117:2184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/34\">",
"      Chockalingam P, Crotti L, Girardengo G, et al. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol 2012; 60:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/35\">",
"      Vincent GM, Schwartz PJ, Denjoy I, et al. High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment \"failures\". Circulation 2009; 119:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/36\">",
"      Shimizu W, Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol 2000; 35:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/37\">",
"      Ackerman MJ, Khositseth A, Tester DJ, et al. Epinephrine-induced QT interval prolongation: a gene-specific paradoxical response in congenital long QT syndrome. Mayo Clin Proc 2002; 77:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/38\">",
"      Shimizu W, Noda T, Takaki H, et al. Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. J Am Coll Cardiol 2003; 41:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/39\">",
"      Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation 2004; 109:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/40\">",
"      Ouriel K, Moss AJ. Long QT syndrome: an indication for cervicothoracic sympathectomy. Cardiovasc Surg 1995; 3:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/41\">",
"      Schwartz PJ. The rationale and the role of left stellectomy for the prevention of malignant arrhythmias. Ann N Y Acad Sci 1984; 427:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/42\">",
"      Schwartz PJ, Stone HL. Left stellectomy and denervation supersensitivity in conscious dogs. Am J Cardiol 1982; 49:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/43\">",
"      Viskin S. Cardiac pacing in the long QT syndrome: review of available data and practical recommendations. J Cardiovasc Electrophysiol 2000; 11:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/44\">",
"      Veldkamp MW, Wilders R, Baartscheer A, et al. Contribution of sodium channel mutations to bradycardia and sinus node dysfunction in LQT3 families. Circ Res 2003; 92:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/45\">",
"      Dorostkar PC, Eldar M, Belhassen B, Scheinman MM. Long-term follow-up of patients with long-QT syndrome treated with beta-blockers and continuous pacing. Circulation 1999; 100:2431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/46\">",
"      Silka MJ, Kron J, Dunnigan A, Dick M 2nd. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The Pediatric Electrophysiology Society. Circulation 1993; 87:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/47\">",
"      Groh WJ, Silka MJ, Oliver RP, et al. Use of implantable cardioverter-defibrillators in the congenital long QT syndrome. Am J Cardiol 1996; 78:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/48\">",
"      Chatrath R, Porter CB, Ackerman MJ. Role of transvenous implantable cardioverter-defibrillators in preventing sudden cardiac death in children, adolescents, and young adults. Mayo Clin Proc 2002; 77:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/49\">",
"      Shah MJ, Rhodes LA. Resolution of electrical storms after discontinuation of ICD therapy in a child with long QT syndrome. Pediatr Cardiol 2002; 23:213.",
"     </a>",
"    </li>",
"    <li>",
"     Berul CI, Barrett KS, Walsh EP. Implantable cardioverter defibrillators in pediatrics. In: Cardiac Arrhythmias in Children and Young Adults with Congenital Heart Disease, Walsh EP, Saul JP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2001. p.321.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/51\">",
"      Bhandari AK, Shapiro WA, Morady F, et al. Electrophysiologic testing in patients with the long QT syndrome. Circulation 1985; 71:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/52\">",
"      Compton SJ, Lux RL, Ramsey MR, et al. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation 1996; 94:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/53\">",
"      Etheridge SP, Compton SJ, Tristani-Firouzi M, Mason JW. A new oral therapy for long QT syndrome: long-term oral potassium improves repolarization in patients with HERG mutations. J Am Coll Cardiol 2003; 42:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/54\">",
"      Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation 1996; 93:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/55\">",
"      Bisinov E, Mitchell JH, January CT. Potassium and long QT syndrome: a new look at an old therapy. J Am Coll Cardiol 2003; 42:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/56\">",
"      Ruan Y, Liu N, Bloise R, et al. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation 2007; 116:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/57\">",
"      Benhorin J, Taub R, Goldmit M, et al. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? Circulation 2000; 101:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/58\">",
"      Priori SG, Napolitano C, Schwartz PJ, et al. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation 2000; 102:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/59\">",
"      Shimizu W, Kurita T, Matsuo K, et al. Improvement of repolarization abnormalities by a K+ channel opener in the LQT1 form of congenital long-QT syndrome. Circulation 1998; 97:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/60\">",
"      Shimizu W, Antzelevitch C. Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation 2000; 102:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/61\">",
"      Ha&iuml;ssaguerre M, Extramiana F, Hocini M, et al. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation 2003; 108:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/62\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/3/26682/abstract/63\">",
"      Zipes DP, Ackerman MJ, Estes NA 3rd, et al. Task Force 7: arrhythmias. J Am Coll Cardiol 2005; 45:1354.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 988 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-4D580CFE0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_3_26682=[""].join("\n");
var outline_f26_3_26682=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiologic studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - International LQTS Registry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Schwartz study",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - International Pediatric Electrophysiology Study",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Importance of genotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Clinical course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Triggers of arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Jervell and Lange-Nielsen syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Influence of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Effect of genotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Left cardiac sympathetic denervation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Use in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Targeted pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Potassium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Mexiletine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Flecainide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Nicorandil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Radiofrequency ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      MAJOR SOCIETY GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Genotype-specific therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - LQT1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - LQT3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Role of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Role of left cardiac sympathetic denervation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Role of DDD pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Role of ICD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/988\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/988|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/37/38493\" title=\"figure 1\">",
"      Cardiac events LQTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/10/37038\" title=\"figure 2\">",
"      Long QT genotype outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/27/9662\" title=\"figure 3\">",
"      Trigger event vs LQTS genotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/13/5342\" title=\"figure 4\">",
"      Events LQTS with beta blocker",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/988|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/27/32189\" title=\"table 1\">",
"      Genetic abnormalities LQTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/48/2830\" title=\"table 2\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/46/30443\" title=\"table 3\">",
"      Rx of torsades de pointes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/51/10045\" title=\"table 4\">",
"      ESC prevention SCD LQTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/988|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/23/43380\" title=\"waveform 1A\">",
"      ECG Torsades de pointes tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/7/43134\" title=\"waveform 1B\">",
"      ECG torsades de pointes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=related_link\">",
"      Diagnosis of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=related_link\">",
"      Genetics of congenital and acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=related_link\">",
"      Implantable cardioverter-defibrillators: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9591?source=related_link\">",
"      Pathophysiology of the long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/25/19859?source=related_link\">",
"      Patient information: Long QT syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14362?source=related_link\">",
"      Supraventricular arrhythmias during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7674?source=related_link\">",
"      Ventricular arrhythmias during pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_3_26683="Symptoms and signs in AIP";
var content_f26_3_26683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F56856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F56856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence of symptoms and signs of acute intermittent porphyria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Abdominal pain",
"      </td>",
"      <td>",
"       85 to 95 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vomiting",
"      </td>",
"      <td>",
"       43 to 88 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Constipation",
"      </td>",
"      <td>",
"       48 to 84 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Muscle weakness",
"      </td>",
"      <td>",
"       42 to 60 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mental symptoms",
"      </td>",
"      <td>",
"       40 to 58 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Limb, head, neck, or chest pain",
"      </td>",
"      <td>",
"       50 to 52 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypertension",
"      </td>",
"      <td>",
"       36 to 54 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tachycardia",
"      </td>",
"      <td>",
"       28 to 80 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Convulsion",
"      </td>",
"      <td>",
"       10 to 20 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sensory loss",
"      </td>",
"      <td>",
"       9 to 38 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fever",
"      </td>",
"      <td>",
"       9 to 37 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Respiratory paralysis",
"      </td>",
"      <td>",
"       9 to 14 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diarrhea",
"      </td>",
"      <td>",
"       5 to 12 percent",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_3_26683=[""].join("\n");
var outline_f26_3_26683=null;
var title_f26_3_26684="Developmental reflexes";
var content_f26_3_26684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common developmental reflexes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Reflex",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age at appearance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age at resolution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moro (startle)",
"       </td>",
"       <td>",
"        The examiner holds the infant supine in his or her arms, then drops the infant's head slightly but suddenly. This leads to the infant extending and abducting the arms, with the palms open, and sometimes crying. Alternatively, the examiner may lift the infant's head off the bed by 1 to 2 inches and allow it to gently drop back; this maneuver elicits a similar response.",
"       </td>",
"       <td>",
"        34-36 weeks PCA",
"       </td>",
"       <td>",
"        5-6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asymmetric tonic neck reflex",
"       </td>",
"       <td>",
"        With the infant relaxed and lying supine, the examiner rotates the head to one side. The infant extends the leg or arm on the side towards which the head has been turned, while flexing the arm on the contralateral side (fencing posture).",
"       </td>",
"       <td>",
"        38-40 weeks PCA",
"       </td>",
"       <td>",
"        2-3 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trunk incurvation (Galant)",
"       </td>",
"       <td>",
"        With the infant in a prone position, the examiner strokes or taps along the side of the spine. The infant twitches his or her hips toward the side of the stimulus.",
"       </td>",
"       <td>",
"        38-40 weeks PCA",
"       </td>",
"       <td>",
"        1-2 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palmar grasp",
"       </td>",
"       <td>",
"        The examiner places a finger in the infant's open palm. The infant closes his or her hand around the finger, tightens the grip if the examiner attempts to withdraw the finger.",
"       </td>",
"       <td>",
"        38-40 weeks PCA",
"       </td>",
"       <td>",
"        5-6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plantar grasp",
"       </td>",
"       <td>",
"        The examiner places a finger under the infant's toes. The infant flexes the toes downwards to \"grasp\" the finger.",
"       </td>",
"       <td>",
"        38-40 weeks PCA",
"       </td>",
"       <td>",
"        9-10 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rooting",
"       </td>",
"       <td>",
"        The examiner strokes the infant's cheek. The infant turns the head toward the side that is stroked, and makes sucking motions.",
"       </td>",
"       <td>",
"        38-40 weeks PCA",
"       </td>",
"       <td>",
"        2-3 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parachute",
"       </td>",
"       <td>",
"        The infant is held upright, back to the examiner. The body is rotated quickly forward (as if falling). The infant reflexively extends the upper extremities towards the ground as if to break a fall.",
"       </td>",
"       <td>",
"        8-9 months of age",
"       </td>",
"       <td>",
"        Persists throughout life",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PCA: post conceptional age.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Suresh Kotagal.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_3_26684=[""].join("\n");
var outline_f26_3_26684=null;
var title_f26_3_26685="History in wheeze II";
var content_f26_3_26685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of wheezing due to lower airway diseases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Aspiration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of risk for pharyngeal dysfunction or gastroesophageal reflux disease.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Testing:",
"       </strong>",
"       Modified barium swallow, 24 hour esophageal pH monitoring, gastroesophagoscopy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Bronchiectasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of episodes of productive cough, fever, or recurrent pneumonias.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Testing:",
"       </strong>",
"       Suggestive chest radiograph or typical high resolution chest CT findings; allergic bronchopulmonary aspergillosis should be considered when bronchiectasis is central.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Bronchiolitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of respiratory infection, connective tissue disease, transplantation, ulcerative colitis, development of chronic airflow obstruction over months to few years rather than over many years in a non-smoker.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Testing:",
"       </strong>",
"       Mixed obstructive and restrictive pattern on pulmonary function tests and hyperinflation and fine nodular infiltrates on chest radiograph, or suggestive chest CT findings.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Carcinoid syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of episodes of flushing and watery diarrhea.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Testing:",
"       </strong>",
"       Elevated 5-hydroxyindoleacetic acid level in a 24 hour urine specimen.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       COPD",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of dyspnea on exertion and productive cough in cigarette smoker; or patient exposed to another environmental irritant; since productive cough is non-specific, it should only be ascribed to COPD when other cough-phlegm syndromes have been excluded forced expiratory time &gt;4 sec, decreased breath-sound intensity, and unforced wheezing during auscultation.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Testing:",
"       </strong>",
"       Irreversible, or only partially reversible, expiratory airflow obstruction on spirometry; chest radiograph may show hyperinflation, bullae.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Cystic fibrosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       Combination of productive cough, digital clubbing, bronchiectasis, progressive chronic obstructive lung disease with Pseudomonas colonization/infection, obstructive azoospermia, family history, pancreatic insufficiency.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Testing:",
"       </strong>",
"       Two sweat chloride determinations &gt;60 meq/L; some patients are not diagnosed until adulthood, in one instance as late as age 69; when sweat test is occasionally normal, definitive diagnosis may require nasal transepithelial voltage measurements and genotyping.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Heart failure (cardiac asthma)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History and physical consistent with passive congestion of the lungs, impaired lung lymphatic drainage; crackles in addition to wheeze.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Testing:",
"       </strong>",
"       Elevated brain natriuretic peptide; abnormal chest radiograph, echocardiogram, radionuclide ventriculography, cardiac catheterization, or combinations of these.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Lymphangitic carcinomatosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of dyspnea or prior malignancy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Testing:",
"       </strong>",
"       Reticulonodular infiltrates with or without pleural effusions; suggestive high resolution chest CT scan; bronchoscopy with transbronchial biopsies may be diagnostic.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Noncardiogenic pulmonary edema",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       Acute onset of dyspnea in setting of risk factors for ARDS; chest imaging shows interstitial/alveolar opacities; substantial gas transfer defect.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Parasitic infections",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       Consider in a non-asthmatic who has traveled to an endemic area and complains of fatigue, weight loss, fever.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Testing:",
"       </strong>",
"       Peripheral blood eosinophilia; infiltrates on chest radiograph; stools for ova and parasites for non-filarial causes; blood serologic studies for filaria/strongyloides.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Pulmonary embolism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of risk factors for thromboembolic disease. Wheezing is rarely heard in venous thromboembolism.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Testing:",
"       </strong>",
"       CT pulmonary angiogram.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_3_26685=[""].join("\n");
var outline_f26_3_26685=null;
var title_f26_3_26686="Patient management";
var content_f26_3_26686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 575px\">",
"   <div class=\"ttl\">",
"    Flow chart for the evaluation and management of choledocholithiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 555px; height: 418px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CBD: common bile duct; ERCP: endoscopic retrograde cholangiopancreatography; EUS: endoscopic ultrasound; IOC: intraoperative cholangiogram; MRCP: magnetic resonance cholangiopancreatography.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: ASGE Standards of Practice Committee. The role of endoscopy in the evaluation of suspected choledocholithiasis. Gastrointest Endosc 2010; 71:1. Copyright &copy; 2010. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_3_26686=[""].join("\n");
var outline_f26_3_26686=null;
var title_f26_3_26687="Acute ulcerative colitis BE";
var content_f26_3_26687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute ulcerative colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 220px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Double contrast barium enema demonstrates extensive mucosal ulceration and inflammation throughout the colon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_3_26687=[""].join("\n");
var outline_f26_3_26687=null;
